WO2002085387A2 - A medicament or a dressing containing a metal such as silver, gold, platinum or palladium as an antimicrobial agent ans their use in the treatment of inflammatory skin conditions - Google Patents

A medicament or a dressing containing a metal such as silver, gold, platinum or palladium as an antimicrobial agent ans their use in the treatment of inflammatory skin conditions Download PDF

Info

Publication number
WO2002085387A2
WO2002085387A2 PCT/CA2002/000549 CA0200549W WO02085387A2 WO 2002085387 A2 WO2002085387 A2 WO 2002085387A2 CA 0200549 W CA0200549 W CA 0200549W WO 02085387 A2 WO02085387 A2 WO 02085387A2
Authority
WO
WIPO (PCT)
Prior art keywords
dressing
antimicrobial
nanocrystalline
silver
metal
Prior art date
Application number
PCT/CA2002/000549
Other languages
French (fr)
Other versions
WO2002085387A3 (en
Inventor
Robert Edward Burrell
Hua Qing Yin
Original Assignee
Nucryst Pharmaceuticals Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/840,637 external-priority patent/US7008647B2/en
Application filed by Nucryst Pharmaceuticals Corp. filed Critical Nucryst Pharmaceuticals Corp.
Priority to EP20020721904 priority Critical patent/EP1383522B1/en
Priority to AU2002252881A priority patent/AU2002252881B2/en
Priority to CA 2445740 priority patent/CA2445740A1/en
Priority to DE2002610441 priority patent/DE60210441T2/en
Priority to JP2002582960A priority patent/JP2004529930A/en
Publication of WO2002085387A2 publication Critical patent/WO2002085387A2/en
Publication of WO2002085387A3 publication Critical patent/WO2002085387A3/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N59/00Biocides, pest repellants or attractants, or plant growth regulators containing elements or inorganic compounds
    • A01N59/16Heavy metals; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/242Gold; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/243Platinum; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/38Silver; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/40Peroxides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007Drug-containing films, membranes or sheets
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42Use of materials characterised by their function or physical properties
    • A61L15/46Deodorants or malodour counteractants, e.g. to inhibit the formation of ammonia or bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L17/00Materials for surgical sutures or for ligaturing blood vessels ; Materials for prostheses or catheters
    • A61L17/14Post-treatment to improve physical properties
    • A61L17/145Coating
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/28Materials for coating prostheses
    • A61L27/30Inorganic materials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L29/00Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/08Materials for coatings
    • A61L29/10Inorganic materials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/08Materials for coatings
    • A61L31/082Inorganic materials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/04Drugs for disorders of the respiratory system for throat disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/08Antiseborrheics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/10Anti-acne agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/10Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
    • A61L2300/102Metals or metal compounds, e.g. salts such as bicarbonates, carbonates, oxides, zeolites, silicates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/10Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
    • A61L2300/102Metals or metal compounds, e.g. salts such as bicarbonates, carbonates, oxides, zeolites, silicates
    • A61L2300/104Silver, e.g. silver sulfadiazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/404Biocides, antimicrobial agents, antiseptic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/452Lubricants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/606Coatings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/62Encapsulated active agents, e.g. emulsified droplets
    • A61L2300/624Nanocapsules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/63Crystals
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00Drug, bio-affecting and body treating compositions
    • Y10S424/15Suppositories
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00Stock material or miscellaneous articles
    • Y10T428/31504Composite [nonstructural laminate]
    • Y10T428/31855Of addition polymer from unsaturated monomers

Definitions

  • the invention relates to the use of antimicrobial metals for the treatment of inflammatory skin conditions.
  • Inflammatory skin conditions are those conditions of the skin in which inflammatory cells (e.g., polymorphonuclear neutrophils and lymphocytes) infiltrate the skin with no overt or known infectious etiology. Symptoms of inflammatory skin conditions generally include erythema (redness), edema (swelling), pain, pruritus, increased surface temperature and loss of function.
  • inflammatory cells e.g., polymorphonuclear neutrophils and lymphocytes
  • Symptoms of inflammatory skin conditions generally include erythema (redness), edema (swelling), pain, pruritus, increased surface temperature and loss of function.
  • inflammatory skin conditions include, but are not limited to, eczema and related conditions, insect bites, erythroderma, mycosis fungoides and related conditions, pyoderma gangrenosum, erythema multiforme, rosacea, onychomycosis, and acne and related conditions, but excluding psoriasis and its related conditions.
  • eczema and related conditions insect bites, erythroderma, mycosis fungoides and related conditions, pyoderma gangrenosum, erythema multiforme, rosacea, onychomycosis, and acne and related conditions, but excluding psoriasis and its related conditions.
  • Eczema relates to a group of conditions characterized by varying degrees of itching, redness, scaling, and blistering of the skin. Eczema occurs as a reaction to many endogenous and exogenous agents, and is characterized in the acute stage by erythema, edema associated with a serious exudate between the cells of the epidermis and an inflammatory infiltrate in the dermis, oozing and vesiculation, crusting and scaling. Chronic stages are characterized by thickened skin areas with accentuated skin markings, signs of traumatized or abraded skin caused by scratching, and hyperpigmentation or hypopigmentation or both.
  • Atopic eczema is the most common type of eczema.
  • Atopic eczema is a chronic, praritic, superficial inflammation of the skin, frequently associated with a personal or family history of allergic disorders such as hay fever and asthma.
  • Topical or oral corticosteroids, or antihistamines are common treatments.
  • Acrodermatitis continua is characterized by painful, often disabling, lesions on the fingertips or the tips of the toes. The nails may become deformed, and the disease can damage bone in the affected area.
  • Treatment may include topical corticosteroids and systemic remedies, such as retinoids or psoralen-UNA, although is difficult due to the rarity of the disease.
  • retinoids or psoralen-UNA retinoids or psoralen-UNA
  • Contact allergic dermatitis is acute or chronic dermatitis caused by materials or substances coming into contact with the skin, which may involve either allergic or nonallergic mechanisms.
  • Materials or substances known to induce contact allergic dermatitis include plant substances such as poison ivy, metals such as nickel or chromium, cosmetics, rubber compounds or chemicals.
  • Contact irritant dermatitis is a nonallergic type of contact dermatitis caused by intense or long term exposure to a substance which directly damages the skin.
  • Dyshydrotic eczema or pompholyx is a chronic condition characterized by deep-seated pruritic vesicles on the palms, sides of the fingers, and soles. Scaling, redness, and oozing often follow vesiculation. Secondary infection with Staphylococcal bacteria is frequent.
  • Lichen simplex chronicus is a chronic, superficial, pruritic inflammation of the skin, characterized by dry, scaling, well-demarcated, hyperpigmented, thickened skin with accentuated markings of oval, irregular, or angular shape. The pruritus may be controlled most effectively with topical corticosteroids.
  • Nummular eczema is characterized by discrete, coin-shaped, ringed or annular lesions which may coalesce to form extensive patches, which may ooze and crust over, and affects the extensor surfaces of the extremities, lower legs, chest, back and buttocks. No treatment is uniformly effective.
  • Oral antibiotics or corticosteroid creams are generally used as treatments. In more resistant cases, ultraviolet B radiation alone or ultraviolet A with oral psoralen may be helpful.
  • Seborrheic dermatitis is chronic and characterized by moderate erythema; dry, moist or greasy scaling; itching; and yellow crusted patches on areas of the body with high densities of large oil glands, especially the face and scalp. Treatment with zinc pyrithione, selenium sulfide, sulfur and salicylic acid, tar shampoo, or a corticosteroid lotion is common, ix) Stasis eczema is a chronic inflammation of the skin of the lower legs, commonly associated with venous incompetency.
  • Insect bites or stings can produce localized pain, redness, swelling and itching of the skin. In serious cases, complications include allergic reaction, infection, disease, reaction to venom, toxic reaction, or shock. Depending upon the specific insect, treatments may include rest and elevation, local application of ice packs and lotions, analgesics, antihistamines, or hospitalization for life threatening, anaphylactic reactions. in Erythroderma
  • Erythroderma relates to any dermatitis where erythema (abnormal redness of the skin) occurs. Erythroderma, involving more than 90% of the skin, is potentially life threatening for a patient, since the barrier function of the skin has been lost. Hospitalization, topical moisturisers and intravenous fluids may be required to maintain hydration of the patient. IN Mycosis fungoides and Related Conditions
  • Mycosis fungoides is an uncommon chronic T-cell lymphoma primarily affecting the skin and occasionally the internal organs. Mycosis fungoides is rare, appearing as a chronic, pruritic rash which is difficult to diagnose. Initially plaquelike, it may spread to involve most of the skin, become nodular, and eventually become systemic. Lesions may become ulcerated. Pathologic diagnosis is delayed because sufficient quantities of lymphoma cells appear in the skin lesions very gradually. Treatment is temporarily effective, and may include psoralen- UNA, cortisone ointments for mild cases, nitrogen mustard, and photochemotherapy. N Pyoderma gangrenosum
  • Pyoderma gangrenosum is characterized by relatively indolent ulcers with extensive necrosis around the edges of the lesions on the lower extremities of the body. While pyoderma gangrenosum may be an isolated finding, it is most often associated with ulcerative colitis or Crohn's disease. The ulcers have ragged bluish-red overhanging edges and a necrotic base. The lesions often start as pustules or tender nodules at the site of trauma, and then gradually increase in size until liquefaction necrosis occurs and an irregular ulcer develops. The ulcers are often multiple and may cover large areas of the leg. Treatments include topical steroids, anti-inflammatory antibiotics, and oral steroids for more severe cases. NI Erythema multiforme
  • Erythema multiforme is an inflammatory eruption characterized by symmetric erythematous, edematous, or bullous lesions of the skin or mucous membranes. Erythema multiforme may be induced by an infectious disease (e.g., herpes simplex, Mycoplasma pneumoniae); drug therapy (e.g., penicillin, sulfonamides, and barbiturates); or a vaccine (e.g., Bacille Calmette-Guerin, poliomyelitis vaccines). The mechanism by which diseases, drugs, or vaccines cause erythema multiforme is unknown, but it is generally considered a hypersensitivity reaction. Treatments include mild topical cortisone, colloidal baths, and wet compresses. VII Rosacea
  • Rosacea is a chronic inflammatory disorder, usually beginning in middle age or later and characterized by prominent cutaneous blood vessels, erythema, papules, and pustules primarily in the central areas of the face. Tissue hypertrophy, particularly of the nose, may result. Rarely, rosacea occurs on the trunk and extremities. The cause is unknown, but the disease is most common in persons with a fair complexion. Rosacea may resemble acne, but comedones are never present. Treatments include topical metronidazole for three months or oral antibiotics. Laser treatments may be required to remove tissue hypertrophy. VHI Onychomycosis
  • Onychomycosis is an infection that causes fingernails or toenails to thicken, discolor, disfigure, and split. Thick toenails cause discomfort in shoes and make standing and walking painful for the patient. If the problem is caused by bacteria such as staphylococcus, streptococcus, and pseudomonas, the condition is called paronychia. In most cases, paronychia infections can be differentiated from onychomycosis by the inflammation they cause to the skin adjacent to the nail.
  • Onychomycosis is caused most commonly by fungi known as dermatophytes (Trichophyton rubrum and Trichophyton mentagrophytes), and less commonly by yeasts (Candida albicans causes fingernail infections), and molds (Scopulariopsis, Fusarium). Infections caused by dermatophytes are generally limited to the nail, but may spread to the surrounding skin and cause inflammation.
  • onychomycosis includes distal and/or lateral subungual onychomycosis affecting the nail bed and nail plate; proximal subungual onychomycosis affecting the proximal nail fold with infection extending distally under the nail plate; superficial white onychomycosis affecting the top of the nail plate; and candidal onychomycosis affecting the nail and skin.
  • Onychomycosis is difficult to treat, in that secondary skin infections including paronychia, and recurrent fungal infections of the nails or other parts of the body may occur.
  • Oral medications such as LamisilTM (terbinafine) or SporanoxTM (itraconazole) may produce adverse side effects in the liver, while topical treatments tend to be ineffective. Further, oral and topical medications work gradually, requiring several months to completely eliminate the infection. IX Acne and Related Conditions
  • acne is a general term to denote inflammatory disorders of the pilosebaceous unit.
  • Acne is a group of disorders whose initial pathology is the comedo and includes acne vulgaris (common acne), neonatal acne, infantile acne, and pomade acne.
  • Acne commonly afflicts adolescents and young adults; however, there is growing number of patients who develop acne in their late twenties or thirties.
  • acne has been linked to endocrine disorders, especially those characterized by elevated levels of circulating testosterone or testosterone congeners. Exogenous agents that could exacerbate acne include medications e.g. iodides, anti-seizure, certain antibiotics and corticosteroids.
  • Acne is a chronic inflammatory disorder affecting the sebaceous glands. Acne lesions primarily involve the sebaceous glands located on the face, neck, chest and back. Both closed comedones (blackheads) and open comedones (whiteheads) are caused by hyperkeratinization of the infundibulum of the sebaceous duct. These keratinous plugs block the flow of sebum. These dilated ducts abound with the colonies of Propionibacterium acnes and other fat splitting organisms. The clinically evident open and closed comedones and the microscopic microcomedo are the signal lesions of acne. The acne process results from a cascade of events.
  • Sebum is comedogenic and causes inflammation by itself.
  • the Propionibacterium has high lipolytic activity and liberates free fatty acids from sebum lipids, whereby the free fatty acids have been shown to cause marked inflammation.
  • microorganisms also produce other extracellular enzymes such as proteases and hyaluronidases, and chemotactic factors, which may be important in the inflammatory process. Aside from these factors, serum hormones, especially dehydroepiandrosterone sulfate, have been found to correlate with acne.
  • Acne treatments generally target the keratinous plugs in sebaceous ducts; large sebaceous glands producing excess sebum; increased numbers of resident follicular bacteria; and inflammatory response to chemical mediators passing through the follicular wall.
  • Most acne treatments are directed at preventing inflammatory lesions, particularly the larger nodulo- cystic lesions which tend to be destructive and lead to permanent scarring. In general, visible comedones are the only minor cosmetic nuisances and do not lead to inflammatory lesions.
  • Topical products used to remove comedones include tretinoin (Retin ATM), adapalene 0.1% (DifferinTM), sodium sulfacetamide 10% / sulfur 5% (Sulfacet-RTM), and salicylic acid 2%.
  • tretinoin Retin ATM
  • DifferinTM adapalene 0.1%
  • Sulfacet-RTM sodium sulfacetamide 10% / sulfur 5%
  • salicylic acid 2% Topical products used to remove comedones
  • a naturally occurring metabolite of Vitamin A, tretinoin or all-trans retinoic acid increases epidermal cell turnover and prevents the formation of new keratinous plugs.
  • Application of tretinoin is normally once nightly. Although tretinoin is the most effective comedolytic, dryness, stinging and redness may occur, and improvement takes 6-8 weeks.
  • Adapalene 0.1% is a topical retinoid-like tretinoin and is usually applied once nightly. Side effects include frequent scaling, burning, redness and dryness, and improvement takes 4-8 weeks. Sodium sulfacetamide 10% / sulfur 5% is both an antibacterial and comedolytic lotion, with improvement taking 4-8 weeks. Salicylic acid 2% exhibits mild activity.
  • isotretinoin (AccutaneTM), which is a metabolite of Vitamin A, is administered orally.
  • Isotretinoin has effective anti-sebum activity, but is teratogenic (causing birth defects), and hepatotoxic (elevating triglycerides and total cholesterol and decreasing high-density lipoproteins).
  • Other side effects include dry skin, dry eyes, itching, headaches, nosebleed, and photosensitivity. Improvement takes 4-5 months. Since estrogens also have anti-sebum activity, acne may also be treated with oral contraceptive pills.
  • Topical and/or oral antimicrobial agents may also be used to decrease bacteria that colonize the follicular duct.
  • Topical agents include benzoyl peroxide (BP), and BP 5% / erythromycin 3% (BenzamycinTM).
  • BP is often tried first for both non-inflammatory and mild inflammatory acne, but can produce erythema and peeling, and improvement takes 1-2 months.
  • Topical antibiotics include clindamycin and erythromycin, with improvements taking 1-2 months.
  • Azelaic acid 20% (AzelexTM) has mild antibacterial effects.
  • systemic antibiotics include tetracycline and its analogs (doxycycline and minocycline), which are used in low doses for years or until the end of the acne prone years. However, bacterial resistance may occur, such that the antibiotics need to be changed or substituted with BP.
  • Intralesional corticosteroids and topical nicotinamide have also been used to control a host's inflammatory response. There are no drugs that directly affect the inflammatory acne. The retinoids do have some anti-inflammatory properties, but these are poorly described. Topical steroid and even systemic steroids have been used to abort a severe flare of fulminant acne, but have undesirable side effects. Treatments for Inflammatory Skin Conditions
  • treatments for different inflammatory skin conditions typically include topical or oral steroids (e.g., for various types of eczema, acne, and erythema multiforme); ultraviolet light (e.g., for nummular eczema and mycosis fungoides); or other anti-inflammatory therapies.
  • topical or oral steroids e.g., for various types of eczema, acne, and erythema multiforme
  • ultraviolet light e.g., for nummular eczema and mycosis fungoides
  • treatments may be ineffective, provide only temporary relief, have deleterious side effects, or take months to treat.
  • no treatment is uniformly effective for nummular eczema or stasis eczema.
  • Current treatments for mycosis fungoides are only temporarily effective.
  • Oral steroids have significant side effects, such that the severity of the skin disease must be carefully assessed. While short term treatment (a few days or weeks) with oral steroids is relatively safe, long term treatment (more than 3 months) may cause undesirable side effects including Cushing's syndrome, skin thinning, and increased susceptibility to infection. Improvements may be delayed, such as with the various acne treatments lasting several months.
  • crystalline antimicrobial metals such as nanocrystalline silver, preferably formed with atomic disorder
  • antimicrobial metals such as silver, formed with atomic disorder
  • can alleviate erythema and edema which are characteristic symptoms of many inflammatory skin conditions.
  • This research has resulted in a new therapeutic treatment for acne, eczema, and other inflammatory skin conditions. In some inflammatory conditions, secondary infection by bacteria or other microbiological agents is a possibility.
  • the antimicrobial metal is silver, this new treatment will have dual advantages of both antimicrobial and anti-inflammatory effects, with fewer side effects and less chance of development of resistant bacteria.
  • antimicrobial metals selected from one or more of silver, gold, platinum and palladium, are effective in the treatment of inflammatory skin conditions. These antimicrobial metals are formed with atomic disorder, such that ions, clusters, atoms or molecules of the metals are released at a concentration sufficient to provide a localized antimicrobial and anti-inflammatory effect. Most preferably, the antimicrobial metals are in a nanocrystalline form, and include sufficient atomic disorder to provide an antimicrobial and anti-inflammatory effect on a sustainable basis.
  • the nanocrystalline antimicrobial metals formed with atomic disorder are capable of releasing highly active clusters of the antimicrobial metal (example clusters of Ag° or Ag + /Ag°), which are responsible for the surprisingly enhanced antimicrobial activity and the surprising presence of the anti- inflammatory activity in the treatment of inflammatory skin conditions, compared with other known antimicrobials such as silver salts (ex. silver nitrate), silver zeolites which release only Ag + , or silver metal and silver oxide which have only minor solubility.
  • Clusters are known to be small groups of atoms, ions or the like, as described by R. P. Andres et al., "Research Opportunities on Cluster and Cluster-Assembled Materials", J. Mater. Res. Vol 4, No 3, 1989, p. 704. For silver, clusters are believed to contain less than the 14 atoms of a normal face centered cubic crystal lattice form of silver.
  • the crystalline forms of these antimicrobial metals may be used in, or formulated from, any of the following formats: i) coatings of the antimicrobial metals on medical grade substrates, for example, dressings, meshes, films, fibres, containers, or vials, from materials composed of for example polyethylene, high density polyethylene, polyvinylchloride, latex, silicone, cotton, rayon, polyester, nylon, cellulose, acetate, carboxymethylcellulose, alginate, chitin, chitosan and hydrofibres; ii) powders, preferably prepared as nanocrystalline powders of the antimicrobial metals, or as nanocrystalline coatings of the antimicrobial metals on biocompatible substrates in powder form, preferably on bioabsorbable and/or hygroscopic substrates such as: Synthetic Bioabsorbable Polymers: for example polyesters/polyactones such as polymers of polyglycolic acid, glycolide, lactic acid, lactide, dioxanone, trimethylene
  • the antimicrobial metals lose some activity with aging and are thus either stabilized or generated fresh for administration.
  • the antimicrobial metals may be packaged for convenient solution generation, for instance in a pervious membrane such as a tea bag type infuser.
  • Other two part or two phase systems may be used in which the nanocrystalline metal is separated from the water or electrolyte solvent, for example in kit form, with the antimicrobial metal being provided in dissolving capsules, as a coating on the inside of vials or containers, on substrates such as dressing, separated by a membrane which can be perforated, or in a separate container from the carrier, in a tea bag-type infuser etc.
  • the nanocrystalline antimicrobial metals are formulated from nanocrystalline coatings or nanocrystalline powders of the nanocrystalline antimicrobial metals, or from solutions prepared by dissolving the nanocrystalline coatings or powders therein.
  • the formulations include a therapeutically effective amount of the coatings or powders, and most preferably, the following amounts:
  • Concentrations of the antimicrobial species in solution will vary according to the application, formulation and subject, but will generally range from 1 - 5000 g/ml, more preferably 20 - 3000 g/ml, more preferably 40 - 800 g/ml, and most preferably 50 - 500 ⁇ g/ml.
  • Nanocrystalline coatings of the antimicrobial metals are most preferably deposited onto substrates such as dressings, for example one or more layers of medical dressing materials which can be laminated with uncoated layers of medical dressing materials.
  • the coatings can be prepared by known techniques for preparing nanocrystalline coatings, but are most preferably prepared by physical vapour deposition under conditions which create atomic disorder.
  • the nanocrystalline coatings may be prepared to create an interference colour so as to provide an indicator, as described in prior patent application WO 98/41095, published September 24, 1998, and naming inventors R. E. Burrell and R. J. Precht.
  • Nanocrystalline powders of the antimicrobial metals may be prepared as nanocrystalline coatings, preferably of the above thickness, on powdered substrates such as chitin, or may be prepared as nanocrystalline coatings on a substrate such as a silicon wafer, and then scraped off as a nanocrystalline powder.
  • fine grained or nanocrystalline powders of the antimicrobial metals may be cold worked to impart atomic disorder, as taught in prior patent applications WO 93/23092, published November 25, 1993, and WO 95/13704, published May 26, 1995, both of which name Burrell et al, as inventors.
  • the invention broadly provides a method of reducing inflammation of an inflammatory skin condition which comprises: contacting a problem area of a patient, with a therapeutically effective amount of the antimicrobial metals in a crystalline form to provide a localized anti-inflammatory effect, wherein the antimicrobial metals are characterized by sufficient atomic disorder, such that the metal, in contact with an alcohol or water-based electrolyte, releases atoms, ions, molecules, or clusters of at least one antimicrobial metal at a concentration sufficient to provide a localized anti-inflammatory and antimicrobial effect.
  • the antimicrobial metal is nanocrystalline and is formed with sufficient atomic disorder such that, in contact with an alcohol or water based electrolyte, the antimicrobial metal releases ions, atoms, molecules or clusters of the antimicrobial metal on a sustainable basis.
  • the antimicrobial metal is selected from the group consisting of silver, gold, platinum and palladium, but preferably is nanocrystalline silver or silver, formed as a composite with oxygen.
  • a method of reducing inflammation of an inflammatory skin condition which comprises: applying a hydrated dressing to contact a problem area of a patient, wherein the hydrated dressing i includes a therapeutically effective amount of one or more antimicrobial metals in a crystalline form to provide a localized antimicrobial and anti-inflammatory effect; or ii occludes a pharmaceutical composition of a nanocrystalline powder of the one or more antimicrobial metals, or a solution containing dissolved species from a nanocrystalline powder or coating of the one or more antimicrobial metals.
  • the invention provides a hydrated dressing for use in reduction of inflammation of an inflammatory skin condition comprising a hydrated dressing, and associated with the dressing, a therapeutically effective amount of one or more antimicrobial metals in a crystalline form to provide localized anti-inflammatory and antimicrobial effects.
  • the invention provides a kit for reducing inflammation of an inflammatory skin condition comprising one or more antimicrobial metals formed with atomic disorder; and one or more pharmaceutically acceptable carriers.
  • Metal or “metals” includes one or more metals whether in the form of substantially pure metals, alloys or compounds such as oxides, nitrides, borides, sulphides, halides or hydrides.
  • Antimicrobial metals are silver, gold, platinum, palladium, iridium, zinc, copper, tin, antimony, bismuth, or mixtures of these metals with same or other metals, silver, gold, platinum and palladium being preferred, and silver being most preferred.
  • Noble metals are silver, gold, platinum and palladium, or mixtures of such metals with same or other metals, with silver metal being the most preferred.
  • Antimicrobial effect means that atoms, ions, molecules or clusters of the antimicrobial or noble metal are released into the electrolyte which the coating contacts in concentration sufficient to inhibit microbial growth on and in the vicinity of the coating.
  • the most common methods of measuring an antimicrobial effect are a zone of inhibition test (which indicates an inhibitory effect, whether microbiostatic or microbiocidal) or a logarithmic reduction test (which indicates a microbiocidal effect).
  • ZOI zone of inhibition test
  • the material to be tested is placed on a bacterial lawn (or a lawn of other microbial species) and incubated. A relatively small or no ZOI (ex.
  • a logarithmic reduction test in viable bacteria is a quantitative measure of the efficacy of an antibacterial treatment; for example, a 5 log reduction means a reduction in the number of microorganisms by 100,000-fold (e.g., if a product contained 100,000 pertinent microorganisms, a 5 log reduction would reduce the number of pertinent microorganisms to 1). Generally, a 3 log reduction represents a bactericidal effect.
  • the logarithmic reduction test involves combining the inoculum with the test treatment, incubating the inoculum with the test treatment, recovering the bacteria or other microbial species, and enumerating the bacteria or other microbial species using serial dilutions. Examples of these tests are set out in the examples which follow.
  • Anti-inflammatory effect means a reduction in one ore more of the symptoms of erythema (redness), edema (swelling), pain and pruritus which are characteristic of inflammatory skin conditions.
  • Inflammatory skin conditions refers to those conditions of the skin in which inflammatory cells (e.g., polymorphonuclear neutrophils and lymphocytes) infiltrate the skin with no overt or known infectious etiology, but excluding psoriasis and its related conditions. Symptoms of inflammatory skin conditions generally include erythema (redness), edema (swelling), pain, pruritus, increased surface temperature and loss of function.
  • inflammatory cells e.g., polymorphonuclear neutrophils and lymphocytes
  • Symptoms of inflammatory skin conditions generally include erythema (redness), edema (swelling), pain, pruritus, increased surface temperature and loss of function.
  • inflammatory skin conditions include, but are not limited to, eczema and related conditions, insect bites, erythroderma, mycosis fungoides and related conditions, pyoderma gangrenosum, erythema multiforme, rosacea, onychomycosis, and acne and related conditions, but excluding psoriasis and its related conditions.
  • Biocompatible means generating no significant undesirable host response for the intended utility. Most preferably, biocompatible materials are non-toxic for the intended utility. Thus, for human utility, biocompatible is most preferably non-toxic to humans or human tissues.
  • sustained release or “sustainable basis” are used to define release of atoms, molecules, ions or clusters of an antimicrobial metal that continues over time measured in hours or days, and thus distinguishes release of such metal species from the bulk metal, which release such species at a rate and concentration which is too low to be therapeutically effective, and from highly soluble salts of antimicrobial metals such as silver nitrate, which releases silver ions virtually instantly, but not continuously, in contact with an alcohol or electrolyte.
  • Atomic disorder includes high concentrations of one or more of: point defects in a crystal lattice, vacancies, line defects such as dislocations, interstitial atoms, amorphous regions, grain and sub grain boundaries and the like relative to its normal ordered crystalline state.
  • Atomic disorder leads to irregularities in surface topography and inhomogeneities in the structure on a nanometer scale.
  • Normal ordered crystalline state means the crystallinity normally found in bulk metal materials, alloys or compounds formed as cast, wrought or plated metal products. Such materials contain only low concentrations of such atomic defects as vacancies, grain boundaries and dislocations.
  • “Diffusion”, when used to describe condition ' s which limit diffusion in processes to create and retain atomic disorder, i.e. which freeze-in atomic disorder, means diffusion of atoms (adatom diffusion) and/or molecules on the surface or in the matrix of the material being formed.
  • Alcohol or water-based electrolyte is meant to include any alcohol or water-based electrolyte that the antimicrobial materials of the present invention might contact in order to activate (i.e. cause the release of species of the antimicrobial metal) into same.
  • the term is meant to include alcohols (short chain (C 6 or less) and preferably C 4 or less), water, gels, fluids, solvents, and tissues containing, secreting, or exuding water or water-based electrolytes, including body fluids (for example blood, urine, or saliva), and body tissue (for example skin).
  • Bioabsorbable as used herein in association includes substrates which are useful in medical devices, that is which are biocompatible, and which are capable of bioabsorption in period of time ranging from hours to years, depending on the particular application.
  • Bioabsorption means the disappearance of materials from their initial application site in the body (human or mammalian) with or without degradation of the dispersed polymer molecules.
  • Cold change is meant to include changes of intensity of light under monochromatic light as well as changes of hue from white light containing more than one wavelength.
  • An “interference colour” is produced when light impinges on two or more partly reflective surfaces separated by a distance which bears the right relationship to the wavelength of the light to be removed by destructive interference.
  • Partly reflective when used to describe the base or top layer materials, means that the material has a surface which reflects a portion of incident light, but which also transmits a portion of the incident light. Reflection occurs when a ray of incoming light encounters a boundary or interface characterized by a change in refractive index between two media.
  • That interface is with air.
  • the interface is with the top layer. The reflectance of the base and top layers is balanced so as to generate an interference colour.
  • Partly light transmissive when used to describe a thin film of the top layer material means that the thin film is capable of transmitting at least a portion of incident visible light through the thin film.
  • Detectable when used to describe a colour change means an observable shift in the dominant wavelength of the reflected light, whether the change is detected by instrument, such as a spectrophotometer, or by the human eye.
  • the dominant wavelength is the wavelength responsible for the colour being observed.
  • Cold working indicates that the material has been mechanically worked such as by milling, grinding, hammering, mortar and pestle or compressing, at temperatures lower than the recrystallization temperature of the material. This ensures that atomic disorder imparted through working is retained in the material.
  • “Pharmaceutically- or therapeutically-acceptable” is used herein to denote a substance which does not significantly interfere with the effectiveness or the biological activity of the active ingredients (antimicrobial and anti-inflammatory activities) and which has an acceptable toxic profile for the host to which it is administered.
  • “Therapeutically effective amount” is used herein to denote any amount of a formulation of the antimicrobial or noble metals which will exhibit either or both of an antimicrobial and optionally an anti-inflammatory effect, when applied to the affected area of the skin.
  • a single application of the formulations of the present invention may be sufficient, or the formulations may be applied repeatedly over a period of time, such as several times a day for a period of days or weeks.
  • the amount of the active ingredient, that is the antimicrobial or noble metal in the form of a coating, powder or dissolved in liquid solution will vary with the conditions being treated, the stage of advancement of the condition, the age and type of host, and the type and concentration of the formulation being applied. Appropriate amounts in any given instance will be readily apparent to those skilled in the art or capable of determination by routine experimentation.
  • Carrier means a suitable vehicle including one or more solid, semisolid or liquid diluents, excipients or encapsulating substances which are suitable for administration to the skin.
  • “Nanocrystalline” is used herein to denote single-phase or multi-phase polycrystals, the grain size of which is less than about 100, more preferably ⁇ 50, even more preferably ⁇ 40, even more preferably ⁇ 30, and most preferably ⁇ 25 nanometers in at least one dimension.
  • the term, as applied to the crystallite or grain size in the crystal lattice of coatings, powders or flakes of the antimicrobial or noble metals, is not meant to restrict the particle size of the materials when used in a powder form.
  • Powder is used herein to include particulates of the antimicrobial or noble metals ranging from nanocrystalline (less than 100 nm) to submicron sized powders up to flakes.
  • powders of the antimicrobial or noble metals used in the present invention are sized at less than 100 ⁇ m, and more preferably less than 40 ⁇ m., and most preferably less than 10 ⁇ m.
  • Gram size or “crystallite size” means the size of the largest dimension of the crystals in the antimicrobial metal coating or powder.
  • Hydrocolloid means a synthetically prepared or naturally occurring polymer capable of forming a thickened gel in the presence of water and polyols (swelling agent).
  • the swelling agent must be capable of swelling the hydrocolloid chosen in order to form the gel phase.
  • Hydrocolloid means a hydrocolloid swollen with water or another hydrophilic liquid which is used for absorbing or retaining moisture or water.
  • Gel means a composition that is of suitable viscosity for such purposes, e.g., a composition that is of a viscosity that enables it to be applied and remain on the skin.
  • nanocrystalline antimicrobial metal and similar terminology, such as “nanocrystalline coatings or powders” is meant to refer to antimicrobial metals formed with atomic disorder and having a nanocrystalline grain size.
  • Figure 1 is a graph showing the efficacy of the nanocrystalline silver powder compared to ProtopicTM or tacrolimus (non-steroidal anti-inflammatory), EloconTM (medium strength steroid) and UltravateTM (high strength steroid), on erythema.
  • Figure 2 is a graph showing the efficacy of the nanocrystalline silver powder compared to ProtopicTM or tacrolimus (non-steroidal anti-inflammatory), EloconTM (medium strength steroid) and UltravateTM (high strength steroid), on edema. DESCRIPTION OF THE PREFERRED EMBODIMENTS
  • Crystalline forms of the antimicrobial metals can be prepared as coatings or powders, or as solutions prepared by dissolving the coatings or powders.
  • the crystalline coatings or powders are most preferably formed with atomic disorder in accordance with the techniques published in the prior patent applications of Burrell et at, see for example WO 93/23092, published November 25, 1993, WO 95/13704, published May 26, 1995 and WO 98/41095, published September 24, 1998.
  • compositions for treatment of inflammatory skin conditions utilize the antimicrobial metals in powder, coatings or solution form.
  • Preparation of the antimicrobial metals as powders or coatings is set out below in section A, format for formulations are set forth in section B, sterilization in section C, and formulating, dosages and treatment are set forth in section D.
  • Dressings or other substrates such as packings, vials, fabric, fibres etc. may be coated with antimicrobial coatings formed with atomic disorder.
  • the description below is directed to coatings on dressing materials, but the coating techniques are equally applicable to coating other substrates.
  • Dressings coated with antimicrobial metals in accordance with the invention include one or more layers of medical dressing materials. Multiple layers may be laminated together by known means such as low temperature thermal fusing, stitching or, most preferably, ultrasonic welding.
  • the dressing may be formed to include an occlusive or semi-occlusive layer such as an adhesive tape or polyurethane film in order to secure the dressing in place, and retain moisture for release of ions, atoms, molecules or clusters of the antimicrobial metal (hereinafter antimicrobial metal species).
  • an occlusive or semi-occlusive layer such as an adhesive tape or polyurethane film in order to secure the dressing in place, and retain moisture for release of ions, atoms, molecules or clusters of the antimicrobial metal (hereinafter antimicrobial metal species).
  • the dressing is formed of a perforated, preferably non-adherent material which allows for fluids to penetrate or diffuse there through in either or both directions.
  • the perforated material may be formed of a woven or non-woven, non-woven being preferred, fabric such as cotton, gauze, a polymeric net or mesh such as polyethylene, nylon, polypropylene or polyester, an elastomer such as polyurethane or polybutadiene elastomers, or a foam such as open cell polyurethane foam.
  • Exemplary perforated, non-adherent materials useful for the dressing include non-woven meshes such as DELNETTM P530, which is a non-woven veil formed of high density polyethylene using extrusion, embossing and orientation processes, produced by Applied Extrusion Technologies, Inc. of Middletown, Delaware, USA. This same product is available as Exu-Dry CONFORMANT 2TM Wound Veil, from Frass Survival Systems, Inc., Bronx, New York, USA as a subset of that company's Wound Dressing Roll (Non- Adherent) products.
  • DELNETTM P530 is a non-woven veil formed of high density polyethylene using extrusion, embossing and orientation processes, produced by Applied Extrusion Technologies, Inc. of Middletown, Delaware, USA.
  • This same product is available as Exu-Dry CONFORMANT 2TM Wound Veil, from Frass Survival Systems, Inc., Bronx, New York, USA as a subset of that company's Wound Dress
  • non- woven meshes include CARELLETM or NYLON 90TM, available from Carolina Formed Fabrics Corp., N-TERFACETM, available from Winfield Laboratories, Inc., of Richardson, Texas, USA.
  • Exemplary woven meshes may be formed from fibreglass or acetate, or cotton gauze.
  • An exemplary hydrophilic polyurethane foam is HYPOLTM, available from W.R. Grace & Co., New York, NY, USA.
  • At least one dressing layer is preferably formed from a polymeric material which is amenable to ultrasonic welding, that is which will melt on the application of localized heat and then fuse multiple layers together on cooling.
  • a second, absorbent layer is formed from an absorbent material for holding sufficient moisture next to the skin in order to activate the antimicrobial metal coating, that is to cause release of ions, molecules, atoms or clusters of the antimicrobial metal in order to cause an antimicrobial and anti-inflammatory effect.
  • the absorbent material is an absorbent needle punched non-woven rayon/polyester core such as SONTARATM 8411, a 70/30 rayon polyester blend commercially available from Dupont Canada, Mississauga, Ontario, Canada. This product is sold by National Patent Medical as an American White Cross sterile gauze pad.
  • absorbent materials include woven or non- woven materials, non-woven being preferred made from fibers such as rayon, polyester, rayon/polyester, polyester/cotton, cotton and cellulosic fibers.
  • woven or non-woven materials non-woven being preferred made from fibers such as rayon, polyester, rayon/polyester, polyester/cotton, cotton and cellulosic fibers.
  • Exemplary are creped cellulose wadding, an air felt of air laid pulp fibers, cotton, gauze, and other well known absorbent materials suitable for medical dressings.
  • a third layer of the dressing is preferably formed of perforated, non-adherent material such as used in the first layer. This allows moisture penetration as sterile water and the like are added in order to activate the antimicrobial metal coating. Additional layers may be included between or above the first, second and third layers as is well known in medical dressings.
  • the coated dressing layers may be combined with an adhesive layer, in a well known manner.
  • the dressing may be used as a single layer, or may be used as multiple layers laminated together at intermittent spaced locations across the dressing by ultrasonic welds.
  • Ultrasonic welding is a known technique in the quilting art. Briefly, heat (generated ultrasonically) and pressure are applied to either side of the dressing at localized spots through an ultrasonic horn so as to cause flowing of at least one of the plastic materials in the first and second layers and the subsequent bonding together of the layers on cooling.
  • the welds appear at localized circular spots and are preferably less than 0.5 cm in diameter.
  • the use of ultrasonic welding of the layers at spaced locations has the advantage of retaining the absorbent and moisture penetration properties of the dressing layers, while retaining the conforming properties of the dressing. Edge seams, stitching and adhesives have the disadvantage of interfering with one or more of these desirable properties of the dressings.
  • the dressing may be cut to smaller sizes, as needed, without causing delamination. Preferred spacings of about 2.5 cm between welds allows the dressing to be cut down to about 2.5 cm sizes, while maintaining at least one weld to hold the laminated layers together, ii) Nanocrystalline Coatings of Antimicrobial Metals
  • the coated substrate for example a dressing, preferably includes a nanocrystalline coating of one or more of the antimicrobial metals.
  • the coating is applied to one or more of the dressing layers, but is most preferably applied at least to the skin facing layer.
  • the nanocrystalline coating is most preferably formed with atomic disorder in accordance with the procedures set out above and as described in WO 93/23092, WO 95/13704, and WO98/41095, and as set out below.
  • the coating is formed as a multilayer coating of the antimicrobial metals, having a top and a base layer, as set below, to produce an interference colour.
  • the coating provides not only the active ingredient for the treatment of inflammatory skin conditions, but also acts as an indicator of activation of the dressing.
  • an alcohol or water-based electrolyte such as sterile water or ethanol, even minor dissolution of the antimicrobial metal results in a detectable colour change, indicating that the coating has been activated.
  • the coated substrates for example dressings may include the antimicrobial metal coating formed with at least two metal layers, a base layer and a top layer over the base layer, so as to produce an interference colour, as set forth in WO 98/41095, the teachings of which are incorporated herewith by reference.
  • the indicator colour can function as an indicator when contacted with a water or alcohol based electrolyte, since the coating will change colour.
  • An exemplary multilayer nanocrystalline coating of silver with a blue interference colour is set forth in Example 1.
  • the coatings of the present invention are formed in a crystalline form from one or more antimicrobial metals with atomic disorder.
  • the production of atomic disorder through physical vapour deposition techniques is described in WO 93/23092 and WO 95/13704, and as outlined below.
  • the antimicrobial metal is deposited as a thin metallic film on one or more surfaces of the dressing by vapour deposition techniques.
  • Physical vapour techniques which are well known in the art, all deposit the metal from the vapour, generally atom by atom, onto a substrate surface.
  • the techniques include vacuum or arc evaporation, sputtering, magnetron sputtering and ion plating.
  • the deposition is conducted in a manner to create atomic disorder in the coating as defined above.
  • Various conditions responsible for producing atomic disorder are useful. These conditions are generally those which one has been taught to avoid in thin film deposition techniques, since the object of most thin film depositions is to create a defect free, smooth and dense film (see for example J.A. Thornton, "Influence of Apparatus Geometry and Deposition Conditions on the Structure and Topography of Thick Sputtered Coatings," J. Vac. Sci. Technol., 11(4), 666-670, 1974).
  • the preferred conditions which are used to create atomic disorder during the deposition process include:
  • a low substrate temperature that is maintaining the surface to be coated at a temperature such that the ratio of the substrate temperature to the melting point of the metal (in degrees Kelvin) is less than about 0.5, more preferably less than about 0.35 and most preferably less than about 0.3; and optionally one or both of:
  • a higher than normal working gas pressure i.e. for vacuum evaporation: e-beam or arc evaporation, greater than 0.001 Pa (0.01 mT), gas scattering evaporation (pressure plating) or reactive arc evaporation, greater than 2.67 Pa (20 mT); for sputtering: greater than 10 Pa (75 mT); for magnetron sputtering: greater than about 1.33 Pa (10 mT); and for ion plating: greater than about 26.67 Pa (200 mT); and
  • the thin metal film has a thickness no greater than that needed to provide release of antimicrobial metal species on a sustainable basis over a suitable period of time, and to generate the desired interference colour.
  • the thickness will vary with the particular metal in the coating (which varies the solubility and abrasion resistance), and with the degree of atomic disorder in (and thus the solubility of) the coating. The thickness will be thin enough that the coating does not interfere with the dimensional tolerances or flexibility of the device for its intended utility.
  • the therapeutic effect of the material so produced is achieved when the coating is brought into contact with an alcohol or a water based electrolyte, thus releasing metal ions, atoms, molecules or clusters.
  • concentration of the metal species which is needed to produce a therapeutic effect will vary from metal to metal.
  • the ability to achieve release of metal atoms, ions, molecules or clusters on a sustainable basis from a coating is dictated by a number of factors, including coating characteristics such as composition, structure, solubility and thickness, and the nature of the environment in which the device is used. As the level of atomic disorder is increased, the amount of metal species released per unit time increases. For instance, a silver metal film deposited by magnetron sputtering at T/Tm ⁇ 0.5 and a working gas pressure of about 0.93 Pa (7 mT) releases approximately 1/3 of the silver ions that a film deposited under similar conditions, but at 4 Pa (30 mT), will release over 10 days. Films that are created with an intermediate structure (ex.
  • the time required for total dissolution will be a function of film thickness and the nature of the environment to which they are exposed.
  • the relationship in respect of thickness is approximately linear, i.e. a two fold increase in film thickness will result in about a two fold increase in longevity.
  • a coating deposited by magnetron sputtering such that the working gas pressure was low (ex. 2 Pa or 15 mT) for 50% of the deposition time and high (ex. 4 Pa or 30 mTorr) for the remaining time, has a rapid initial release of metal ions, followed by a longer period of slow release.
  • This type of coating is extremely effective on devices such as urinary catheters for which an initial rapid release is required to achieve immediate antimicrobial concentrations followed by a lower release rate to sustain the concentration of metal ions over a period of weeks.
  • the substrate temperature used during vapour deposition should not be so low that annealing or recrystallization of the coating takes place as the coating warms to ambient temperatures or the temperatures at which it is to be used (ex. body temperature).
  • This allowable ⁇ T that the temperature differential between the substrate temperature during deposition and the ultimate temperature of use, will vary from metal to metal.
  • metal For the most preferred metal, Ag, preferred substrate temperatures of -20 to 200°C , more preferably -10°C to 100°C are used.
  • Atomic order may also be achieved, in either or both of the base and top layers by preparing composite metal materials, that is materials which contain one or more antimicrobial metals in a metal matrix which includes atoms or molecules different from the antimicrobial metals.
  • the preferred technique for preparing a composite material is to co- or sequentially deposit the antimicrobial metal(s) with one or more other inert, biocompatible metals selected from Ta, Ti, Nb, Zn, V, Hf, Mo, Si, Al and alloys of these metals or other metal elements, typically other transition metals.
  • inert metals have a different atomic radii from that of the antimicrobial metals, which results in atomic disorder during deposition. Alloys of this kind can also serve to reduce atomic diffusion and thus stabilize the disordered structure.
  • Thin film deposition equipment with multiple targets for the placement of each of the antimicrobial and biocompatible metals is preferably utilized.
  • the layer(s) of the biocompatible metal(s) should be discontinuous, for example as islands within the antimicrobial metal matrix.
  • the final weight ratio of the antimicrobial metal(s) to biocompatible metal(s) should be greater than about 0.2.
  • the most preferable biocompatible metals are Ti, Ta, Zn and Nb. It is also possible to form the antimicrobial coating from oxides, carbides, nitrides, sulphides, borides, halides or hydrides of one or more of the antimicrobial metals and/or one or more of the biocompatible metals to achieve the desired atomic disorder.
  • Another composite material may be formed by reactively co- or sequentially depositing, by physical vapour techniques, a reacted material into the thin film of the antimicrobial metal(s).
  • the reacted material is an oxide, nitride, carbide, boride, sulphide, hydride or halide of the antimicrobial and/or biocompatible metal, formed in situ by injecting the appropriate reactants, or gases containing same, (ex. air, oxygen, water, nitrogen, hydrogen, boron, sulphur, halogens) into the deposition chamber. Atoms or molecules of these gases may also become absorbed or trapped in the metal film to create atomic disorder.
  • the reactant may be continuously supplied during deposition for codeposition or it may be pulsed to provide for sequential deposition.
  • the final weight ratio of reaction product to antimicrobial metal(s) should be greater than about 0.05. Air, oxygen, nitrogen and hydrogen are particularly preferred reactants, with oxygen being most preferred.
  • the above deposition techniques to prepare composite coatings may be used with or without the conditions of lower substrate temperatures, high working gas pressures and low angles of incidence previously discussed. One or more of these conditions are preferred to retain and enhance the amount of atomic disorder created in the coating.
  • the most preferred composite coatings are formed by sputtering silver, under conditions set out above, in an atmosphere containing oxygen, so as to form a coating of silver as a composite coating with oxygen.
  • Dressings coated with the antimicrobial coatings of this invention may be sterilized in the manner set out below. b) Powders of Atomically Disordered Antimicrobial Metals
  • Crystalline powder forms of the antimicrobial or noble metals can be prepared as free standing powders, by coating powdered substrates, or from coatings on substrates which are then collected, for example by scaping and then sized.
  • the powders may be prepared as pure metals, metal alloys or compounds such as metal oxides or metal salts, by vapour deposition, mechanical working, or compressing to impart the atomic disorder.
  • the crystalline powders are formed with atomic disorder in accordance with the techniques set out above and as published in the prior patent applications of Burrell et al., see for example WO 93/23092, published November 25, 1993, and WO 95/13704, published May 26, 1995.
  • the atomic disorder will most typically be formed in the metal powders during physical vapour deposition as set out above for coatings or by mechanically imparting the disorder, such as by milling, grinding, hammering, mortar and pestle or compressing, under conditions of low temperature (i.e., temperatures less than the temperature of recrystallization of the material) to ensure that annealing or recyrstallization does not take place.
  • the powders may be formed by inert-gas condensation techniques, which are modified to provide atomic disorder in the powder produced, as taught in WO 95/13704 to Burrell et al.
  • Powders of the antimicrobial or noble metals are preferably formed by physical vapour deposition (PVD) onto a substrate such as a cold finger, a silicon wafer, solid plates, a rotating cylinder, a continuous belt in a roll coater, or on steel collectors in known PVD coaters.
  • PVD physical vapour deposition
  • Preparation of powders of the present invention by sputtering onto a continuous belt in a roll coater, or other some other moving or rotating substrate surface is particularly advantageous, inasmuch as it can quickly and easily yield a relatively large supply of free-standing powder at a relatively low cost.
  • a stainless steel belt can be used in the roll coating process without the need to provide additional cooling of the substrate.
  • the powders or coatings and then are then scraped off to form a powder, and may be sized to avoid overly large particulates.
  • the powders are scraped off the moving surface with scrapers which contact the moving surface at an angle sufficient to remove the coating in flake or powder form.
  • the coating may be scraped off with scrapers angled for forward cutting of the coating from the moving surface, or with scrapers which remove the coating from the moving surface by reverse dragging action on the surface.
  • the scrapers may be suspended above the belt, and either weighted or spring loaded to apply pressure sufficient to remove the coating from the moving surface. With a continuous belt, the scrapers can conveniently be located above the end rollers to remove the coating with a reverse dragging action as the belt rounds the end roller.
  • the powders of the antimicrobial or noble metals may be formed on powdered substrates which are biocompatible, or otherwise compatible for the end use of the powder.
  • powdered substrates are hydrocolloids, particularly those which are bioabsorbable and/or hygroscopic powders such as chitin.
  • Exemplary bioabsorbable and/or hygroscopic powders are composed of :
  • Synthetic Bioabsorbable Polymers for example polyesters/polyactones such as polymers of polyglycolic acid, glycolide, lactic acid, lactide, dioxanone, trimethylene carbonate etc., polyanhydrides, polyesteramides, polyortheoesters, polyphosphazenes, and copolymers of these and related polymers or monomers.
  • Naturally Derived Polymers Proteins: albumin, fibrin, collagen, elastin; Polysaccharides: chitosan, alginates, hyaluronic acid; and Biosynthetic Polyesters: 3-hydroxybutyrate polymers.
  • the powders may be incorporated into or onto medical dressings or pharmaceutical formulations, by any methods known in the art.
  • the powders may be layered onto the substrates (dressings or powders), mechanically fixed within the fibres of the dressings, impregnated into dressings by physical blowing, or added to topical pharmaceutical ingredients.
  • powders of the present invention are sized at less than 100 ⁇ m, and more preferably less than 40 ⁇ m, and most preferably about 3 - 5 ⁇ m in size.
  • powders are preferably sized less than 2 ⁇ m, and more preferably less than 1 ⁇ m.
  • Coated substrates coated with antimicrobial metals formed with atomic disorder are well described above. These techniques can be used to coat dressings, meshes, films, packing fibres, the insides of vials or containers etc.
  • the coated substrates in the form of dressings for example, can be used directly on the affected area of the skin, or they can be used to generate powders, liquid or other formulations as set out below.
  • Powders of the antimicrobial metals formed with atomic disorder are set out above, and may be used in that form directly on the affected area of the skin, or in other formulations such as dressings, occlusions, creams, liquids etc.
  • powders may be formulated within liquid pervious membranes such as filters, meshes and the like, such as a tea bag-type infuser, for generating liquids containing dissolved species of the antimicrobial metal.
  • Occlusions may include a hydrated dressing, with a sealing material overlaid on the outside, to the area of skin to be treated.
  • the term hydrated dressing is meant to include non-hydrated dressings which become hydrated upon contact with an alcohol or water-based electrolyte. Occlusion prevents loss of the therapeutic agent from the skin, promotes skin hydration, and increases skin temperature.
  • Examples of hydrated dressings include hydrocolloids, hydrogels, polyethylene, polyurethane, polyvinylidine, and siloxane or silicone dressings.
  • a hydrated dressing may also comprise a non-hydrated dressing which becomes hydrated upon contact with an alcohol or water-based electrolyte.
  • the hydrated dressing can either be impregnated with a solution or powder of the antimicrobial metals of this invention, or can be used with a topical formulation of the antimicrobial metals of this invention.
  • An exemplary occlusion is a hydrocolloid dressing impregnated with nanocrystalline silver.
  • a non-impregnated hydrocolloid dressing to occlude a nanocrystalline silver-containing gel placed on a problematic area of the skin.
  • a hydrocolloid is a synthetically prepared or naturally occurring polymer capable of forming a thickened gel in the presence of water and polyols (swelling agent).
  • the swelling agent is a hydrophilic liquid capable of swelling the hydrocolloid chosen in order to form the gel phase.
  • the hydrocolloid may be selected from the group comprising: i representative natural or synthetically modified polysaccharides (e.g., cellulose or its derivatives such as carboxymethylcellulose, hydroxypropylcellulose, methylcellulose, hydroxypropylmethylcellulose or hydroxyethylcellulose, starch, glycogen, gelatin, pectin, chitosan and chitin; and ii representative gums from algal extracts, seed extracts, or plant exudates (e.g., gum arabic, locust bean gum, karaya gum, gum tragacanth, ghatti gum, agar-agar, carrageenans, alginates, carob gum, guar gum, xanthan gum); and iii synthetic polymers which may be either linear or crosslinked (e.g.
  • i representative natural or synthetically modified polysaccharides e.g., cellulose or its derivatives such as carboxymethylcellulose, hydroxypropylcellulose, methylcellulose,
  • polymers prepared from N-vinyl lactams e.g. N-vinyl-2-pyrrolidone, 5-methyl-N-vinyl-2-pyrrolidone).
  • the hydrocolloid is present in an amount of from about 0.1% to 20% of the weight and preferably 1% to 10%.
  • the hydrocolloid can range for example, from 1 to 10% of the total weight of the composition.
  • the hydrocolloid may be in the form of a powder whose average particle size is less than 100 ⁇ m, preferably less than 50 ⁇ m.
  • the swelling agent should be non-volatile, and allow the gel to remain as a gel during use, hence preserving the swollen condition of the hydrocolloid.
  • non- volatile swelling agents include room temperature liquid polyols (including polyhydric alcohols) such as glycerol; room temperature solid polyols (including polyhydric alcohols) such as sorbitol, erytbritol, threitol, ribotol, arabinitol, xylitol, allitol, talitol, mannitol, glucitol, glactitol, iditol, pentaerythritol, heptitol, octitol, nonitol, decitol, and dodecitol, blended with a room temperature liquid polyol; monoanhydroalditols (such as styracitol, polyalitol, D-fructose, 1,4 an
  • Hydrocolloid dressings often comprise a wafer constructed from a thin layer of polyurethane film with an adhesive skin contact layer containing a hydrocolloid composition and securing the dressing to the skin, and the polyurethane film being impermeable to water and microorganisms.
  • Hydrocolloid dressings may be prepared by dispersing a composition in gel form of hydrocolloids with a swelling agent into a strong pressure sensitive adhesive.
  • the gel and the adhesive may be mixed in a latex solution.
  • exemplary products are available commercially, for example DuoDERMTM (ConvaTec Canada, 555, Dr.
  • the hydrocolloid dressing may be impregnated with a solution or powder of the antimicrobial metals by blending the solution or powder of the antimicrobial metal into a liquid phase during the manufacture of the hydrocolloid dressing, or by sprinkling and then pressing a powder of the antimicrobial metal into the surface of the hydrocolloid dressing. Further, the hydrocolloid dressing can be used with a topical formulation of the antimicrobial metals of this invention. Upon application, the dressing surface gels upon continued contact with moisture or exudate from the skin.
  • the dressing With the incorporation of an antimicrobial metal such as silver (0.01-10%, preferably 0.1-1% by weight), the dressing is advantageous in being impermeable to water and microorganisms, and presenting antimicrobial and anti-inflammatory effects as mediated by the antimicrobial metal.
  • an antimicrobial metal such as silver (0.01-10%, preferably 0.1-1% by weight
  • Gels - Nanocrystalline gels may be formed from the nanocrystalline metal powder in admixture with gelling agents such as hydrocolloids and hydrogels in powder form.
  • Exemplary gelling agents include carboxymethyl cellulose (CMC), polyvinyl alcohol (PVA), collagen, pectin, gelatin, agarose, chitin, chitosan, and alginate, with the gelling agent comprising between about 0.01 . 20 % w/v.
  • Examples of gel preparations are set out in Example 11.
  • Example 12 demonstrates the use of a nanocrystalline silver gel preparation as set forth in Example 11, with a non-impregnated hydrocolloid dressing to occlude the nanocrystalline silver gel placed on a problematic area of the skin.
  • the antimicrobial metals may be incorporated into creams, lotions, pastes, ointments or foams formulated with nanocrystalline powders or solutions of the antimicrobial metals, for example as emulsions or with drying emollients.
  • Ointments and creams can be formulated with an aqueous or oily base with the addition of suitable thickening and/or gelling agents.
  • bases may include water and/or an oil such as liquid paraffin or a vegetable oil such as peanut oil or castor oil.
  • An exemplary base is water.
  • Thickening agents which can be used according to the nature of the base include aluminum stearate, hydrogenated lanolin, and the like.
  • lotions can be formulated with an aqueous base and will, in general, also include one or more of the following: stabilizing agents, emulsifying agents, dispersing agents, suspending agents, thickening agents, coloring agents, perfumes, and the like.
  • Ointments and creams can also contain excipients, such as starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, and talc, or mixtures thereof.
  • Lotions may be formulated with an aqueous or oily base and will, in general, also include one or more of the following: stabilizing agents, emulsifying agents, dispersing agents, suspending agents, thickening agents, coloring agents, perfumes, and the like.
  • Foams may be formed with known foaming or surface active agents.
  • Liquids - The crystalline forms of the antimicrobial metals may be incorporated into liquids, formulated as solutions, dispersions or suspensions by dissolving nanocrystalline coatings or powders of the antimicrobial metals, for example as topical solutions, aerosols, mists, sprays, or drops.
  • Topical administration of the antimicrobial metal to the skin may be performed by aerosol, which can be generated by a nebulizer, or by instillation.
  • the antimicrobial metal may be administered alone, or with a carrier such as saline solution, an alcohol, water, or DMSO.
  • An effective daily amount of the antimicrobial metal will vary with the subject, but will be less than is toxic while still providing a therapeutic effect.
  • Solutions and formulations of the antimicrobial metals may lose some activity with aging and are thus either stabilized or generated fresh for administration.
  • the antimicrobial metals may be packaged for convenient solution generation, for instance as tea bag type infusers.
  • Other two part or two phase systems may be used in which the nanocrystalline metal is separated from the water or alcohol-based electrolyte, for example in a multicomponent kit form, as set out herein.
  • Concentrations of the antimicrobial metal species in solution will vary according to the application, formulation and subject, but will generally range from 1 - 5000 ⁇ g/ml, more preferably 20 - 3000 ⁇ g/ml, more preferably 40 - 800 ⁇ g/ml, and most preferably 50 - 500 ⁇ g/ml. Methods of generating liquids with appropriate concentrations of the antimicrobial metal through pH control are set out below. 7. Transdermal Patch
  • Transdermal patches may provide controlled delivery of the antimicrobial metal to the skin.
  • an adhesive patch or adhesive matrix patch can be prepared from a backing material and an adhesive, such as an acrylate adhesive. Powders or solutions of the antimicrobial metal may be formulated into the adhesive casting solution and allowed to mix thoroughly. The solution is cast directly onto the backing material and the casting solvent is evaporated in an oven, leaving an adhesive film.
  • a polyurethane matrix patch can be employed to deliver the antimicrobial metal to the skin.
  • the layers of this patch comprise a backing, a polyurethane drug/enhancer matrix, a membrane, an adhesive, and a release liner.
  • the polyurethane matrix is prepared using a room temperature curing polyurethane prepolymer. Addition of water, alcohol, and drug to the prepolymer results in the formation of a tacky firm elastomer that can be directly cast onto the backing material.
  • Dressings with nanocrystalline coatings of a antimicrobial metal formed with atomic disorder are preferably sterilized without applying excessive thermal energy, which can anneal out the atomic disorder, thereby reducing or eliminating a useful release of antimicrobial metal species.
  • Gamma radiation is preferred for sterilizing such dressings, as discussed in WO 95/13704.
  • Electron beam and ethylene oxide sterilization techniques can also be used.
  • the sterilized dressings, coating, powders or formulations should be sealed in packaging, containers, or kits which limit moisture and light penetration to avoid additional oxidation or reduction of the antimicrobial metal. Polyester peelable pouches are preferred. The shelf life of coatings or powders thus sealed is over one year. D. Formulating, Dosages and Treatment
  • the nanocrystalline antimicrobial metals will be formulated from the active ingredient, namely nanocrystalline powders or coatings of the antimicrobial metals, or dissolved species from such powders or coatings, in the one or more of the formats set out above.
  • Dressing or powders of the nanocrystalline antimicrobial metals may be applied directly to the skin, or they may be formulated as set out below.
  • the powder size might be controlled to less than 2 ⁇ m, more preferably to less than 1 ⁇ m.
  • the amount of the nanocrystalline metal powder may range broadly from about 0.001% to about 30% by weight, but will more preferably fall in the range of from about 0.1 to 10% by weight, and most preferably in the range of about 0.01 to 5% by weight.
  • Typical coating thicknesses are in the range of 150 to 3000 nm thick. Thicker coatings, up to 10,000 nm thick, can be used to generate powders of the antimicrobial metal. Coatings of the nanocrystalline antimicrobial metals may be very thin, or thick, depending on the desired duration of application on the patient.
  • the amount of dissolved antimicrobial metal will typically range between about 0.001 to 10% by weight, more preferably 0.01 to 1% by weight.
  • compositions may also include non-toxic, pharmaceutically acceptable carriers, diluents and excipients, suitable for topical application, as are well known, see for example Merck Index, Merck & Co., Rahway, N.J.; and Gilman et al., (eds) (1996) Goodman and Gilman's: The Pharmacological Bases of Therapeutics, 8 th Ed., Pergamon Press.
  • pharmaceutically acceptable carriers such as are well known, see for example Merck Index, Merck & Co., Rahway, N.J.; and Gilman et al., (eds) (1996) Goodman and Gilman's: The Pharmacological Bases of Therapeutics, 8 th Ed., Pergamon Press.
  • For standard dosages of conventional pharmacological agents see, e.g., Physicians Desk Reference (1997 Edition); and U.S. Pharmacopeia National Formulary (1995) United States Pharmacopeial Convention Inc., Rockville, Maryland.
  • compositions of the nanocrystalline antimicrobial metals include various mixtures and combinations that can be applied topically and will permit even spreading and absorption into the cutaneous surfaces. Examples include sprays, mists, aerosols, lotions, creams, solutions, gels, ointments, pastes, emulsions, foams and suspensions.
  • the active compound can be mixed under sterile conditions with a pharmaceutically acceptable carrier, and with any preservatives, buffers, or propellants which may be required.
  • Topical preparations can be prepared by combining the antimicrobial metal powder with conventional pharmaceutically acceptable carriers commonly used in topical dry, liquid, cream and aerosol formulations.
  • infection may extend under the nail plate; thus, topical formulations such as a liquid, solid, or gel must thus be able to pass through the hard nail plate in order to contact the affected area.
  • the affected nail can be initially hydrated using urea (1-40%) or lactic acid (10-15%), and then treated with the antimicrobial metal (0.1-2%, more preferably 0.1-1%) in DMSO (0.4-50%), a carrier which can infiltrate the nail.
  • Ointment and creams can, for example, be formulated with an aqueous or oily base with the addition of suitable thickening and/or gelling agents.
  • An exemplary base is water.
  • Thickening agents can be used according to the nature of the base.
  • Lotions can be formulated with an aqueous base and will, in general, also include one or more of the following: stabilizing agents, emulsifying agents, dispersing agents, suspending agents, thickening agents, coloring agents, perfumes, and the like.
  • Powders can be formed with the aid of any suitable powder base, e.g., talc, lactose starch and the like.
  • Drops can be formulated with an aqueous base or non-aqueous base, and can also include one or more dispersing agents, suspending agents, solubilizing agents, surface active agents and the like.
  • Ointments, pastes, creams and gels also can contain excipients, such as starch, tragacanth, cellulose derivatives, silicones, bentonites, silicic acid, and talc, or mixtures thereof.
  • Powders and sprays also can contain excipients such as lactose, talc, silicic acid, aluminum hydroxide, and calcium silicates, or mixtures of these substances.
  • Solutions of nanocrystalline antimicrobial metals can be converted into aerosols or sprays by any of the known means routinely used for making aerosol pharmaceuticals. In general, such methods comprise pressurizing or providing a means for pressurizing a container of the solution, usually with an inert carrier gas, and passing the pressurized gas through a small orifice.
  • Sprays can additionally contain customary propellants, such inert gases such as nitrogen, carbon dioxide, argon or neon.
  • ingredients are generally incorporated in topical formulations to improve cosmetic acceptability, and are optional ingredients in the formulations. Such ingredients are included only in therapeutically acceptable forms and amounts.
  • ingredients are emulsifiers, emollients, thickening agents, solvents, hydrating or swelling agents, flavours, sweetening agents, surface active agents, colouring agents, anti-foaming agents, preservatives, fragrances, and fillers may also be added, as is well known in the art; for example, preservatives such as methyl paraben and propyl paraben, texturizing agents, thickeners, anticoagulants such as heparin, ⁇ -glucan, hormones, hyaluronic acid, immune potentiating agents such as adjuvants and cytokines such as epidermal growth factor, platelet derived growth factor, transforming growth factor and interleukins, and bone morphogenetic proteins, and the like.
  • Polyvinyl alcohol is a particularly preferred gelling polymer and also acts as a texturizing agent, methyl or propyl parabens are particularly preferred preservatives. These other agents may be included in amounts in the range of 0.1 to 5 wt %.
  • Surface active agents or foaming agents may be added to the formulations and are particularly advantageous for addition to liquid formulations for use as skin cleansers or for aerosol or foam applications.
  • Surface active agents selected for use should not substantially interfere with the antimicrobial or anti-inflammatory effects of the nanocrystalline antimicrobial metals.
  • All agents must be non-toxic and physiologically acceptable for the intended purpose, and must not substantially interfere with the activity of the nanocrystalline antimicrobial metals so as to deleteriously affect the antimicrobial and anti-inflammatory effect. Ingredients are thus only included in therapeutically acceptable amounts. Ingredients to be generally avoided or limited in the formulations of the present invention, at least in amounts greater than 0.01 wt %, are glycerin, glycerols, chloride salts, aldehydes, ketones, long chain alcohols, and triethanolamii
  • the dosage of the active ingredients depends upon many factors that are well known to those skilled in the art, for example, the particular form of the active ingredient, the condition being treated, the age, weight, and clinical condition of the recipient patient, and the experience and judgement of the clinician or practitioner administering the therapy.
  • a therapeutically effective amount of the nanocrystalline antimicrobial metal provides either subjective relief of symptoms or an objectively identifiable improvement as noted by the clinician or other qualified observer.
  • the dosing range varies with the metal used, its form, the route of administration and the potency of the particular compound.
  • the dressing When the formulation is in the form of a dressing, the dressing is placed on the affected area of the skin and, depending on the degree of moisture at the membrane, may be further moistened with drops of sterile water, tap water, body fluids such as exudate, or, for example 70% ethanol, in order to activate the coating for release of antimicrobial or noble metal species.
  • the dressing may be then secured in place with an occlusive or semi-occlusive layer, such as an adhesive tape or polyurethane film, which keeps the dressing in a moist environment.
  • dressings carrying a bi-layer nanocrystalline antimicrobial metal coating formed with silver having atomic disorder have shown substantial clinical response in treating inflammatory skin conditions.
  • Dressings prepared with a single layer of silver having a reduced content of oxygen in the coating gave similar clinical results, without staining the skin.
  • the dressings are kept moist, at 100% relative humidity. Adding sterile water initially to activate the antimicrobial metal coating is needed, and then as needed to maintain the dressing in a moist condition.
  • Dressings may be changed as required for observation and cleaning. Preferably dressings are changed daily, but could be left longer, such as 3 days, and can provide a therapeutic effect for a much longer period of time.
  • formulations such as occlusions, gels, pastes, ointments, creams, emulsions, foams, and liquids may be prepared in stable forms, or more preferably are prepared fresh from one or more phases, for instance in multicomponent kit form, so as to avoid aging and to maximize the therapeutic effectiveness of the antimicrobial metal component.
  • Formulations are best used within about 30 days after combining the phases. Suitable kits or containers are well known for maintaining the phases of formulations separate until the time of use.
  • the antimicrobial metal in powder or coated substrate form may be packages separately from therapeutically acceptable carriers, and possibly other ingredients for mixing at the time of use.
  • the separate coated substrate may be in dressing or patch form for direct application, or may take other suitable forms to generate liquid formulations and the like, such as a coating on the inside surface of a vial or container, a mesh, or a film.
  • the antimicrobial metal may be provided in a "tea bag"-type infuser or pouch, for generating liquid formulations at the time of use.
  • the tea bag-type infuser is advantageous in that the pouch may serve as a filter for small particulates of the powder that may be detrimental to administration for some applications such as aerosols for respiratory disorders.
  • a kit containing the dressing, coated substrate or powder may provide a sterile carrier such as water (and other ingredients) in a separate container in dosage specific amounts.
  • kit is meant to refer to packaged formulations, whether the ingredients are in separate phases or mixed, and thus for example, may include a gel in a tube with all ingredients in admixture, or any formulation wherein the ingredients are separated from each other.
  • the pH of the solution during dissolution may be lowered to less than pH 6.5, more preferably to the range of 3.5 to 6.5, with such acidifying agents as carbon dioxide (which generated carbonic acid in solution).
  • This pH range will typically generate concentrations of silver from atomic disordered silver from 85 ⁇ g/ml to 370 ⁇ g/ml, and can be adjusted for different desired concentrations.
  • Dissolution of the antimicrobial metal will typically raise the pH to 6.5 to 7.0.
  • Administration as aerosols produces droplets preferably less than 10 ⁇ m in size, more preferably less than 5 ⁇ m in size, most preferably 1 - 3 ⁇ m in size.
  • Control of the droplet size is important both to control the dosage delivered and to enhance delivery to the target tissue; thus, depending on the dosage required and the target tissue, it may be important to regulate the droplet size of the aerosol.
  • droplet size can be regulated, to at least some extent, by the mechanical mister which is used to produce the aerosol.
  • the aerosol's droplet size can be adjusted, to at least some extent, by modifying the surface tension of the solution.
  • the solution of the antimicrobial metal typically has water as its solvent, and water has a relatively high surface tension, so it is relatively straightforward to create an aerosol having relatively small droplet size.
  • Surface active agents can be added to the solution so as to reduce the surface tension of the solution, whereby to create an aerosol having a relatively large droplet size.
  • surfactants may comprise sodium alkyl sulfates, sodium laryl sulfate, sodium lauroyl sarconsinate, phospholipids, e.g., lecithin, sphingomyelin, etc.
  • solutions generated from powders of the antimicrobial metal should avoid inclusion of particulates larger than 2 ⁇ m, and more preferably no larger than l ⁇ m (i.e., submicron) to avoid deleterious immune responses or toxic effects.
  • Larger particulates may be removed by, for example filtration.
  • Particulates may be formed in the liquid and can be removed, for example by filtration.
  • silver carbonates may be formed on reaction with the carbonic acid used to acidify the solution. Particulate generation may also be limited by diluting the carbonic acid in solution.
  • the aerosol may be created by passing a liquid solution of the antimicrobial metal through a mechanical mister (e.g., a nebulizer) and may be applied directly with a pressurized pack (e.g., via a hand inhaler with a propellant such as carbon dioxide or other gas, with a valve metered dosage) or through some other delivery system (e.g., an oxygen tent, etc.).
  • a mechanical mister e.g., a nebulizer
  • a pressurized pack e.g., via a hand inhaler with a propellant such as carbon dioxide or other gas, with a valve metered dosage
  • some other delivery system e.g., an oxygen tent, etc.
  • the invention provides methods of treatment by administering a therapeutically effective amount of a nanocrystalline antimicrobial or noble metal powder, or a solution derived from a nanocrystalline antimicrobial or noble metal, as either a topical formulation, or as a coating on medical dressing, applied to the locally affected area of the skin.
  • a therapeutically effective amount may be determined by testing formulations containing the nanocrystalline antimicrobial or noble metals by in vitro or in vivo testing. Formulations may be applied one or more times a day.
  • Dressings coated with the nanocrystalline antimicrobial or noble metals may be changed daily, or even less frequently, and should be kept in a moist condition with the addition of saline, alcohols, or more preferably sterile water, in order to release ions, atoms, molecules or clusters of the nanocrystalline metal, on a sustained basis.
  • Example 1 - Preparation of Nanocrystalline Silver Coatings on Dressings This example shows the preparation of a bilayer nanocrystalline silver coating on a dressing material.
  • a high density polyethylene dressing, DELNETTM or CONFORMANT 2TM was coated with a silver base layer and a silver/oxide top layer to generate a coloured antimicrobial coating having indicator value.
  • the coating layers were formed by magnetron sputtering under the conditions set out in Table 1. Table 1 - Sputtering conditions
  • the resulting coating was blue in appearance. A fingertip touch was sufficient to cause a colour change to yellow.
  • the base layer was about 900 nm thick, while the top layer was 100 nm thick.
  • the coating was analyzed by nitric acid digestion and atomic absorption analysis to contain 0.24 +/- 0.04 mg silver per mg high density polyethylene.
  • the coating was a binary alloy of silver (>97%) and oxygen with negligible contaminants, based on secondary ion mass spectroscopy.
  • the coating as viewed by SEM, was highly porous and consisted of equiaxed nanocrystals organized into coarse columnar structures with an average grain size of 10 nm.
  • Silver release studies in water demonstrated that silver was released continuously from the coating until an equilibrium concentration of about 66 mg/L was reached (determined by atomic absorption), a level that is 50 to 100 times higher than is expected from bulk silver metal (solubility ⁇ lmg/L).
  • top layer By varying the coating conditions for the top layer to lengthen the sputtering time to 2 min, 15 sec, a yellow coating was produced.
  • the top layer had a thickness of about 140 nm and went through a colour change to purple with a fingertip touch.
  • a purple coating was produced by shortening the sputtering time to 1 min, to achieve a top layer thickness of about 65 nm. A fingertip touch caused a colour change to yellow.
  • the dressing may be used with either the blue coating side or the silver side in the skin facing position. For indicator value, it might be preferable to have the blue coating visible.
  • the three layers were laminated together by ultasonic welding to produce welds between all three layers spaced at about 2.5 cm intervals across the dressing. This allowed the dressing to be cut down to about 2.5 cm size portions for smaller dressing needs while still providing at least one weld in the dressing portion.
  • the coated dressings were sterilized using gamma radiation and a sterilization dose of 25 kGy.
  • the finished dressing was packaged individually in sealed polyester peelable pouches, and has shown a shelf life greater than 1 year in this form.
  • the coated dressings can be cut in ready to use sizes, such as 5.1 x 10.2 cm strips, before packaging. Alternatively, the dressings may be packaged with instructions for the patient or clinician to cut the dressing to size.
  • Additional silver coated dressings were prepared in a full scale roll coater under conditions to provide coatings having the same properties set out above, as follows: i the dressing material included a first layer of silver coated DELNET, as set out above, laminated to STRATEX, AET, 8.0NP 2 -A QW, which is a layer of 100% rayon on a polyurethane film. ii Silver Foam Dressing - three layers of silver coated high density polyethylene prepared as above, alternating with two layers of polyurethane foam, L-00562-6 Medical Foam, available from Rynel Ltd., Bootbay, Maine, USA.
  • the HDPE mesh coated with silver can be used to generate solutions containing silver species for liquid formulations and the like.
  • the silver coated mesh was produced, as set forth in Example 1, by sputtering silver onto Delnet, a HDPE mesh (Applied Extrusion Technologies, Inc., Middletown, DE, USA) using Westaim Biomedical TMRC unit under the following conditions: Table 2 - Sputtering conditions
  • the coating was tested and found to have a weight ratio of reaction product to silver of between 0.05 and 0.1.
  • the dressing was non-staining to human skin.
  • Nanocrystalline silver coatings were prepared by sputtering silver in an oxygen- containing atmosphere directly onto an endless stainless steel belt of a magnetron sputtering roll coater, or onto silicon wafers on the belt.
  • the belt did not need to be cooled.
  • the coatings were scraped off with the belt with suspended metal scrapers as the belt rounded the end rollers.
  • the coatings were scraped off with a knife edge.
  • the sputtering conditions were as follows: Table 3 - Sputtering Conditions
  • the powder had a particle size ranging from 2 ⁇ m to 100 ⁇ m, with grain or crystallite size of 8 to 10 nm (i.e., nanocrystalline), and demonstrated a positive rest potential.
  • the silver solution was obtained by static elution of ActicoatTM Burn Wound Dressing (lot #: 00403 A-05, Westaim Biomedical Corp., Fort Saskatchewan, Canada) with nanopure water in a ratio of one square inch of dressing in five milliliters of water for 24 hours at room temperature.
  • the silver concentration of the silver solution was determined by an atomic absorption method.
  • the silver elute was diluted with nanopure water to 20 ⁇ g/ml.
  • the Propionibacterium acne (ATCC No. 0919) was provided by Biofilm Research Group, University of Calgary.
  • the inoculum was prepared by inoculating freshly autoclaved and cooled tubes of Tryptic soy broth (TSB) with P. acne and incubating them for 2 days at 37 °C in an anaerobic jar. At this time, the optical density of the suspensions was ⁇ 0.3 at a wavelength of 625 nm.
  • TLB Tryptic soy broth
  • the bacterial suspension (100 ⁇ L) was mixed with 100 ⁇ L of the silver solution being tested. The final concentration of silver in these mixtures was 10 //g/ml. The mixtures were incubated in an anaerobic jar at 37 °C for two hours. The silver was neutralized by addition of 0.4% STS (0.85% NaCl, 0.4% Sodium thioglycolate, 1% TweenTM 20) and the solution was serially 10-fold diluted with phosphate-buffered saline. 20 ⁇ L aliquots of the original solution and subsequent dilutions were plated onto TSA drop plates.
  • the drops were allowed to dry and the plates were incubated in an anaerobic jar at 37° C for 72 hours at which time the colonies were counted.
  • the control consisted of 100 ⁇ of bacterial suspension mixed with 100 ⁇ L of nanopure water and treated as above.
  • Example 8 Treatment of Adult Acne with Silver-Impregnated Hydrocolloid Dressing
  • Skin allergic contact hypersensitivity is caused by excessive infiltration of eosinophils.
  • An animal model may be used for in vivo evaluation of eosinophil infiltration in the contact sensitivity reaction and to determine whether it is associated with allergic skin conditions such as contact dermatitis. On a gross histology level, this can be measured by the degree of erythema and edema at the dermatitis site.
  • Current drugs used for treatment of this and other related eczema conditions include high potency steroids (UltravateTM), medium potency steroids (EloconTM) and non steroidal anti-inflammatory compounds (ProtopicTM or tacrolimus). These compounds do not always work and may have undesirable side effects.
  • Several commercially available anti-inflammatory products were compared to a nanocrystalline silver powder for the treatment of allergic contact dermatitis as follows.
  • Treatment groups are shown in Table 4.
  • ProtopicTM tacrolimus
  • EloconTM and UltravateTM were purchased as creams from the local pharmacy.
  • the nanocrystalline silver powder (1 g/L) was mixed into a 2% sodium carboxymethyl cellulose (CMC) and water solution at 30 °C using a magnetic stirrer at a high speed (Vista Scientific).
  • Petrolatum commercially known as VaselineTM, was used as a control for EloconTM and UltravateTM.
  • a commercial carboxymethyl cellulose/pectin gel (DuoDERMTM, ConvaTec Canada, 555, Dr. Frederik Philips, Suite 110, St-Laurent, Quebec, H4M 2X4) was combined with nanocrystalline silver powder prepared as set forth in Example 3 to produce a gel with 0.1% silver.
  • a logarithmic reduction test was performed as follows in the gel using Pseudomonas aeruginosa.
  • the inoculum was prepared by placing 1 bacteriologic loopful of the organism in 5 mL of trypticase soy broth and incubating it for 3-4 h. The inoculum (0.1 mL) was then added to 0.1 mL of gel and vortexed (triplicate samples).
  • Carboxymethyl cellulose (CMC) fibers were coated directly to produce an atomic disordered nanocrystalline silver coating, using magnetron sputtering conditions similar to those set forth in Example 1.
  • the CMC was then gelled in water by adding 2.9 g to 100 mL volume. This material was tested using the method of No. 1.
  • the material generated a 5.2 logarithmic reduction of Pseudomonas aeruginosa , demonstrating that the gel had a significant bactericidal effect.
  • a commercial gel containing CMC and alginate (Purilin gel, Coloplast) was mixed with a atomic disordered nanocrystalline silver powder to give a product with 0.1% silver. This was tested as above with both Pseudomonas aeruginosa and Staphylococcus aureus. Zone of inhibition data was also generated for this gel as follows.
  • An inoculum (Pseudomonas aeruginosa and Staphylococcus aureus) was prepared as in No. 1 and 0.1 mL of this was spread onto the surface of Mueller-Hinton agar in a Petri dish. A six mm hole was then cut into the agar at the center of the Petri dish and removed.
  • the well was filled with either 0.1 mL of the silver containing gel, a mupirocin containing cream or a mupirocin containing ointment.
  • the Petri plates were then incubated for 24 h and the diameter of the zone of inhibition was measured and recorded.
  • the silver containing gel produced 9 mm zone of inhibition against both Pseudomonas aeruginosa and Staphylococcus aureus, while the mupirocin cream and ointment produced 42 and 48 mm zones against Staphylococcus aureus and 0 mm zones against Pseudomonas aeruginosa.
  • the silver containing gel reduced the Pseudomonas aeruginosa and Staphylococcus aureus properties by 4.4 and 0.6 log reductions, respectively, showing good bactericidal activity.
  • the mupirocin cream and ointment generated 0.4 and 0.8, and 0.8 and 1.6, log reductions against Staphylococcus aureus and Pseudomonas aeruginosa, respectively.
  • the silver gel had both a greater bactericidal effect and spectrum of activity than the mupirocin containing products. Nos. 5-10
  • a commercially available gel (glyceryl polymethacrylate) was blended with nanocrystalline silver powder to produce a gel with a silver content of 0.1%. This gel was tested as in Nos. 5-10 and was found to produce zones of 15 mm against both Staphylococcus aureus and Pseudomonas aeruginosa. Log reductions of 1.7 and >5 were produced against Staphylococcus aureus and Pseudomonas aeruginosa. This gel product had a greater spectrum of activity than did mupirocin cream or ointment.
  • Example 12 Treatment of Adult Acne with Nanocrystalline Silver Gel Occluded by a Hydrocolloid Dressing

Abstract

The invention relates to the use of one or more antimicrobial metals, most preferably silver, preferably formed with atomic disorder, and preferably in a nanocrystalline form,for the treatment of inflammatory skin conditions. The nanocrystalline antimicrobial metal of choise may be used in the form of a nanocrystalline coating of one or more antimicrobial metals, a nanocrystalline powder of one or more antimicrobial metals, or a solution containing dissolved species from a nanocrystalline powder or coating of one or more antimicrobial metals.

Description

TREATMENT OF INFLAMMATORY SKIN CONDITIONS
FIELD OF THE INVENTION
The invention relates to the use of antimicrobial metals for the treatment of inflammatory skin conditions.
BACKGROUND OF THE INVENTION
Inflammatory skin conditions are those conditions of the skin in which inflammatory cells (e.g., polymorphonuclear neutrophils and lymphocytes) infiltrate the skin with no overt or known infectious etiology. Symptoms of inflammatory skin conditions generally include erythema (redness), edema (swelling), pain, pruritus, increased surface temperature and loss of function. As used herein, inflammatory skin conditions include, but are not limited to, eczema and related conditions, insect bites, erythroderma, mycosis fungoides and related conditions, pyoderma gangrenosum, erythema multiforme, rosacea, onychomycosis, and acne and related conditions, but excluding psoriasis and its related conditions. The following is an overview of these inflammatory skin conditions. I Eczema and Related Conditions
Eczema relates to a group of conditions characterized by varying degrees of itching, redness, scaling, and blistering of the skin. Eczema occurs as a reaction to many endogenous and exogenous agents, and is characterized in the acute stage by erythema, edema associated with a serious exudate between the cells of the epidermis and an inflammatory infiltrate in the dermis, oozing and vesiculation, crusting and scaling. Chronic stages are characterized by thickened skin areas with accentuated skin markings, signs of traumatized or abraded skin caused by scratching, and hyperpigmentation or hypopigmentation or both. The various types of eczema include the following: i) Atopic eczema is the most common type of eczema. Atopic eczema is a chronic, praritic, superficial inflammation of the skin, frequently associated with a personal or family history of allergic disorders such as hay fever and asthma. Topical or oral corticosteroids, or antihistamines are common treatments. ii) Acrodermatitis continua is characterized by painful, often disabling, lesions on the fingertips or the tips of the toes. The nails may become deformed, and the disease can damage bone in the affected area. Treatment may include topical corticosteroids and systemic remedies, such as retinoids or psoralen-UNA, although is difficult due to the rarity of the disease. iii) Contact allergic dermatitis is acute or chronic dermatitis caused by materials or substances coming into contact with the skin, which may involve either allergic or nonallergic mechanisms. Materials or substances known to induce contact allergic dermatitis include plant substances such as poison ivy, metals such as nickel or chromium, cosmetics, rubber compounds or chemicals. iv) Contact irritant dermatitis is a nonallergic type of contact dermatitis caused by intense or long term exposure to a substance which directly damages the skin. Following exposure, skin inflammation can occur immediately or gradually after repeated exposure; for example, sunburn caused by overexposure to ultraviolet light; or exposure to acids and alkalis in household cleaning products. v) Dyshydrotic eczema or pompholyx is a chronic condition characterized by deep-seated pruritic vesicles on the palms, sides of the fingers, and soles. Scaling, redness, and oozing often follow vesiculation. Secondary infection with Staphylococcal bacteria is frequent.
Treatments include topical steroids and cold compresses, or oral steroids for acute cases. vi) Lichen simplex chronicus is a chronic, superficial, pruritic inflammation of the skin, characterized by dry, scaling, well-demarcated, hyperpigmented, thickened skin with accentuated markings of oval, irregular, or angular shape. The pruritus may be controlled most effectively with topical corticosteroids. vii) Nummular eczema is characterized by discrete, coin-shaped, ringed or annular lesions which may coalesce to form extensive patches, which may ooze and crust over, and affects the extensor surfaces of the extremities, lower legs, chest, back and buttocks. No treatment is uniformly effective. Oral antibiotics or corticosteroid creams are generally used as treatments. In more resistant cases, ultraviolet B radiation alone or ultraviolet A with oral psoralen may be helpful. viii) Seborrheic dermatitis is chronic and characterized by moderate erythema; dry, moist or greasy scaling; itching; and yellow crusted patches on areas of the body with high densities of large oil glands, especially the face and scalp. Treatment with zinc pyrithione, selenium sulfide, sulfur and salicylic acid, tar shampoo, or a corticosteroid lotion is common, ix) Stasis eczema is a chronic inflammation of the skin of the lower legs, commonly associated with venous incompetency. Edema, erythema, mild scaling, and brown discoloration occur. Elevating the ankle above the heart while resting, wearing properly fitted support hose, and applying topical therapy are necessary. However, unless circulation improves, these approaches will be relatively ineffective. The choice of topical therapy depends upon the disease stage, with therapies including compresses, dressings, and corticosteroid creams. II Insect Bites
Insect bites or stings can produce localized pain, redness, swelling and itching of the skin. In serious cases, complications include allergic reaction, infection, disease, reaction to venom, toxic reaction, or shock. Depending upon the specific insect, treatments may include rest and elevation, local application of ice packs and lotions, analgesics, antihistamines, or hospitalization for life threatening, anaphylactic reactions. in Erythroderma
Erythroderma relates to any dermatitis where erythema (abnormal redness of the skin) occurs. Erythroderma, involving more than 90% of the skin, is potentially life threatening for a patient, since the barrier function of the skin has been lost. Hospitalization, topical moisturisers and intravenous fluids may be required to maintain hydration of the patient. IN Mycosis fungoides and Related Conditions
Mycosis fungoides is an uncommon chronic T-cell lymphoma primarily affecting the skin and occasionally the internal organs. Mycosis fungoides is rare, appearing as a chronic, pruritic rash which is difficult to diagnose. Initially plaquelike, it may spread to involve most of the skin, become nodular, and eventually become systemic. Lesions may become ulcerated. Pathologic diagnosis is delayed because sufficient quantities of lymphoma cells appear in the skin lesions very gradually. Treatment is temporarily effective, and may include psoralen- UNA, cortisone ointments for mild cases, nitrogen mustard, and photochemotherapy. N Pyoderma gangrenosum
Pyoderma gangrenosum is characterized by relatively indolent ulcers with extensive necrosis around the edges of the lesions on the lower extremities of the body. While pyoderma gangrenosum may be an isolated finding, it is most often associated with ulcerative colitis or Crohn's disease. The ulcers have ragged bluish-red overhanging edges and a necrotic base. The lesions often start as pustules or tender nodules at the site of trauma, and then gradually increase in size until liquefaction necrosis occurs and an irregular ulcer develops. The ulcers are often multiple and may cover large areas of the leg. Treatments include topical steroids, anti-inflammatory antibiotics, and oral steroids for more severe cases. NI Erythema multiforme
Erythema multiforme is an inflammatory eruption characterized by symmetric erythematous, edematous, or bullous lesions of the skin or mucous membranes. Erythema multiforme may be induced by an infectious disease (e.g., herpes simplex, Mycoplasma pneumoniae); drug therapy (e.g., penicillin, sulfonamides, and barbiturates); or a vaccine (e.g., Bacille Calmette-Guerin, poliomyelitis vaccines). The mechanism by which diseases, drugs, or vaccines cause erythema multiforme is unknown, but it is generally considered a hypersensitivity reaction. Treatments include mild topical cortisone, colloidal baths, and wet compresses. VII Rosacea
Rosacea is a chronic inflammatory disorder, usually beginning in middle age or later and characterized by prominent cutaneous blood vessels, erythema, papules, and pustules primarily in the central areas of the face. Tissue hypertrophy, particularly of the nose, may result. Rarely, rosacea occurs on the trunk and extremities. The cause is unknown, but the disease is most common in persons with a fair complexion. Rosacea may resemble acne, but comedones are never present. Treatments include topical metronidazole for three months or oral antibiotics. Laser treatments may be required to remove tissue hypertrophy. VHI Onychomycosis
Onychomycosis is an infection that causes fingernails or toenails to thicken, discolor, disfigure, and split. Thick toenails cause discomfort in shoes and make standing and walking painful for the patient. If the problem is caused by bacteria such as staphylococcus, streptococcus, and pseudomonas, the condition is called paronychia. In most cases, paronychia infections can be differentiated from onychomycosis by the inflammation they cause to the skin adjacent to the nail. Onychomycosis is caused most commonly by fungi known as dermatophytes (Trichophyton rubrum and Trichophyton mentagrophytes), and less commonly by yeasts (Candida albicans causes fingernail infections), and molds (Scopulariopsis, Fusarium). Infections caused by dermatophytes are generally limited to the nail, but may spread to the surrounding skin and cause inflammation. The four types of onychomycosis include distal and/or lateral subungual onychomycosis affecting the nail bed and nail plate; proximal subungual onychomycosis affecting the proximal nail fold with infection extending distally under the nail plate; superficial white onychomycosis affecting the top of the nail plate; and candidal onychomycosis affecting the nail and skin. Onychomycosis is difficult to treat, in that secondary skin infections including paronychia, and recurrent fungal infections of the nails or other parts of the body may occur. Oral medications such as Lamisil™ (terbinafine) or Sporanox™ (itraconazole) may produce adverse side effects in the liver, while topical treatments tend to be ineffective. Further, oral and topical medications work gradually, requiring several months to completely eliminate the infection. IX Acne and Related Conditions
The term "acne" is a general term to denote inflammatory disorders of the pilosebaceous unit. Acne is a group of disorders whose initial pathology is the comedo and includes acne vulgaris (common acne), neonatal acne, infantile acne, and pomade acne. Acne commonly afflicts adolescents and young adults; however, there is growing number of patients who develop acne in their late twenties or thirties. There are data that suggest a familial or genetic tendency for patients to develop severe cystic or conglobate acne. Additionally, acne has been linked to endocrine disorders, especially those characterized by elevated levels of circulating testosterone or testosterone congeners. Exogenous agents that could exacerbate acne include medications e.g. iodides, anti-seizure, certain antibiotics and corticosteroids.
Acne is a chronic inflammatory disorder affecting the sebaceous glands. Acne lesions primarily involve the sebaceous glands located on the face, neck, chest and back. Both closed comedones (blackheads) and open comedones (whiteheads) are caused by hyperkeratinization of the infundibulum of the sebaceous duct. These keratinous plugs block the flow of sebum. These dilated ducts abound with the colonies of Propionibacterium acnes and other fat splitting organisms. The clinically evident open and closed comedones and the microscopic microcomedo are the signal lesions of acne. The acne process results from a cascade of events. First, at puberty a spike in androgen production heralds an increase in sebum production and begins the hyperkeratinization process causing microcomedones and sebum blockade. With this blockage, the number of resident follicular flora increases dramatically. These bacteria produce inflammatory products, which permeate through thin walls of dilated sebum-filled duct. Once in the perifollicular dermis, they trigger the body's own immune defenses (both acute and granulaomatous) to produce the characteristic inflammatory papules, pustules and nodules characteristic of inflammatory acne.
Increased sebum production; comedo formation, in which the follicular infundibulum hypercornifies, hyperkeratinizes, and hypodesquamates; colonization of the follicule by anaerobic Propionibacterium (mainly P. acnes); and the host's inflammatory response are generally believed to contribute to the development of acne. These four factors are interrelated. Sebum is comedogenic and causes inflammation by itself. The Propionibacterium has high lipolytic activity and liberates free fatty acids from sebum lipids, whereby the free fatty acids have been shown to cause marked inflammation. The microorganisms also produce other extracellular enzymes such as proteases and hyaluronidases, and chemotactic factors, which may be important in the inflammatory process. Aside from these factors, serum hormones, especially dehydroepiandrosterone sulfate, have been found to correlate with acne.
Acne treatments generally target the keratinous plugs in sebaceous ducts; large sebaceous glands producing excess sebum; increased numbers of resident follicular bacteria; and inflammatory response to chemical mediators passing through the follicular wall. Most acne treatments are directed at preventing inflammatory lesions, particularly the larger nodulo- cystic lesions which tend to be destructive and lead to permanent scarring. In general, visible comedones are the only minor cosmetic nuisances and do not lead to inflammatory lesions.
Topical products used to remove comedones ("comedolytics") include tretinoin (Retin A™), adapalene 0.1% (Differin™), sodium sulfacetamide 10% / sulfur 5% (Sulfacet-R™), and salicylic acid 2%. A naturally occurring metabolite of Vitamin A, tretinoin or all-trans retinoic acid increases epidermal cell turnover and prevents the formation of new keratinous plugs. Application of tretinoin is normally once nightly. Although tretinoin is the most effective comedolytic, dryness, stinging and redness may occur, and improvement takes 6-8 weeks. Adapalene 0.1% is a topical retinoid-like tretinoin and is usually applied once nightly. Side effects include frequent scaling, burning, redness and dryness, and improvement takes 4-8 weeks. Sodium sulfacetamide 10% / sulfur 5% is both an antibacterial and comedolytic lotion, with improvement taking 4-8 weeks. Salicylic acid 2% exhibits mild activity.
For severe cystic or conglobate acne, isotretinoin (Accutane™), which is a metabolite of Vitamin A, is administered orally. Isotretinoin has effective anti-sebum activity, but is teratogenic (causing birth defects), and hepatotoxic (elevating triglycerides and total cholesterol and decreasing high-density lipoproteins). Other side effects include dry skin, dry eyes, itching, headaches, nosebleed, and photosensitivity. Improvement takes 4-5 months. Since estrogens also have anti-sebum activity, acne may also be treated with oral contraceptive pills.
Topical and/or oral antimicrobial agents may also be used to decrease bacteria that colonize the follicular duct. Topical agents include benzoyl peroxide (BP), and BP 5% / erythromycin 3% (Benzamycin™). BP is often tried first for both non-inflammatory and mild inflammatory acne, but can produce erythema and peeling, and improvement takes 1-2 months. Topical antibiotics include clindamycin and erythromycin, with improvements taking 1-2 months. Azelaic acid 20% (Azelex™) has mild antibacterial effects. Further, systemic antibiotics include tetracycline and its analogs (doxycycline and minocycline), which are used in low doses for years or until the end of the acne prone years. However, bacterial resistance may occur, such that the antibiotics need to be changed or substituted with BP.
Intralesional corticosteroids and topical nicotinamide have also been used to control a host's inflammatory response. There are no drugs that directly affect the inflammatory acne. The retinoids do have some anti-inflammatory properties, but these are poorly described. Topical steroid and even systemic steroids have been used to abort a severe flare of fulminant acne, but have undesirable side effects. Treatments for Inflammatory Skin Conditions
While a range of treatments have been developed for inflammatory skin conditions, none are completely effective or free of adverse side effects. As outlined above, treatments for different inflammatory skin conditions typically include topical or oral steroids (e.g., for various types of eczema, acne, and erythema multiforme); ultraviolet light (e.g., for nummular eczema and mycosis fungoides); or other anti-inflammatory therapies. However, such treatments may be ineffective, provide only temporary relief, have deleterious side effects, or take months to treat. As an example, no treatment is uniformly effective for nummular eczema or stasis eczema. Current treatments for mycosis fungoides are only temporarily effective. Oral steroids have significant side effects, such that the severity of the skin disease must be carefully assessed. While short term treatment (a few days or weeks) with oral steroids is relatively safe, long term treatment (more than 3 months) may cause undesirable side effects including Cushing's syndrome, skin thinning, and increased susceptibility to infection. Improvements may be delayed, such as with the various acne treatments lasting several months.
While the patent literature reports that silver metal or silver salts such as silver nitrate, silver halides or silver sulphadiazine are among useful antibacterial agents for skin treatment, they have not, to the inventor's knowledge, been widely adopted for treatment of inflammatory skin conditions. In some inflammatory conditions, secondary infection is a possibility; thus, a treatment which contributes both anti-inflammatory and antimicrobial effects is advantageous. Further, there still exists a need for the treatment of inflammatory skin conditions including eczema, acne, and other related inflammatory skin conditions, with such a treatment being effective, lacking undesirable side effects, and showing improvement without a lengthy delay.
SUMMARY OF THE INVENTION
Through research, the inventors have established that crystalline antimicrobial metals such as nanocrystalline silver, preferably formed with atomic disorder, are effective antimicrobial agents against bacteria associated with inflammatory skin conditions such as acne. Further, the inventors have established through clinical observations with acne and eczema patients, and in animal experiments for allergic contact dermatitis, that antimicrobial metals such as silver, formed with atomic disorder, also reduce the inflammatory reaction. Further, the inventors have demonstrated that antimicrobial metals such as silver, formed with atomic disorder, can alleviate erythema and edema, which are characteristic symptoms of many inflammatory skin conditions. This research has resulted in a new therapeutic treatment for acne, eczema, and other inflammatory skin conditions. In some inflammatory conditions, secondary infection by bacteria or other microbiological agents is a possibility. When the antimicrobial metal is silver, this new treatment will have dual advantages of both antimicrobial and anti-inflammatory effects, with fewer side effects and less chance of development of resistant bacteria.
The inventors have discovered that antimicrobial metals selected from one or more of silver, gold, platinum and palladium, are effective in the treatment of inflammatory skin conditions. These antimicrobial metals are formed with atomic disorder, such that ions, clusters, atoms or molecules of the metals are released at a concentration sufficient to provide a localized antimicrobial and anti-inflammatory effect. Most preferably, the antimicrobial metals are in a nanocrystalline form, and include sufficient atomic disorder to provide an antimicrobial and anti-inflammatory effect on a sustainable basis.
Without being bound by the same, it is believed that the nanocrystalline antimicrobial metals formed with atomic disorder are capable of releasing highly active clusters of the antimicrobial metal (example clusters of Ag° or Ag+/Ag°), which are responsible for the surprisingly enhanced antimicrobial activity and the surprising presence of the anti- inflammatory activity in the treatment of inflammatory skin conditions, compared with other known antimicrobials such as silver salts (ex. silver nitrate), silver zeolites which release only Ag+, or silver metal and silver oxide which have only minor solubility. Clusters are known to be small groups of atoms, ions or the like, as described by R. P. Andres et al., "Research Opportunities on Cluster and Cluster-Assembled Materials", J. Mater. Res. Vol 4, No 3, 1989, p. 704. For silver, clusters are believed to contain less than the 14 atoms of a normal face centered cubic crystal lattice form of silver.
The crystalline forms of these antimicrobial metals may be used in, or formulated from, any of the following formats: i) coatings of the antimicrobial metals on medical grade substrates, for example, dressings, meshes, films, fibres, containers, or vials, from materials composed of for example polyethylene, high density polyethylene, polyvinylchloride, latex, silicone, cotton, rayon, polyester, nylon, cellulose, acetate, carboxymethylcellulose, alginate, chitin, chitosan and hydrofibres; ii) powders, preferably prepared as nanocrystalline powders of the antimicrobial metals, or as nanocrystalline coatings of the antimicrobial metals on biocompatible substrates in powder form, preferably on bioabsorbable and/or hygroscopic substrates such as: Synthetic Bioabsorbable Polymers: for example polyesters/polyactones such as polymers of polyglycolic acid, glycolide, lactic acid, lactide, dioxanone, trimethylene carbonate etc., polyanhydrides, polyesteramides, polyortheoesters, polyphosphazenes, and copolymers of these and related polymers or monomers, or Naturally Derived Polymers: Proteins: albumin, fibrin, collagen, elastin; Polysaccharides: chitosan, alginates, hyaluronic acid; and Biosynthetic Polyesters: 3-hydroxybutyrate polymers; iii) occlusions or hydrated dressings, in which the dressing is impregnated with a powder or solution of the antimicrobial metals, or is used with a topical formulation of the antimicrobial metals, with such dressings for example as hydrocolloids, hydrogels, polyethylene, polyurethane, polyvinylidine, siloxane or silicone dressings; iv) gels, formulated with nanocrystalline powders or solutions of the antimicrobial metals with such materials as carboxymethylcellulose, alginate, chitin, chitosan and hydrofibres, together with such ingredients as preservatives, pectin and viscosity enhancers; v) creams, lotions, pastes, foams and ointments formulated with nanocrystalline powders or solutions of the antimicrobial metals, for example as emulsions or with drying emollients; and vi) liquids, formulated as solutions, dispersions, or suspensions, by dissolving nanocrystalline coatings or powders of the antimicrobial metals, for example as topical solutions, aerosols, mists, sprays, or drops.
Solutions of the antimicrobial metals lose some activity with aging and are thus either stabilized or generated fresh for administration. Alternatively, the antimicrobial metals may be packaged for convenient solution generation, for instance in a pervious membrane such as a tea bag type infuser. Other two part or two phase systems may be used in which the nanocrystalline metal is separated from the water or electrolyte solvent, for example in kit form, with the antimicrobial metal being provided in dissolving capsules, as a coating on the inside of vials or containers, on substrates such as dressing, separated by a membrane which can be perforated, or in a separate container from the carrier, in a tea bag-type infuser etc. In the above formats, the nanocrystalline antimicrobial metals are formulated from nanocrystalline coatings or nanocrystalline powders of the nanocrystalline antimicrobial metals, or from solutions prepared by dissolving the nanocrystalline coatings or powders therein. The formulations include a therapeutically effective amount of the coatings or powders, and most preferably, the following amounts:
For coatings: 150 - 3000 nm thick coatings for substrates, or thicker for forming powders (such coatings can be used to generate 0.001 to 10% by weight solutions) For gels, creams etc.: 0.01 - 30% by weight, more preferably 0.01 - 10% by weight and most preferably 0.1 - 5% by weight of the antimicrobial or noble metal powder For liquids: 0.001 - 10% by weight, more preferably 0.01 to 5% by weight and most preferably 0.1 to 1% by weight of the antimicrobial or noble metal (generated from any format, including coatings, flakes, powders). Concentrations of the antimicrobial species in solution will vary according to the application, formulation and subject, but will generally range from 1 - 5000 g/ml, more preferably 20 - 3000 g/ml, more preferably 40 - 800 g/ml, and most preferably 50 - 500 μg/ml.
Nanocrystalline coatings of the antimicrobial metals are most preferably deposited onto substrates such as dressings, for example one or more layers of medical dressing materials which can be laminated with uncoated layers of medical dressing materials. The coatings can be prepared by known techniques for preparing nanocrystalline coatings, but are most preferably prepared by physical vapour deposition under conditions which create atomic disorder. The nanocrystalline coatings may be prepared to create an interference colour so as to provide an indicator, as described in prior patent application WO 98/41095, published September 24, 1998, and naming inventors R. E. Burrell and R. J. Precht.
Nanocrystalline powders of the antimicrobial metals may be prepared as nanocrystalline coatings, preferably of the above thickness, on powdered substrates such as chitin, or may be prepared as nanocrystalline coatings on a substrate such as a silicon wafer, and then scraped off as a nanocrystalline powder. Alternatively, fine grained or nanocrystalline powders of the antimicrobial metals may be cold worked to impart atomic disorder, as taught in prior patent applications WO 93/23092, published November 25, 1993, and WO 95/13704, published May 26, 1995, both of which name Burrell et al, as inventors.
Thus, the invention broadly provides a method of reducing inflammation of an inflammatory skin condition which comprises: contacting a problem area of a patient, with a therapeutically effective amount of the antimicrobial metals in a crystalline form to provide a localized anti-inflammatory effect, wherein the antimicrobial metals are characterized by sufficient atomic disorder, such that the metal, in contact with an alcohol or water-based electrolyte, releases atoms, ions, molecules, or clusters of at least one antimicrobial metal at a concentration sufficient to provide a localized anti-inflammatory and antimicrobial effect. The antimicrobial metal is nanocrystalline and is formed with sufficient atomic disorder such that, in contact with an alcohol or water based electrolyte, the antimicrobial metal releases ions, atoms, molecules or clusters of the antimicrobial metal on a sustainable basis. The antimicrobial metal is selected from the group consisting of silver, gold, platinum and palladium, but preferably is nanocrystalline silver or silver, formed as a composite with oxygen.
In another broad aspect of the invention, there is provided a method of reducing inflammation of an inflammatory skin condition which comprises: applying a hydrated dressing to contact a problem area of a patient, wherein the hydrated dressing i includes a therapeutically effective amount of one or more antimicrobial metals in a crystalline form to provide a localized antimicrobial and anti-inflammatory effect; or ii occludes a pharmaceutical composition of a nanocrystalline powder of the one or more antimicrobial metals, or a solution containing dissolved species from a nanocrystalline powder or coating of the one or more antimicrobial metals.
In another broad aspect, the invention provides a hydrated dressing for use in reduction of inflammation of an inflammatory skin condition comprising a hydrated dressing, and associated with the dressing, a therapeutically effective amount of one or more antimicrobial metals in a crystalline form to provide localized anti-inflammatory and antimicrobial effects.
In yet another broad aspect, the invention provides a kit for reducing inflammation of an inflammatory skin condition comprising one or more antimicrobial metals formed with atomic disorder; and one or more pharmaceutically acceptable carriers.
As used herein and in the claims, the terms and phrases set out below have the meanings which follow.
"Metal" or "metals" includes one or more metals whether in the form of substantially pure metals, alloys or compounds such as oxides, nitrides, borides, sulphides, halides or hydrides.
"Antimicrobial metals" are silver, gold, platinum, palladium, iridium, zinc, copper, tin, antimony, bismuth, or mixtures of these metals with same or other metals, silver, gold, platinum and palladium being preferred, and silver being most preferred.
"Noble metals" are silver, gold, platinum and palladium, or mixtures of such metals with same or other metals, with silver metal being the most preferred.
"Antimicrobial effect" means that atoms, ions, molecules or clusters of the antimicrobial or noble metal are released into the electrolyte which the coating contacts in concentration sufficient to inhibit microbial growth on and in the vicinity of the coating. The most common methods of measuring an antimicrobial effect are a zone of inhibition test (which indicates an inhibitory effect, whether microbiostatic or microbiocidal) or a logarithmic reduction test (which indicates a microbiocidal effect). In a zone of inhibition test (ZOI) the material to be tested is placed on a bacterial lawn (or a lawn of other microbial species) and incubated. A relatively small or no ZOI (ex. less than 1 mm) indicates a non-useful antimicrobial effect, while a larger ZOI (ex. greater than 5 mm) indicates a highly useful antimicrobial effect. The ZOI is generally reported as a corrected zone of inhibition (CZOI), wherein the size of the test sample is subtracted from the zone. A logarithmic reduction test in viable bacteria is a quantitative measure of the efficacy of an antibacterial treatment; for example, a 5 log reduction means a reduction in the number of microorganisms by 100,000-fold (e.g., if a product contained 100,000 pertinent microorganisms, a 5 log reduction would reduce the number of pertinent microorganisms to 1). Generally, a 3 log reduction represents a bactericidal effect. The logarithmic reduction test involves combining the inoculum with the test treatment, incubating the inoculum with the test treatment, recovering the bacteria or other microbial species, and enumerating the bacteria or other microbial species using serial dilutions. Examples of these tests are set out in the examples which follow.
"Anti-inflammatory effect" means a reduction in one ore more of the symptoms of erythema (redness), edema (swelling), pain and pruritus which are characteristic of inflammatory skin conditions.
"Inflammatory skin conditions" refers to those conditions of the skin in which inflammatory cells (e.g., polymorphonuclear neutrophils and lymphocytes) infiltrate the skin with no overt or known infectious etiology, but excluding psoriasis and its related conditions. Symptoms of inflammatory skin conditions generally include erythema (redness), edema (swelling), pain, pruritus, increased surface temperature and loss of function. As used herein, inflammatory skin conditions include, but are not limited to, eczema and related conditions, insect bites, erythroderma, mycosis fungoides and related conditions, pyoderma gangrenosum, erythema multiforme, rosacea, onychomycosis, and acne and related conditions, but excluding psoriasis and its related conditions.
"Biocompatible" means generating no significant undesirable host response for the intended utility. Most preferably, biocompatible materials are non-toxic for the intended utility. Thus, for human utility, biocompatible is most preferably non-toxic to humans or human tissues.
"Sustained release" or "sustainable basis" are used to define release of atoms, molecules, ions or clusters of an antimicrobial metal that continues over time measured in hours or days, and thus distinguishes release of such metal species from the bulk metal, which release such species at a rate and concentration which is too low to be therapeutically effective, and from highly soluble salts of antimicrobial metals such as silver nitrate, which releases silver ions virtually instantly, but not continuously, in contact with an alcohol or electrolyte.
"Atomic disorder" includes high concentrations of one or more of: point defects in a crystal lattice, vacancies, line defects such as dislocations, interstitial atoms, amorphous regions, grain and sub grain boundaries and the like relative to its normal ordered crystalline state. Atomic disorder leads to irregularities in surface topography and inhomogeneities in the structure on a nanometer scale. "Normal ordered crystalline state" means the crystallinity normally found in bulk metal materials, alloys or compounds formed as cast, wrought or plated metal products. Such materials contain only low concentrations of such atomic defects as vacancies, grain boundaries and dislocations.
"Diffusion", when used to describe condition's which limit diffusion in processes to create and retain atomic disorder, i.e. which freeze-in atomic disorder, means diffusion of atoms (adatom diffusion) and/or molecules on the surface or in the matrix of the material being formed.
"Alcohol or water-based electrolyte" is meant to include any alcohol or water-based electrolyte that the antimicrobial materials of the present invention might contact in order to activate (i.e. cause the release of species of the antimicrobial metal) into same. The term is meant to include alcohols (short chain (C6or less) and preferably C4or less), water, gels, fluids, solvents, and tissues containing, secreting, or exuding water or water-based electrolytes, including body fluids (for example blood, urine, or saliva), and body tissue (for example skin).
"Bioabsorbable" as used herein in association includes substrates which are useful in medical devices, that is which are biocompatible, and which are capable of bioabsorption in period of time ranging from hours to years, depending on the particular application.
"Bioabsorption" means the disappearance of materials from their initial application site in the body (human or mammalian) with or without degradation of the dispersed polymer molecules.
"Colour change" is meant to include changes of intensity of light under monochromatic light as well as changes of hue from white light containing more than one wavelength.
An "interference colour" is produced when light impinges on two or more partly reflective surfaces separated by a distance which bears the right relationship to the wavelength of the light to be removed by destructive interference.
"Partly reflective" when used to describe the base or top layer materials, means that the material has a surface which reflects a portion of incident light, but which also transmits a portion of the incident light. Reflection occurs when a ray of incoming light encounters a boundary or interface characterized by a change in refractive index between two media. For the top layer of the antimicrobial materials of this invention, that interface is with air. For the base layer, the interface is with the top layer. The reflectance of the base and top layers is balanced so as to generate an interference colour.
"Partly light transmissive" when used to describe a thin film of the top layer material means that the thin film is capable of transmitting at least a portion of incident visible light through the thin film.
"Detectable" when used to describe a colour change means an observable shift in the dominant wavelength of the reflected light, whether the change is detected by instrument, such as a spectrophotometer, or by the human eye. The dominant wavelength is the wavelength responsible for the colour being observed.
"Cold working" as used herein indicates that the material has been mechanically worked such as by milling, grinding, hammering, mortar and pestle or compressing, at temperatures lower than the recrystallization temperature of the material. This ensures that atomic disorder imparted through working is retained in the material.
"Pharmaceutically- or therapeutically-acceptable" is used herein to denote a substance which does not significantly interfere with the effectiveness or the biological activity of the active ingredients (antimicrobial and anti-inflammatory activities) and which has an acceptable toxic profile for the host to which it is administered.
"Therapeutically effective amount" is used herein to denote any amount of a formulation of the antimicrobial or noble metals which will exhibit either or both of an antimicrobial and optionally an anti-inflammatory effect, when applied to the affected area of the skin. A single application of the formulations of the present invention may be sufficient, or the formulations may be applied repeatedly over a period of time, such as several times a day for a period of days or weeks. The amount of the active ingredient, that is the antimicrobial or noble metal in the form of a coating, powder or dissolved in liquid solution, will vary with the conditions being treated, the stage of advancement of the condition, the age and type of host, and the type and concentration of the formulation being applied. Appropriate amounts in any given instance will be readily apparent to those skilled in the art or capable of determination by routine experimentation.
"Carrier" means a suitable vehicle including one or more solid, semisolid or liquid diluents, excipients or encapsulating substances which are suitable for administration to the skin. "Nanocrystalline" is used herein to denote single-phase or multi-phase polycrystals, the grain size of which is less than about 100, more preferably < 50, even more preferably <40, even more preferably <30, and most preferably < 25 nanometers in at least one dimension. The term, as applied to the crystallite or grain size in the crystal lattice of coatings, powders or flakes of the antimicrobial or noble metals, is not meant to restrict the particle size of the materials when used in a powder form.
"Powder" is used herein to include particulates of the antimicrobial or noble metals ranging from nanocrystalline (less than 100 nm) to submicron sized powders up to flakes. Preferably, powders of the antimicrobial or noble metals used in the present invention are sized at less than 100 μm, and more preferably less than 40 μm., and most preferably less than 10 μm.
"Grain size", or "crystallite size" means the size of the largest dimension of the crystals in the antimicrobial metal coating or powder.
"Hydrocolloid" means a synthetically prepared or naturally occurring polymer capable of forming a thickened gel in the presence of water and polyols (swelling agent). The swelling agent must be capable of swelling the hydrocolloid chosen in order to form the gel phase.
"Hydrogels" means a hydrocolloid swollen with water or another hydrophilic liquid which is used for absorbing or retaining moisture or water.
"Gel" means a composition that is of suitable viscosity for such purposes, e.g., a composition that is of a viscosity that enables it to be applied and remain on the skin.
When used herein and in the claims, the term "nanocrystalline antimicrobial metal" and similar terminology, such as "nanocrystalline coatings or powders" is meant to refer to antimicrobial metals formed with atomic disorder and having a nanocrystalline grain size.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 is a graph showing the efficacy of the nanocrystalline silver powder compared to Protopic™ or tacrolimus (non-steroidal anti-inflammatory), Elocon™ (medium strength steroid) and Ultravate™ (high strength steroid), on erythema.
Figure 2 is a graph showing the efficacy of the nanocrystalline silver powder compared to Protopic™ or tacrolimus (non-steroidal anti-inflammatory), Elocon™ (medium strength steroid) and Ultravate™ (high strength steroid), on edema. DESCRIPTION OF THE PREFERRED EMBODIMENTS
Crystalline forms of the antimicrobial metals can be prepared as coatings or powders, or as solutions prepared by dissolving the coatings or powders. The crystalline coatings or powders are most preferably formed with atomic disorder in accordance with the techniques published in the prior patent applications of Burrell et at, see for example WO 93/23092, published November 25, 1993, WO 95/13704, published May 26, 1995 and WO 98/41095, published September 24, 1998.
Pharmaceutical formulations for treatment of inflammatory skin conditions utilize the antimicrobial metals in powder, coatings or solution form. Preparation of the antimicrobial metals as powders or coatings is set out below in section A, format for formulations are set forth in section B, sterilization in section C, and formulating, dosages and treatment are set forth in section D.
A. Preparation of Crystalline Forms of the Antimicrobial Metals with Atomic Disorder a) Antimicrobial Metal Coatings on Dressings or Other Substrates
Dressings or other substrates such as packings, vials, fabric, fibres etc. may be coated with antimicrobial coatings formed with atomic disorder. The description below is directed to coatings on dressing materials, but the coating techniques are equally applicable to coating other substrates. Dressings coated with antimicrobial metals in accordance with the invention include one or more layers of medical dressing materials. Multiple layers may be laminated together by known means such as low temperature thermal fusing, stitching or, most preferably, ultrasonic welding.
The dressing may be formed to include an occlusive or semi-occlusive layer such as an adhesive tape or polyurethane film in order to secure the dressing in place, and retain moisture for release of ions, atoms, molecules or clusters of the antimicrobial metal (hereinafter antimicrobial metal species).
The preferred and alternate compositions of the dressing layers, together with the preferred nanocrystalline antimicrobial metal coatings, are set out in further detail below, i) Dressing Materials
The dressing is formed of a perforated, preferably non-adherent material which allows for fluids to penetrate or diffuse there through in either or both directions. The perforated material may be formed of a woven or non-woven, non-woven being preferred, fabric such as cotton, gauze, a polymeric net or mesh such as polyethylene, nylon, polypropylene or polyester, an elastomer such as polyurethane or polybutadiene elastomers, or a foam such as open cell polyurethane foam. Exemplary perforated, non-adherent materials useful for the dressing include non-woven meshes such as DELNET™ P530, which is a non-woven veil formed of high density polyethylene using extrusion, embossing and orientation processes, produced by Applied Extrusion Technologies, Inc. of Middletown, Delaware, USA. This same product is available as Exu-Dry CONFORMANT 2™ Wound Veil, from Frass Survival Systems, Inc., Bronx, New York, USA as a subset of that company's Wound Dressing Roll (Non- Adherent) products. Other useful non- woven meshes include CARELLE™ or NYLON 90™, available from Carolina Formed Fabrics Corp., N-TERFACE™, available from Winfield Laboratories, Inc., of Richardson, Texas, USA. Exemplary woven meshes may be formed from fibreglass or acetate, or cotton gauze. An exemplary hydrophilic polyurethane foam is HYPOL™, available from W.R. Grace & Co., New York, NY, USA.
For ease of ultrasonic welding for lamination, at least one dressing layer is preferably formed from a polymeric material which is amenable to ultrasonic welding, that is which will melt on the application of localized heat and then fuse multiple layers together on cooling.
If desired, a second, absorbent layer is formed from an absorbent material for holding sufficient moisture next to the skin in order to activate the antimicrobial metal coating, that is to cause release of ions, molecules, atoms or clusters of the antimicrobial metal in order to cause an antimicrobial and anti-inflammatory effect. Preferably, the absorbent material is an absorbent needle punched non-woven rayon/polyester core such as SONTARA™ 8411, a 70/30 rayon polyester blend commercially available from Dupont Canada, Mississauga, Ontario, Canada. This product is sold by National Patent Medical as an American White Cross sterile gauze pad. However, other suitable absorbent materials include woven or non- woven materials, non-woven being preferred made from fibers such as rayon, polyester, rayon/polyester, polyester/cotton, cotton and cellulosic fibers. Exemplary are creped cellulose wadding, an air felt of air laid pulp fibers, cotton, gauze, and other well known absorbent materials suitable for medical dressings.
A third layer of the dressing, if used, is preferably formed of perforated, non-adherent material such as used in the first layer. This allows moisture penetration as sterile water and the like are added in order to activate the antimicrobial metal coating. Additional layers may be included between or above the first, second and third layers as is well known in medical dressings. The coated dressing layers may be combined with an adhesive layer, in a well known manner.
The dressing may be used as a single layer, or may be used as multiple layers laminated together at intermittent spaced locations across the dressing by ultrasonic welds. Ultrasonic welding is a known technique in the quilting art. Briefly, heat (generated ultrasonically) and pressure are applied to either side of the dressing at localized spots through an ultrasonic horn so as to cause flowing of at least one of the plastic materials in the first and second layers and the subsequent bonding together of the layers on cooling. The welds appear at localized circular spots and are preferably less than 0.5 cm in diameter.
The use of ultrasonic welding of the layers at spaced locations has the advantage of retaining the absorbent and moisture penetration properties of the dressing layers, while retaining the conforming properties of the dressing. Edge seams, stitching and adhesives have the disadvantage of interfering with one or more of these desirable properties of the dressings. Furthermore, by spacing the welds at intermittent locations across the dressing, the dressing may be cut to smaller sizes, as needed, without causing delamination. Preferred spacings of about 2.5 cm between welds allows the dressing to be cut down to about 2.5 cm sizes, while maintaining at least one weld to hold the laminated layers together, ii) Nanocrystalline Coatings of Antimicrobial Metals
The coated substrate, for example a dressing, preferably includes a nanocrystalline coating of one or more of the antimicrobial metals. The coating is applied to one or more of the dressing layers, but is most preferably applied at least to the skin facing layer.
The nanocrystalline coating is most preferably formed with atomic disorder in accordance with the procedures set out above and as described in WO 93/23092, WO 95/13704, and WO98/41095, and as set out below. Most preferably, the coating is formed as a multilayer coating of the antimicrobial metals, having a top and a base layer, as set below, to produce an interference colour. In this way, the coating provides not only the active ingredient for the treatment of inflammatory skin conditions, but also acts as an indicator of activation of the dressing. As the top layer of the coating is activated with an alcohol or water-based electrolyte, such as sterile water or ethanol, even minor dissolution of the antimicrobial metal results in a detectable colour change, indicating that the coating has been activated. If there is no colour change, additional moisture might be provided to the dressing by adding water, until a colour change is detected. Once activated, the dressing should be maintained in a moist condition, for example by the addition of sterile water, if necessary, iii) Multilayer Nanocrystalline Coatings of Antimicrobial Metals With Interference Colour
The coated substrates, for example dressings may include the antimicrobial metal coating formed with at least two metal layers, a base layer and a top layer over the base layer, so as to produce an interference colour, as set forth in WO 98/41095, the teachings of which are incorporated herewith by reference. The indicator colour can function as an indicator when contacted with a water or alcohol based electrolyte, since the coating will change colour. An exemplary multilayer nanocrystalline coating of silver with a blue interference colour is set forth in Example 1. iv) Nanocrystalline Coatings of Antimicrobial Metals Containing Atomic Disorder
The coatings of the present invention are formed in a crystalline form from one or more antimicrobial metals with atomic disorder. The production of atomic disorder through physical vapour deposition techniques is described in WO 93/23092 and WO 95/13704, and as outlined below.
The antimicrobial metal is deposited as a thin metallic film on one or more surfaces of the dressing by vapour deposition techniques. Physical vapour techniques, which are well known in the art, all deposit the metal from the vapour, generally atom by atom, onto a substrate surface. The techniques include vacuum or arc evaporation, sputtering, magnetron sputtering and ion plating. The deposition is conducted in a manner to create atomic disorder in the coating as defined above. Various conditions responsible for producing atomic disorder are useful. These conditions are generally those which one has been taught to avoid in thin film deposition techniques, since the object of most thin film depositions is to create a defect free, smooth and dense film (see for example J.A. Thornton, "Influence of Apparatus Geometry and Deposition Conditions on the Structure and Topography of Thick Sputtered Coatings," J. Vac. Sci. Technol., 11(4), 666-670, 1974).
The preferred conditions which are used to create atomic disorder during the deposition process include:
- a low substrate temperature, that is maintaining the surface to be coated at a temperature such that the ratio of the substrate temperature to the melting point of the metal (in degrees Kelvin) is less than about 0.5, more preferably less than about 0.35 and most preferably less than about 0.3; and optionally one or both of:
- a higher than normal working gas pressure (or ambient pressure in depositions not using a working gas), i.e. for vacuum evaporation: e-beam or arc evaporation, greater than 0.001 Pa (0.01 mT), gas scattering evaporation (pressure plating) or reactive arc evaporation, greater than 2.67 Pa (20 mT); for sputtering: greater than 10 Pa (75 mT); for magnetron sputtering: greater than about 1.33 Pa (10 mT); and for ion plating: greater than about 26.67 Pa (200 mT); and
- maintaining the angle of incidence of the coating flux on the surface to be coated at less than about 75°, and preferably less than about 30°.
For economic reasons, the thin metal film has a thickness no greater than that needed to provide release of antimicrobial metal species on a sustainable basis over a suitable period of time, and to generate the desired interference colour. Within the preferred ranges of thicknesses set out above, the thickness will vary with the particular metal in the coating (which varies the solubility and abrasion resistance), and with the degree of atomic disorder in (and thus the solubility of) the coating. The thickness will be thin enough that the coating does not interfere with the dimensional tolerances or flexibility of the device for its intended utility.
The therapeutic effect of the material so produced is achieved when the coating is brought into contact with an alcohol or a water based electrolyte, thus releasing metal ions, atoms, molecules or clusters. The concentration of the metal species which is needed to produce a therapeutic effect will vary from metal to metal.
The ability to achieve release of metal atoms, ions, molecules or clusters on a sustainable basis from a coating is dictated by a number of factors, including coating characteristics such as composition, structure, solubility and thickness, and the nature of the environment in which the device is used. As the level of atomic disorder is increased, the amount of metal species released per unit time increases. For instance, a silver metal film deposited by magnetron sputtering at T/Tm < 0.5 and a working gas pressure of about 0.93 Pa (7 mT) releases approximately 1/3 of the silver ions that a film deposited under similar conditions, but at 4 Pa (30 mT), will release over 10 days. Films that are created with an intermediate structure (ex. lower pressure, lower angle of incidence etc.) have Ag release values intermediate to these values as determined by bioassays. This then provides a method for producing controlled release metallic coatings. Slow release coatings are prepared such that the degree of disorder is low while fast release coatings are prepared such that the degree of disorder is high.
For continuous, uniform coatings, the time required for total dissolution will be a function of film thickness and the nature of the environment to which they are exposed. The relationship in respect of thickness is approximately linear, i.e. a two fold increase in film thickness will result in about a two fold increase in longevity.
It is also possible to control the metal release from a coating by forming a thin film coating with a modulated structure. For instance, a coating deposited by magnetron sputtering such that the working gas pressure was low (ex. 2 Pa or 15 mT) for 50% of the deposition time and high (ex. 4 Pa or 30 mTorr) for the remaining time, has a rapid initial release of metal ions, followed by a longer period of slow release. This type of coating is extremely effective on devices such as urinary catheters for which an initial rapid release is required to achieve immediate antimicrobial concentrations followed by a lower release rate to sustain the concentration of metal ions over a period of weeks.
The substrate temperature used during vapour deposition should not be so low that annealing or recrystallization of the coating takes place as the coating warms to ambient temperatures or the temperatures at which it is to be used (ex. body temperature). This allowable ΔT, that the temperature differential between the substrate temperature during deposition and the ultimate temperature of use, will vary from metal to metal. For the most preferred metal, Ag, preferred substrate temperatures of -20 to 200°C , more preferably -10°C to 100°C are used.
Atomic order may also be achieved, in either or both of the base and top layers by preparing composite metal materials, that is materials which contain one or more antimicrobial metals in a metal matrix which includes atoms or molecules different from the antimicrobial metals.
The preferred technique for preparing a composite material is to co- or sequentially deposit the antimicrobial metal(s) with one or more other inert, biocompatible metals selected from Ta, Ti, Nb, Zn, V, Hf, Mo, Si, Al and alloys of these metals or other metal elements, typically other transition metals. Such inert metals have a different atomic radii from that of the antimicrobial metals, which results in atomic disorder during deposition. Alloys of this kind can also serve to reduce atomic diffusion and thus stabilize the disordered structure. Thin film deposition equipment with multiple targets for the placement of each of the antimicrobial and biocompatible metals is preferably utilized. When layers are sequentially deposited the layer(s) of the biocompatible metal(s) should be discontinuous, for example as islands within the antimicrobial metal matrix. The final weight ratio of the antimicrobial metal(s) to biocompatible metal(s) should be greater than about 0.2. The most preferable biocompatible metals are Ti, Ta, Zn and Nb. It is also possible to form the antimicrobial coating from oxides, carbides, nitrides, sulphides, borides, halides or hydrides of one or more of the antimicrobial metals and/or one or more of the biocompatible metals to achieve the desired atomic disorder.
Another composite material may be formed by reactively co- or sequentially depositing, by physical vapour techniques, a reacted material into the thin film of the antimicrobial metal(s). The reacted material is an oxide, nitride, carbide, boride, sulphide, hydride or halide of the antimicrobial and/or biocompatible metal, formed in situ by injecting the appropriate reactants, or gases containing same, (ex. air, oxygen, water, nitrogen, hydrogen, boron, sulphur, halogens) into the deposition chamber. Atoms or molecules of these gases may also become absorbed or trapped in the metal film to create atomic disorder. The reactant may be continuously supplied during deposition for codeposition or it may be pulsed to provide for sequential deposition. The final weight ratio of reaction product to antimicrobial metal(s) should be greater than about 0.05. Air, oxygen, nitrogen and hydrogen are particularly preferred reactants, with oxygen being most preferred.
The above deposition techniques to prepare composite coatings may be used with or without the conditions of lower substrate temperatures, high working gas pressures and low angles of incidence previously discussed. One or more of these conditions are preferred to retain and enhance the amount of atomic disorder created in the coating.
The most preferred composite coatings are formed by sputtering silver, under conditions set out above, in an atmosphere containing oxygen, so as to form a coating of silver as a composite coating with oxygen.
Dressings coated with the antimicrobial coatings of this invention may be sterilized in the manner set out below. b) Powders of Atomically Disordered Antimicrobial Metals
Crystalline powder forms of the antimicrobial or noble metals (particularly preferred being Ag, Au, Pt, and Pd) can be prepared as free standing powders, by coating powdered substrates, or from coatings on substrates which are then collected, for example by scaping and then sized. The powders may be prepared as pure metals, metal alloys or compounds such as metal oxides or metal salts, by vapour deposition, mechanical working, or compressing to impart the atomic disorder. The crystalline powders are formed with atomic disorder in accordance with the techniques set out above and as published in the prior patent applications of Burrell et al., see for example WO 93/23092, published November 25, 1993, and WO 95/13704, published May 26, 1995. The atomic disorder will most typically be formed in the metal powders during physical vapour deposition as set out above for coatings or by mechanically imparting the disorder, such as by milling, grinding, hammering, mortar and pestle or compressing, under conditions of low temperature (i.e., temperatures less than the temperature of recrystallization of the material) to ensure that annealing or recyrstallization does not take place.
Alternatively, the powders may be formed by inert-gas condensation techniques, which are modified to provide atomic disorder in the powder produced, as taught in WO 95/13704 to Burrell et al.
Powders of the antimicrobial or noble metals are preferably formed by physical vapour deposition (PVD) onto a substrate such as a cold finger, a silicon wafer, solid plates, a rotating cylinder, a continuous belt in a roll coater, or on steel collectors in known PVD coaters. Preparation of powders of the present invention by sputtering onto a continuous belt in a roll coater, or other some other moving or rotating substrate surface is particularly advantageous, inasmuch as it can quickly and easily yield a relatively large supply of free-standing powder at a relatively low cost. A stainless steel belt can be used in the roll coating process without the need to provide additional cooling of the substrate. The powders or coatings and then are then scraped off to form a powder, and may be sized to avoid overly large particulates. The powders are scraped off the moving surface with scrapers which contact the moving surface at an angle sufficient to remove the coating in flake or powder form. The coating may be scraped off with scrapers angled for forward cutting of the coating from the moving surface, or with scrapers which remove the coating from the moving surface by reverse dragging action on the surface. The scrapers may be suspended above the belt, and either weighted or spring loaded to apply pressure sufficient to remove the coating from the moving surface. With a continuous belt, the scrapers can conveniently be located above the end rollers to remove the coating with a reverse dragging action as the belt rounds the end roller.
Alternatively, the powders of the antimicrobial or noble metals may be formed on powdered substrates which are biocompatible, or otherwise compatible for the end use of the powder. Particularly preferred powdered substrates are hydrocolloids, particularly those which are bioabsorbable and/or hygroscopic powders such as chitin. Exemplary bioabsorbable and/or hygroscopic powders are composed of :
Synthetic Bioabsorbable Polymers: for example polyesters/polyactones such as polymers of polyglycolic acid, glycolide, lactic acid, lactide, dioxanone, trimethylene carbonate etc., polyanhydrides, polyesteramides, polyortheoesters, polyphosphazenes, and copolymers of these and related polymers or monomers. Naturally Derived Polymers: Proteins: albumin, fibrin, collagen, elastin; Polysaccharides: chitosan, alginates, hyaluronic acid; and Biosynthetic Polyesters: 3-hydroxybutyrate polymers.
The powders may be incorporated into or onto medical dressings or pharmaceutical formulations, by any methods known in the art. For example, the powders may be layered onto the substrates (dressings or powders), mechanically fixed within the fibres of the dressings, impregnated into dressings by physical blowing, or added to topical pharmaceutical ingredients.
Preferably, powders of the present invention are sized at less than 100 μm, and more preferably less than 40 μm, and most preferably about 3 - 5 μm in size. For direct application to the skin, powders are preferably sized less than 2 μm, and more preferably less than 1 μm. B. Formulations for Administration to the Skin
1. Coated substrates coated with antimicrobial metals formed with atomic disorder are well described above. These techniques can be used to coat dressings, meshes, films, packing fibres, the insides of vials or containers etc. The coated substrates in the form of dressings for example, can be used directly on the affected area of the skin, or they can be used to generate powders, liquid or other formulations as set out below. 2. Powders of the antimicrobial metals formed with atomic disorder are set out above, and may be used in that form directly on the affected area of the skin, or in other formulations such as dressings, occlusions, creams, liquids etc. Alternatively, powders may be formulated within liquid pervious membranes such as filters, meshes and the like, such as a tea bag-type infuser, for generating liquids containing dissolved species of the antimicrobial metal.
3. Occlusions may include a hydrated dressing, with a sealing material overlaid on the outside, to the area of skin to be treated. The term hydrated dressing is meant to include non-hydrated dressings which become hydrated upon contact with an alcohol or water-based electrolyte. Occlusion prevents loss of the therapeutic agent from the skin, promotes skin hydration, and increases skin temperature. Examples of hydrated dressings include hydrocolloids, hydrogels, polyethylene, polyurethane, polyvinylidine, and siloxane or silicone dressings. A hydrated dressing may also comprise a non-hydrated dressing which becomes hydrated upon contact with an alcohol or water-based electrolyte. The hydrated dressing can either be impregnated with a solution or powder of the antimicrobial metals of this invention, or can be used with a topical formulation of the antimicrobial metals of this invention.
An exemplary occlusion is a hydrocolloid dressing impregnated with nanocrystalline silver. Alternatively, one might use a non-impregnated hydrocolloid dressing to occlude a nanocrystalline silver-containing gel placed on a problematic area of the skin. A hydrocolloid is a synthetically prepared or naturally occurring polymer capable of forming a thickened gel in the presence of water and polyols (swelling agent). The swelling agent is a hydrophilic liquid capable of swelling the hydrocolloid chosen in order to form the gel phase. The hydrocolloid may be selected from the group comprising: i representative natural or synthetically modified polysaccharides (e.g., cellulose or its derivatives such as carboxymethylcellulose, hydroxypropylcellulose, methylcellulose, hydroxypropylmethylcellulose or hydroxyethylcellulose, starch, glycogen, gelatin, pectin, chitosan and chitin; and ii representative gums from algal extracts, seed extracts, or plant exudates (e.g., gum arabic, locust bean gum, karaya gum, gum tragacanth, ghatti gum, agar-agar, carrageenans, alginates, carob gum, guar gum, xanthan gum); and iii synthetic polymers which may be either linear or crosslinked (e.g. polymers prepared from N-vinyl lactams, e.g. N-vinyl-2-pyrrolidone, 5-methyl-N-vinyl-2-pyrrolidone). The hydrocolloid is present in an amount of from about 0.1% to 20% of the weight and preferably 1% to 10%. The hydrocolloid can range for example, from 1 to 10% of the total weight of the composition. Alternatively, the hydrocolloid may be in the form of a powder whose average particle size is less than 100 μm, preferably less than 50 μm.
The swelling agent should be non-volatile, and allow the gel to remain as a gel during use, hence preserving the swollen condition of the hydrocolloid. Varieties of non- volatile swelling agents include room temperature liquid polyols (including polyhydric alcohols) such as glycerol; room temperature solid polyols (including polyhydric alcohols) such as sorbitol, erytbritol, threitol, ribotol, arabinitol, xylitol, allitol, talitol, mannitol, glucitol, glactitol, iditol, pentaerythritol, heptitol, octitol, nonitol, decitol, and dodecitol, blended with a room temperature liquid polyol; monoanhydroalditols (such as styracitol, polyalitol, D-fructose, 1,4 anhydro-D-mannitol and 1,4 anhydro-D-glucitol) blended with a room temperature liquid polyol; monosaccharides (such as pentoses, hexoses, and heptoses) blended with a room temperature liquid polyol; and ether alcohols blended with a room temperature liquid polyol.
Hydrocolloid dressings often comprise a wafer constructed from a thin layer of polyurethane film with an adhesive skin contact layer containing a hydrocolloid composition and securing the dressing to the skin, and the polyurethane film being impermeable to water and microorganisms. Hydrocolloid dressings may be prepared by dispersing a composition in gel form of hydrocolloids with a swelling agent into a strong pressure sensitive adhesive. Alternatively, the gel and the adhesive may be mixed in a latex solution. Alternatively, exemplary products are available commercially, for example DuoDERM™ (ConvaTec Canada, 555, Dr. Frederik Philips, Suite 110, St-Laurent, Quebec, H4M 2X4); and Tegasorb™ (3M Health Care, 300 Tartan Drive, London, Ontario, Canada, N5V 4M9). The hydrocolloid dressing may be impregnated with a solution or powder of the antimicrobial metals by blending the solution or powder of the antimicrobial metal into a liquid phase during the manufacture of the hydrocolloid dressing, or by sprinkling and then pressing a powder of the antimicrobial metal into the surface of the hydrocolloid dressing. Further, the hydrocolloid dressing can be used with a topical formulation of the antimicrobial metals of this invention. Upon application, the dressing surface gels upon continued contact with moisture or exudate from the skin. With the incorporation of an antimicrobial metal such as silver (0.01-10%, preferably 0.1-1% by weight), the dressing is advantageous in being impermeable to water and microorganisms, and presenting antimicrobial and anti-inflammatory effects as mediated by the antimicrobial metal.
4. Gels - Nanocrystalline gels may be formed from the nanocrystalline metal powder in admixture with gelling agents such as hydrocolloids and hydrogels in powder form. Exemplary gelling agents include carboxymethyl cellulose (CMC), polyvinyl alcohol (PVA), collagen, pectin, gelatin, agarose, chitin, chitosan, and alginate, with the gelling agent comprising between about 0.01 . 20 % w/v. Examples of gel preparations are set out in Example 11. Example 12 demonstrates the use of a nanocrystalline silver gel preparation as set forth in Example 11, with a non-impregnated hydrocolloid dressing to occlude the nanocrystalline silver gel placed on a problematic area of the skin.
5. Creams, Lotions. Pastes. Ointments, Foams - The antimicrobial metals may be incorporated into creams, lotions, pastes, ointments or foams formulated with nanocrystalline powders or solutions of the antimicrobial metals, for example as emulsions or with drying emollients. Ointments and creams can be formulated with an aqueous or oily base with the addition of suitable thickening and/or gelling agents. Such bases may include water and/or an oil such as liquid paraffin or a vegetable oil such as peanut oil or castor oil. An exemplary base is water. Thickening agents which can be used according to the nature of the base include aluminum stearate, hydrogenated lanolin, and the like. Further, lotions can be formulated with an aqueous base and will, in general, also include one or more of the following: stabilizing agents, emulsifying agents, dispersing agents, suspending agents, thickening agents, coloring agents, perfumes, and the like. Ointments and creams can also contain excipients, such as starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, and talc, or mixtures thereof. Lotions may be formulated with an aqueous or oily base and will, in general, also include one or more of the following: stabilizing agents, emulsifying agents, dispersing agents, suspending agents, thickening agents, coloring agents, perfumes, and the like. Foams may be formed with known foaming or surface active agents.
6. Liquids - The crystalline forms of the antimicrobial metals may be incorporated into liquids, formulated as solutions, dispersions or suspensions by dissolving nanocrystalline coatings or powders of the antimicrobial metals, for example as topical solutions, aerosols, mists, sprays, or drops. Topical administration of the antimicrobial metal to the skin may be performed by aerosol, which can be generated by a nebulizer, or by instillation. The antimicrobial metal may be administered alone, or with a carrier such as saline solution, an alcohol, water, or DMSO. An effective daily amount of the antimicrobial metal will vary with the subject, but will be less than is toxic while still providing a therapeutic effect.
Solutions and formulations of the antimicrobial metals may lose some activity with aging and are thus either stabilized or generated fresh for administration. Alternatively, the antimicrobial metals may be packaged for convenient solution generation, for instance as tea bag type infusers. Other two part or two phase systems may be used in which the nanocrystalline metal is separated from the water or alcohol-based electrolyte, for example in a multicomponent kit form, as set out herein.
Concentrations of the antimicrobial metal species in solution will vary according to the application, formulation and subject, but will generally range from 1 - 5000 μg/ml, more preferably 20 - 3000 μg/ml, more preferably 40 - 800 μg/ml, and most preferably 50 - 500 μg/ml. Methods of generating liquids with appropriate concentrations of the antimicrobial metal through pH control are set out below. 7. Transdermal Patch
Transdermal patches may provide controlled delivery of the antimicrobial metal to the skin. For example, an adhesive patch or adhesive matrix patch, can be prepared from a backing material and an adhesive, such as an acrylate adhesive. Powders or solutions of the antimicrobial metal may be formulated into the adhesive casting solution and allowed to mix thoroughly. The solution is cast directly onto the backing material and the casting solvent is evaporated in an oven, leaving an adhesive film. Alternatively, a polyurethane matrix patch can be employed to deliver the antimicrobial metal to the skin. The layers of this patch comprise a backing, a polyurethane drug/enhancer matrix, a membrane, an adhesive, and a release liner. The polyurethane matrix is prepared using a room temperature curing polyurethane prepolymer. Addition of water, alcohol, and drug to the prepolymer results in the formation of a tacky firm elastomer that can be directly cast onto the backing material. C. Sterilization
Dressings with nanocrystalline coatings of a antimicrobial metal formed with atomic disorder are preferably sterilized without applying excessive thermal energy, which can anneal out the atomic disorder, thereby reducing or eliminating a useful release of antimicrobial metal species. Gamma radiation is preferred for sterilizing such dressings, as discussed in WO 95/13704. Electron beam and ethylene oxide sterilization techniques can also be used.
It should be appreciated that the use of ultrasonic welding to laminate the layers of dressings with nanocrystalline coatings formed from antimicrobial metals with atomic disorder is advantageous since it achieves bonding in localized spots and avoids applying heat to any significant portion of the dressing, thereby avoiding any significant reduction in the solubility of the antimicrobial metals through annealing out of the atomic disorder.
The sterilized dressings, coating, powders or formulations should be sealed in packaging, containers, or kits which limit moisture and light penetration to avoid additional oxidation or reduction of the antimicrobial metal. Polyester peelable pouches are preferred. The shelf life of coatings or powders thus sealed is over one year. D. Formulating, Dosages and Treatment
Typically, the nanocrystalline antimicrobial metals will be formulated from the active ingredient, namely nanocrystalline powders or coatings of the antimicrobial metals, or dissolved species from such powders or coatings, in the one or more of the formats set out above. Dressing or powders of the nanocrystalline antimicrobial metals may be applied directly to the skin, or they may be formulated as set out below. Depending on the particular application and dosage form, the powder size might be controlled to less than 2 μm, more preferably to less than 1 μm.
In the pharmaceutical compositions, the amount of the nanocrystalline metal powder may range broadly from about 0.001% to about 30% by weight, but will more preferably fall in the range of from about 0.1 to 10% by weight, and most preferably in the range of about 0.01 to 5% by weight. Typical coating thicknesses are in the range of 150 to 3000 nm thick. Thicker coatings, up to 10,000 nm thick, can be used to generate powders of the antimicrobial metal. Coatings of the nanocrystalline antimicrobial metals may be very thin, or thick, depending on the desired duration of application on the patient. As liquid formulations, the amount of dissolved antimicrobial metal will typically range between about 0.001 to 10% by weight, more preferably 0.01 to 1% by weight.
Besides the active ingredient, pharmaceutical compositions may also include non-toxic, pharmaceutically acceptable carriers, diluents and excipients, suitable for topical application, as are well known, see for example Merck Index, Merck & Co., Rahway, N.J.; and Gilman et al., (eds) (1996) Goodman and Gilman's: The Pharmacological Bases of Therapeutics, 8th Ed., Pergamon Press. For standard dosages of conventional pharmacological agents, see, e.g., Physicians Desk Reference (1997 Edition); and U.S. Pharmacopeia National Formulary (1995) United States Pharmacopeial Convention Inc., Rockville, Maryland.
Dosage forms for the topical administration of compositions of the nanocrystalline antimicrobial metals include various mixtures and combinations that can be applied topically and will permit even spreading and absorption into the cutaneous surfaces. Examples include sprays, mists, aerosols, lotions, creams, solutions, gels, ointments, pastes, emulsions, foams and suspensions. The active compound can be mixed under sterile conditions with a pharmaceutically acceptable carrier, and with any preservatives, buffers, or propellants which may be required. Topical preparations can be prepared by combining the antimicrobial metal powder with conventional pharmaceutically acceptable carriers commonly used in topical dry, liquid, cream and aerosol formulations. For example, in cases of distal and/or lateral subungual onychomycosis and proximal subungual onychomycosis, infection may extend under the nail plate; thus, topical formulations such as a liquid, solid, or gel must thus be able to pass through the hard nail plate in order to contact the affected area. The affected nail can be initially hydrated using urea (1-40%) or lactic acid (10-15%), and then treated with the antimicrobial metal (0.1-2%, more preferably 0.1-1%) in DMSO (0.4-50%), a carrier which can infiltrate the nail.
Ointment and creams can, for example, be formulated with an aqueous or oily base with the addition of suitable thickening and/or gelling agents. An exemplary base is water. Thickening agents can be used according to the nature of the base. Lotions can be formulated with an aqueous base and will, in general, also include one or more of the following: stabilizing agents, emulsifying agents, dispersing agents, suspending agents, thickening agents, coloring agents, perfumes, and the like. Powders can be formed with the aid of any suitable powder base, e.g., talc, lactose starch and the like. Drops can be formulated with an aqueous base or non-aqueous base, and can also include one or more dispersing agents, suspending agents, solubilizing agents, surface active agents and the like.
Ointments, pastes, creams and gels also can contain excipients, such as starch, tragacanth, cellulose derivatives, silicones, bentonites, silicic acid, and talc, or mixtures thereof. Powders and sprays also can contain excipients such as lactose, talc, silicic acid, aluminum hydroxide, and calcium silicates, or mixtures of these substances. Solutions of nanocrystalline antimicrobial metals can be converted into aerosols or sprays by any of the known means routinely used for making aerosol pharmaceuticals. In general, such methods comprise pressurizing or providing a means for pressurizing a container of the solution, usually with an inert carrier gas, and passing the pressurized gas through a small orifice. Sprays can additionally contain customary propellants, such inert gases such as nitrogen, carbon dioxide, argon or neon.
Multiple inactive ingredients are generally incorporated in topical formulations to improve cosmetic acceptability, and are optional ingredients in the formulations. Such ingredients are included only in therapeutically acceptable forms and amounts. Examples of ingredients are emulsifiers, emollients, thickening agents, solvents, hydrating or swelling agents, flavours, sweetening agents, surface active agents, colouring agents, anti-foaming agents, preservatives, fragrances, and fillers may also be added, as is well known in the art; for example, preservatives such as methyl paraben and propyl paraben, texturizing agents, thickeners, anticoagulants such as heparin, β-glucan, hormones, hyaluronic acid, immune potentiating agents such as adjuvants and cytokines such as epidermal growth factor, platelet derived growth factor, transforming growth factor and interleukins, and bone morphogenetic proteins, and the like. Polyvinyl alcohol is a particularly preferred gelling polymer and also acts as a texturizing agent, methyl or propyl parabens are particularly preferred preservatives. These other agents may be included in amounts in the range of 0.1 to 5 wt %.
Surface active agents or foaming agents may be added to the formulations and are particularly advantageous for addition to liquid formulations for use as skin cleansers or for aerosol or foam applications. Surface active agents selected for use should not substantially interfere with the antimicrobial or anti-inflammatory effects of the nanocrystalline antimicrobial metals.
All agents must be non-toxic and physiologically acceptable for the intended purpose, and must not substantially interfere with the activity of the nanocrystalline antimicrobial metals so as to deleteriously affect the antimicrobial and anti-inflammatory effect. Ingredients are thus only included in therapeutically acceptable amounts. Ingredients to be generally avoided or limited in the formulations of the present invention, at least in amounts greater than 0.01 wt %, are glycerin, glycerols, chloride salts, aldehydes, ketones, long chain alcohols, and triethanolamii
The dosage of the active ingredients depends upon many factors that are well known to those skilled in the art, for example, the particular form of the active ingredient, the condition being treated, the age, weight, and clinical condition of the recipient patient, and the experience and judgement of the clinician or practitioner administering the therapy. A therapeutically effective amount of the nanocrystalline antimicrobial metal provides either subjective relief of symptoms or an objectively identifiable improvement as noted by the clinician or other qualified observer. The dosing range varies with the metal used, its form, the route of administration and the potency of the particular compound.
When the formulation is in the form of a dressing, the dressing is placed on the affected area of the skin and, depending on the degree of moisture at the membrane, may be further moistened with drops of sterile water, tap water, body fluids such as exudate, or, for example 70% ethanol, in order to activate the coating for release of antimicrobial or noble metal species. The dressing may be then secured in place with an occlusive or semi-occlusive layer, such as an adhesive tape or polyurethane film, which keeps the dressing in a moist environment.
As set out in Examples 6 and 7 for acne, and Example 9 for eczema, dressings carrying a bi-layer nanocrystalline antimicrobial metal coating formed with silver having atomic disorder, manufactured as set out above and as described in greater detail in Example 1, have shown substantial clinical response in treating inflammatory skin conditions. Dressings prepared with a single layer of silver having a reduced content of oxygen in the coating, as set forth in Example 5, gave similar clinical results, without staining the skin. In use, the dressings are kept moist, at 100% relative humidity. Adding sterile water initially to activate the antimicrobial metal coating is needed, and then as needed to maintain the dressing in a moist condition. Dressings may be changed as required for observation and cleaning. Preferably dressings are changed daily, but could be left longer, such as 3 days, and can provide a therapeutic effect for a much longer period of time.
Other forms of formulations, such as occlusions, gels, pastes, ointments, creams, emulsions, foams, and liquids may be prepared in stable forms, or more preferably are prepared fresh from one or more phases, for instance in multicomponent kit form, so as to avoid aging and to maximize the therapeutic effectiveness of the antimicrobial metal component. Formulations are best used within about 30 days after combining the phases. Suitable kits or containers are well known for maintaining the phases of formulations separate until the time of use. For instance, the antimicrobial metal in powder or coated substrate form may be packages separately from therapeutically acceptable carriers, and possibly other ingredients for mixing at the time of use. The separate coated substrate may be in dressing or patch form for direct application, or may take other suitable forms to generate liquid formulations and the like, such as a coating on the inside surface of a vial or container, a mesh, or a film. For example, the antimicrobial metal may be provided in a "tea bag"-type infuser or pouch, for generating liquid formulations at the time of use. The tea bag-type infuser is advantageous in that the pouch may serve as a filter for small particulates of the powder that may be detrimental to administration for some applications such as aerosols for respiratory disorders. A kit containing the dressing, coated substrate or powder may provide a sterile carrier such as water (and other ingredients) in a separate container in dosage specific amounts. As used herein, the term "kit" is meant to refer to packaged formulations, whether the ingredients are in separate phases or mixed, and thus for example, may include a gel in a tube with all ingredients in admixture, or any formulation wherein the ingredients are separated from each other.
For liquid formulations, in order to increase the amount of antimicrobial or noble metal solubilized in the solution, the pH of the solution during dissolution may be lowered to less than pH 6.5, more preferably to the range of 3.5 to 6.5, with such acidifying agents as carbon dioxide (which generated carbonic acid in solution). This pH range will typically generate concentrations of silver from atomic disordered silver from 85 μg/ml to 370 μg/ml, and can be adjusted for different desired concentrations. Dissolution of the antimicrobial metal will typically raise the pH to 6.5 to 7.0.
Administration as aerosols produces droplets preferably less than 10 μm in size, more preferably less than 5 μm in size, most preferably 1 - 3 μm in size. Control of the droplet size is important both to control the dosage delivered and to enhance delivery to the target tissue; thus, depending on the dosage required and the target tissue, it may be important to regulate the droplet size of the aerosol. In this respect, it has been found that droplet size can be regulated, to at least some extent, by the mechanical mister which is used to produce the aerosol. In addition, the aerosol's droplet size can be adjusted, to at least some extent, by modifying the surface tension of the solution. More particularly, the solution of the antimicrobial metal typically has water as its solvent, and water has a relatively high surface tension, so it is relatively straightforward to create an aerosol having relatively small droplet size. Surface active agents can be added to the solution so as to reduce the surface tension of the solution, whereby to create an aerosol having a relatively large droplet size. By way of example, such surfactants may comprise sodium alkyl sulfates, sodium laryl sulfate, sodium lauroyl sarconsinate, phospholipids, e.g., lecithin, sphingomyelin, etc.
Depending on the application, solutions generated from powders of the antimicrobial metal should avoid inclusion of particulates larger than 2μm, and more preferably no larger than lμm (i.e., submicron) to avoid deleterious immune responses or toxic effects. Larger particulates may be removed by, for example filtration. Particulates may be formed in the liquid and can be removed, for example by filtration. For instance, silver carbonates may be formed on reaction with the carbonic acid used to acidify the solution. Particulate generation may also be limited by diluting the carbonic acid in solution.
The aerosol may be created by passing a liquid solution of the antimicrobial metal through a mechanical mister (e.g., a nebulizer) and may be applied directly with a pressurized pack (e.g., via a hand inhaler with a propellant such as carbon dioxide or other gas, with a valve metered dosage) or through some other delivery system (e.g., an oxygen tent, etc.).
The invention provides methods of treatment by administering a therapeutically effective amount of a nanocrystalline antimicrobial or noble metal powder, or a solution derived from a nanocrystalline antimicrobial or noble metal, as either a topical formulation, or as a coating on medical dressing, applied to the locally affected area of the skin. A therapeutically effective amount may be determined by testing formulations containing the nanocrystalline antimicrobial or noble metals by in vitro or in vivo testing. Formulations may be applied one or more times a day. Dressings coated with the nanocrystalline antimicrobial or noble metals may be changed daily, or even less frequently, and should be kept in a moist condition with the addition of saline, alcohols, or more preferably sterile water, in order to release ions, atoms, molecules or clusters of the nanocrystalline metal, on a sustained basis. E. Examples Example 1 - Preparation of Nanocrystalline Silver Coatings on Dressings This example shows the preparation of a bilayer nanocrystalline silver coating on a dressing material. A high density polyethylene dressing, DELNET™ or CONFORMANT 2™ was coated with a silver base layer and a silver/oxide top layer to generate a coloured antimicrobial coating having indicator value. The coating layers were formed by magnetron sputtering under the conditions set out in Table 1. Table 1 - Sputtering conditions
Figure imgf000038_0001
The resulting coating was blue in appearance. A fingertip touch was sufficient to cause a colour change to yellow. The base layer was about 900 nm thick, while the top layer was 100 nm thick.
To establish that silver species were released from the coated dressings, a zone of inhibition test was conducted. Mueller Hinton agar was dispensed into Petri dishes. The agar plates were allowed to surface dry prior to being inoculated with a lawn of Staphylococcus aureus ATCC No. 25923. The inoculant was prepared from Bactrol Discs (Difco, M.), which were reconstituted as per the manufacturer's directions. Immediately after inoculation, the coated materials to be tested were placed on the surface of the agar. The dishes were incubated for 24 hr. at 37 °C. After this incubation period, the zone of inhibition was calculated (corrected zone of inhibition = zone of inhibition - diameter of the test material in contact with the agar). The results showed a corrected ZOI of about 10 mm, demonstrating good release of silver species.
The coating was analyzed by nitric acid digestion and atomic absorption analysis to contain 0.24 +/- 0.04 mg silver per mg high density polyethylene. The coating was a binary alloy of silver (>97%) and oxygen with negligible contaminants, based on secondary ion mass spectroscopy. The coating, as viewed by SEM, was highly porous and consisted of equiaxed nanocrystals organized into coarse columnar structures with an average grain size of 10 nm. Silver release studies in water demonstrated that silver was released continuously from the coating until an equilibrium concentration of about 66 mg/L was reached (determined by atomic absorption), a level that is 50 to 100 times higher than is expected from bulk silver metal (solubility < lmg/L).
By varying the coating conditions for the top layer to lengthen the sputtering time to 2 min, 15 sec, a yellow coating was produced. The top layer had a thickness of about 140 nm and went through a colour change to purple with a fingertip touch. Similarly, a purple coating was produced by shortening the sputtering time to 1 min, to achieve a top layer thickness of about 65 nm. A fingertip touch caused a colour change to yellow.
To form a three layer dressing, two layers of this coated dressing material were placed above and below an absorbent core material formed from needle punched rayon/polyester (SONTARA™ 8411). With the silver coating on both the first and third layers, the dressing may be used with either the blue coating side or the silver side in the skin facing position. For indicator value, it might be preferable to have the blue coating visible. The three layers were laminated together by ultasonic welding to produce welds between all three layers spaced at about 2.5 cm intervals across the dressing. This allowed the dressing to be cut down to about 2.5 cm size portions for smaller dressing needs while still providing at least one weld in the dressing portion.
The coated dressings were sterilized using gamma radiation and a sterilization dose of 25 kGy. The finished dressing was packaged individually in sealed polyester peelable pouches, and has shown a shelf life greater than 1 year in this form. The coated dressings can be cut in ready to use sizes, such as 5.1 x 10.2 cm strips, before packaging. Alternatively, the dressings may be packaged with instructions for the patient or clinician to cut the dressing to size. Additional silver coated dressings were prepared in a full scale roll coater under conditions to provide coatings having the same properties set out above, as follows: i the dressing material included a first layer of silver coated DELNET, as set out above, laminated to STRATEX, AET, 8.0NP2-A QW, which is a layer of 100% rayon on a polyurethane film. ii Silver Foam Dressing - three layers of silver coated high density polyethylene prepared as above, alternating with two layers of polyurethane foam, L-00562-6 Medical Foam, available from Rynel Ltd., Bootbay, Maine, USA.
The HDPE mesh coated with silver can be used to generate solutions containing silver species for liquid formulations and the like. Example 2 - Preparation of Nanocrystalline Silver Coating on HDPE Mesh
The silver coated mesh was produced, as set forth in Example 1, by sputtering silver onto Delnet, a HDPE mesh (Applied Extrusion Technologies, Inc., Middletown, DE, USA) using Westaim Biomedical TMRC unit under the following conditions: Table 2 - Sputtering conditions
Figure imgf000040_0001
The coating was tested and found to have a weight ratio of reaction product to silver of between 0.05 and 0.1. The dressing was non-staining to human skin. Example 3 - Preparation of Atomic Disordered Nanocrystalline Silver Powders
Nanocrystalline silver coatings were prepared by sputtering silver in an oxygen- containing atmosphere directly onto an endless stainless steel belt of a magnetron sputtering roll coater, or onto silicon wafers on the belt. The belt did not need to be cooled. The coatings were scraped off with the belt with suspended metal scrapers as the belt rounded the end rollers. For the coated silicon wafers, the coatings were scraped off with a knife edge. The sputtering conditions were as follows: Table 3 - Sputtering Conditions
Figure imgf000041_0001
Note - pressure conversions to Pa herein may not be accurate, most accurate numbers are in torr, mTorr units.
The powder had a particle size ranging from 2 μm to 100 μm, with grain or crystallite size of 8 to 10 nm (i.e., nanocrystalline), and demonstrated a positive rest potential.
Similar atomic disordered nanocrystalline silver powders were formed as set forth hereinabove by magnetron sputtering onto cooled steel collectors, under conditions taught in the prior Burrell et al. patents to produce atomic disorder. Example 4 - In vitro Activity of Silver Solution against Propionibacterium acne
An in vitro test was conducted to determine if silver solutions according to the present invention effectively control Propionibacterium acne. The silver solution was obtained by static elution of Acticoat™ Burn Wound Dressing (lot #: 00403 A-05, Westaim Biomedical Corp., Fort Saskatchewan, Canada) with nanopure water in a ratio of one square inch of dressing in five milliliters of water for 24 hours at room temperature. The silver concentration of the silver solution was determined by an atomic absorption method. The silver elute was diluted with nanopure water to 20 μg/ml. The Propionibacterium acne (ATCC No. 0919) was provided by Biofilm Research Group, University of Calgary. The inoculum was prepared by inoculating freshly autoclaved and cooled tubes of Tryptic soy broth (TSB) with P. acne and incubating them for 2 days at 37 °C in an anaerobic jar. At this time, the optical density of the suspensions was ~ 0.3 at a wavelength of 625 nm.
The bacterial suspension (100 μL) was mixed with 100 μL of the silver solution being tested. The final concentration of silver in these mixtures was 10 //g/ml. The mixtures were incubated in an anaerobic jar at 37 °C for two hours. The silver was neutralized by addition of 0.4% STS (0.85% NaCl, 0.4% Sodium thioglycolate, 1% Tween™ 20) and the solution was serially 10-fold diluted with phosphate-buffered saline. 20 μL aliquots of the original solution and subsequent dilutions were plated onto TSA drop plates. The drops were allowed to dry and the plates were incubated in an anaerobic jar at 37° C for 72 hours at which time the colonies were counted. The control consisted of 100 μ of bacterial suspension mixed with 100 μL of nanopure water and treated as above.
The results showed that the silver solution according to the present invention, at a final concentration of 10 g/ml, gave 4.3 logarithm reduction in viable P. acne counts in two hours. Example 5 - Treatment of Acne
A sixteen year old female was diagnosed with acne vulgaris. She had numerous red papules and pustules on her forehead. Various skin cleansing regimes and antibiotic (erythromycin and clindomycin) treatments had been tried and had failed to control the acne. Prior to bed time, the papules and pustules on one side of her forehead were moistened and covered with a nanocrystalline silver coated high density polyethylene mesh, prepared as in Example 1 (single layer, blue coating). The mesh was then occluded with a thin film dressing which remained in place for 10 hours. Upon removal, the papules and pustules were no longer red and were only slightly raised. Some brown staining of the skin was observed. Example 6 - Treatment of Acne
A sixteen year old male was diagnosed with acne vulgaris. He had numerous raised, red papules and pustules on his forehead. Various skin cleansing regimes and antibiotic treatments had been tried and had failed to control the acne. The patient was placed on isotretinoin treatment which controlled his acne well. He did develop a single large pustule on his forehead which was embarrassing for him. Prior to bed time, the pustule was moistened and covered with a nanocrystalline silver coated high density polyethylene mesh prepared as in Example 2. The mesh was then occluded with a thin film dressing which remained in place for 10 hours. Upon removal the pustule was no longer red and was only slightly raised. A second treatment resulted in the disappearance of the pustule. Example 7 - Treatment of Acne
A sixteen year old female was diagnosed with acne vulgaris. She had numerous red papules and pustules on her forehead. Various skin cleansing regimes and antibiotic (erythromycin and clindomycin) treatments had been tried and had failed to control the acne. Prior to bed time, the papules and pustules on one side of her forehead were moistened and covered with a nanocrystalline silver coated high density polyethylene mesh, prepared as in Example 2. The mesh was then occluded with a thin film dressing which remained in place for 10 hours. Upon removal the papules and pustules were no longer red and were only slightly raised. A second treatment resulted in the disappearance of the papules and virtual elimination of the pustules. The silver coated mesh, when prepared as set forth in Example 2, did not result in any staining of the skin. Example 8 - Treatment of Adult Acne with Silver-Impregnated Hydrocolloid Dressing
A 49 year old white male experienced occasional acne vulgaris. He had painful, raised, red papules and pustules on his shoulders. The patient was treated with a thin hydrocolloid dressing (Craig Medical Products Ltd., Clay Gate House 46 Albert Rd. North Reigate, Surrey, United Kingdom) which was impregnated with 1% nanocrystalline silver powder formed with atomic disorder as in Example 3. Following cleansing, the pustule was covered with a small disc of the dressing, which remained in place for 24 hours. Upon removal, the pustule was no longer painful, red, or raised. Example 9 - Treatment of Eczema
A twenty-nine year old white female presented with acrodermatitis. The erythematous area was located on the dorsal surface of the first web space of the left hand. It was bounded by the metacarpal bones of the thumb and index finger. The patient also complained of pruritus associated with the dermatitis. A gel consisting of 0.1% nanocrystalline silver powder (formed with atomic disorder as in Example 3) and 2% carboxymethylcellulose was applied to the inflamed area before bedtime. There was an immediate antipruritic effect that provided the patient with relief in the short term. The next morning all evidence of acrodermatitis (i.e. redness disappeared) was gone. The condition had not returned after two weeks. Example 10 - Allergic Contact Dermatitis
Skin allergic contact hypersensitivity is caused by excessive infiltration of eosinophils. An animal model may be used for in vivo evaluation of eosinophil infiltration in the contact sensitivity reaction and to determine whether it is associated with allergic skin conditions such as contact dermatitis. On a gross histology level, this can be measured by the degree of erythema and edema at the dermatitis site. Current drugs used for treatment of this and other related eczema conditions include high potency steroids (Ultravate™), medium potency steroids (Elocon™) and non steroidal anti-inflammatory compounds (Protopic™ or tacrolimus). These compounds do not always work and may have undesirable side effects. Several commercially available anti-inflammatory products were compared to a nanocrystalline silver powder for the treatment of allergic contact dermatitis as follows.
Four healthy domestic pigs (approximate weight 20 kg) were used in the study. All pigs had normal skin prior to induction of eczema with 10% 2,4-dinitrochlorobenzene (DNCB) in acetone. The animals were housed in appropriate animal facilities with 12 hour light-dark cycles. The pigs were fed antibiotic-free feed and water ad libitum. The pigs were housed and cared for in accordance with Canadian Council of Animal Care guidelines. On day 0, the hair on both left and right back and side were clipped. The DNCB solution was painted over this area. This was repeated on day 7 and 11. On day 11, the solution was painted approximately 4 hours before treatment was initiated.
Treatment groups are shown in Table 4. Protopic™ (tacrolimus), Elocon™ and Ultravate™ were purchased as creams from the local pharmacy. The nanocrystalline silver powder (1 g/L) was mixed into a 2% sodium carboxymethyl cellulose (CMC) and water solution at 30 °C using a magnetic stirrer at a high speed (Vista Scientific). Petrolatum, commercially known as Vaseline™, was used as a control for Elocon™ and Ultravate™.
Figure imgf000045_0001
Pigs were placed under general anesthetic with ketamine (Ketalean™, MTC Pharmaceuticals, Cambridge, ON; 4-500 mg) and halothane (MTC Pharmaceuticals). The skin was wiped with a moist gauze and allowed to dry. Bandages (n = 8) containing each treatment were applied to the left side of the thoracolumbar area of the pig, while control bandages (n = 8) were applied to the right side of the thoracolumbar area of the pig. Following placement of bandages, they were covered with Tegaderm™ (3M Corp., Minneapolis, MN) which was secured with an Elastoplast™ (Smith and Nephew, Lachine, QC) wrap. Bandages with active agents were changed daily. The skin associated with each bandage site was scored for severity of erythema (0= normal, 1= slight, 2= moderate, 3= severe, 4= very severe) and swelling (0= normal, 1= slight, 2= moderate, 3= severe, 4= very severe). This was performed on days 0, 1, 2 and 3.
All pigs remained healthy during the study. Results are shown in Tables 5 and 6, and indicated in Figures 1 and 2. Figures 1 and 2 show the efficacy of the nanocrystalline silver powder compared to Protopic™, Elocon™ and Ultravate™ in the treatment of contact dermatitis in the pig model.
Table 5 - Results of Effects of Treatments Upon Erythema
Figure imgf000046_0001
The pigs treated with the high (Ultravate™) and medium (Elocon™) strength steroids showed little to no improvement in the degree of erythema associated with contact dermatitis. They did, however, improve in terms of edema in that at Day 3, no swelling was apparent. Protopic™ showed a marked improvement when compared to the steroids in both the degree of erythema and edema. The largest improvement occurred with the nanocrystalline silver powder suspended in a 2% carboxymethyl cellulose gel. Both erythema and edema scores were lower after a single treatment and were normal after Day 2 (edema) and Day 3 (erythema) of treatment. Clearly the nanocrystalline silver product was more efficacious in treating contact dermatitis than the commercially available products. Example 11 - Preparation of Gels No. 1
A commercial carboxymethyl cellulose/pectin gel (DuoDERM™, ConvaTec Canada, 555, Dr. Frederik Philips, Suite 110, St-Laurent, Quebec, H4M 2X4) was combined with nanocrystalline silver powder prepared as set forth in Example 3 to produce a gel with 0.1% silver. A logarithmic reduction test was performed as follows in the gel using Pseudomonas aeruginosa. The inoculum was prepared by placing 1 bacteriologic loopful of the organism in 5 mL of trypticase soy broth and incubating it for 3-4 h. The inoculum (0.1 mL) was then added to 0.1 mL of gel and vortexed (triplicate samples). The mixture was incubated for one- half hour. Then 1.8 mL of sodium thioglycollate-saline (STS) solution was added to the test tube and vortexed. Serial dilutions were prepared on 10"1 to 10"7. A 0.1 mL aliquot of each dilution was plated in duplicate into Petri plates containing Mueller-Hinton agar. The plates were incubated for 48 h and then colonies were counted. Surviving members of organisms were determined and the logarithmic reduction compared to the initial inoculum was calculated. The logarithmic reduction for this mixture was 6.2, indicating a significant bactericidal effect. No. 2
Carboxymethyl cellulose (CMC) fibers were coated directly to produce an atomic disordered nanocrystalline silver coating, using magnetron sputtering conditions similar to those set forth in Example 1. The CMC was then gelled in water by adding 2.9 g to 100 mL volume. This material was tested using the method of No. 1. The material generated a 5.2 logarithmic reduction of Pseudomonas aeruginosa , demonstrating that the gel had a significant bactericidal effect. No. 3
An alginate fibrous substrate was directly coated with an atomic disordered nanocrystalline silver coating using magnetron sputtering conditions similar to those set forth in Example 1. The alginate (5.7 g) was added to 100 mL volume of water to create a gel. This material was tested using the method of No. 1. The material generated a 5.2 logarithmic reduction of Pseudomonas aeruginosa, demonstrating that the gel had a significant bactericidal effect. No. 4
A commercial gel containing CMC and alginate (Purilin gel, Coloplast) was mixed with a atomic disordered nanocrystalline silver powder to give a product with 0.1% silver. This was tested as above with both Pseudomonas aeruginosa and Staphylococcus aureus. Zone of inhibition data was also generated for this gel as follows. An inoculum (Pseudomonas aeruginosa and Staphylococcus aureus) was prepared as in No. 1 and 0.1 mL of this was spread onto the surface of Mueller-Hinton agar in a Petri dish. A six mm hole was then cut into the agar at the center of the Petri dish and removed. The well was filled with either 0.1 mL of the silver containing gel, a mupirocin containing cream or a mupirocin containing ointment. The Petri plates were then incubated for 24 h and the diameter of the zone of inhibition was measured and recorded.
The silver containing gel produced 9 mm zone of inhibition against both Pseudomonas aeruginosa and Staphylococcus aureus, while the mupirocin cream and ointment produced 42 and 48 mm zones against Staphylococcus aureus and 0 mm zones against Pseudomonas aeruginosa.
The silver containing gel reduced the Pseudomonas aeruginosa and Staphylococcus aureus properties by 4.4 and 0.6 log reductions, respectively, showing good bactericidal activity. The mupirocin cream and ointment generated 0.4 and 0.8, and 0.8 and 1.6, log reductions against Staphylococcus aureus and Pseudomonas aeruginosa, respectively. The silver gel had both a greater bactericidal effect and spectrum of activity than the mupirocin containing products. Nos. 5-10
The formula for Nos. 5-10 are summarized in Table 7. Zones of inhibitions were determined as in No. 4 and log reductions were determined as in No. 1.
All formulae provided a broader spectrum of activity and a greater bactericidal effect than did mupirocin in a cream or ointment form. The mupirocin cream produced zones of inhibition of 42 and 0, and log reduction of 0.4 and 0.8, against Staphylococcus aureus and Pseudomonas aeruginosa, respectively. Table 7 - Formulae for Gel Nos. 5-10 and Efficacy Results
Figure imgf000048_0001
No. 11
A commercially available gel (glyceryl polymethacrylate) was blended with nanocrystalline silver powder to produce a gel with a silver content of 0.1%. This gel was tested as in Nos. 5-10 and was found to produce zones of 15 mm against both Staphylococcus aureus and Pseudomonas aeruginosa. Log reductions of 1.7 and >5 were produced against Staphylococcus aureus and Pseudomonas aeruginosa. This gel product had a greater spectrum of activity than did mupirocin cream or ointment. Example 12 - Treatment of Adult Acne with Nanocrystalline Silver Gel Occluded by a Hydrocolloid Dressing
A 49 year old white male experienced occasional acne vulgaris. He had painful, raised, red papules and pustules on his shoulders. The patient was treated with gel formulation No. 5 as set forth in Example 11. Gel formulation No. 5 was applied to the problem area of the patient's shoulders and then occluded by a thin hydrocolloid dressing (Craig Medical Products Ltd., Clay Gate House 46 Albert Rd. North Reigate, Surrey, United Kingdom). The dressing remained in place for 24 hours. Upon removal the pustule was no longer painful, red, or raised.
All publications mentioned in this specification are indicative of the level of skill of those skilled in the art to which this invention pertains. All publications are herein incorporated by reference to the same extent as if each individual publication was specifically and individually indicated to be incorporated by reference.
The terms and expressions in this specification are, unless otherwise specifically defined herein, used as terms of description and not of limitation. There is no intention, in using such terms and expressions, of excluding equivalents of the features illustrated and described, it being recognized that the scope of the invention is defined and limited only by the claims which follow.

Claims

We claim:
1. Use of a therapeutically effective amount of one or more antimicrobial metals in a crystalline form to reduce inflammation of an inflammtory skin condition, wherein the one or more antimicrobial metals are characterized by sufficient atomic disorder, such that the metal, in contact with an alcohol or water-based electrolyte, releases atoms, ions, molecules, or clusters of at least one antimicrobial metal at a concentration sufficient to provide a localized anti-inflammatory effect.
2. The use of claim 1 , wherein the one or more antimicrobial metals further provide a localized antimicrobial effect. \
3. The use of claim 2, wherein the antimicrobial metal is nanocrystalline and is formed with sufficient atomic disorder such that, in contact with an alcohol or water based electrolyte, the antimicrobial metal releases ions, atoms, molecules or clusters of the antimicrobial metal on a sustainable basis.
4. The use of claim 3, wherein the antimicrobial metal is selected from the group consisting of silver, gold, platinum and palladium.
5. The use of claim 4, wherein the condition is selected from the group consisting of eczema, an insect bite, an insect sting, sunburn, erythoderma, mycosis fungoides, pyoderma gangrenosum, erythema multiforme, rosacea, onychomycosis, and acne.
6. The use of claim 4, wherein the condition is acne, eczema or related conditions.
7. The use of claim 5, wherein the antimicrobial metal is nanocrystalline silver.
8. The use of claim 6, wherein the antimicrobial metal is silver, formed as a composite with oxygen.
9. The use of claim 4, wherein the condition is eczema selected from the group consisting of atopic eczema, acrodermatitis eczema, contact allergic dermatitis, contact irritant dermatitis, dyshydrotic eczema, lichen simplex chronicus, nummular eczema, seborrheic dermatitis, and stasis eczema.
10. The use of claim 4, wherein the condition is acne selected from the group consisting of acne vulgaris, neonatal acne, infantile acne, and pomade acne.
11. The use of claim 5, wherein the one or more antimicrobial metals are provided as a coating on, or filler in, a dressing, or in a pharmaceutical composition with one or more pharmaceutically and dermatogically acceptable carriers, diluents, or excipients suitable for topical application.
12. The use of claim 11, wherein the pharmaceutical composition includes a nanocrystalline powder of the one or more antimicrobial metals, or a solution containing dissolved species from a nanocrystalline powder or coating of one or more antimicrobial metals.
13. The use of claim 12, wherein the pharmaceutical composition is a gel, cream, lotion, paste or ointment containing the antimicrobial metal powder in an amount of 0.01 - 10% by weight, or a liquid formulated as a topical solution, spray, mist, or drops containing 0.001 - 10% by weight of the antimicrobial metal.
14. The use of claim 13, wherein the antimicrobial metal is nanocrystalline silver.
15. The use of claim 13, wherein the antimicrobial metal is silver, formed as a composite with oxygen.
16. The use of claim 11 , wherein the dressing or pharmaceutical composition is fixed in place or occluded with an occlusive or semi-occlusive layer which maintains the dressing or composition in a moist condition.
17. The use of claim 11, wherein the coating is provided on a dressing.
18. The use of claim 18, wherein the coating is 150 - 3000 nm thick.
19. The use of claim 12, wherein the one or more antimicrobial metals are provided in a hydrated dressing.
20. The use of claim 12, wherein the gel, cream, lotion, paste, or ointment is occluded by a hydrated dressing.
21. The use of claim 19 or 20, wherein the hydrated dressing is selected from the group consisting of a hydrocolloid, hydrogel, polyethylene, polyurethane, polyvinylidine, siloxane and silicone dressing.
22. The use of claim 21, wherein the hydrated dressing is a hydrocolloid dressing.
23. The use of claim 22, wherein the hydrocolloid dressing comprises a hydrocolloid selected from the group consisting of alginate, starch, glycogen, gelatin, pectin, chitosan, chitin, cellulose and derivatives thereof, gum arabic, locust bean gum, karaya gum, gum tragacanth, ghatti gum, agar-agar, carrageenans, carob gum, guar gum, and xathan gum.
24. The use of claim 23, wherein the hydrocolloid is one or more of carboxymethyl cellulose, alginates, pectin, and glyceryl polymethacrylate.
25. The use of claim 6, wherein the antimicrobial metal is in a powder form and is delivered directly to the skin.
26. The use of claim 25, wherein the powder is sized with particulates no larger than 2 μm.
27. The use of claim 26, wherein the powder is sized with particulates no larger than 1 μm.
28. The use of claim 27, wherein the antimicrobial metal is nanocrystalline silver.
29. The use of claim 27, wherein the antimicrobial metal is nanocrystalline silver, formed as a composite with oxygen.
30. A hydrated dressing for use in reduction of inflammation of an inflammatory skin condition comprising a hydrated dressing, and associated with the dressing, a therapeutically effective amount of one or more antimicrobial metals in a crystalline form to provide localized anti-inflammatory and antimicrobial effects.
31. The dressing of claim 30, wherein the dressing i includes a therapeutically effective amount of one or more antimicrobial metals in a crystalline form to provide localized antimicrobial and anti-inflammatory effects; or ii occludes a pharmaceutical composition of a nanocrystalline powder of the one or more antimicrobial metals, or a solution containing dissolved species from a nanocrystalline powder or coating of the one or more antimicrobial metals.
32. The dressing of claim 31 , wherein the one or more antimicrobial metals are characterized by sufficient atomic disorder, such that the metal, in contact with an alcohol or water-based electrolyte, releases atoms, ions, molecules, or clusters of at least one antimicrobial metal at a concentration sufficient to provide a localized antimicrobial and anti- inflammatory effect.
33. The dressing of claim 32, wherein the antimicrobial metal is nanocrystalline and is formed with sufficient atomic disorder such that, in contact with an alcohol or water based electrolyte, the antimicrobial metal releases ions, atoms, molecules or clusters of the antimicrobial metal on a sustainable basis.
34. The dressing of claim 33, wherein the antimicrobial metal is selected from the group consisting of silver, gold, platinum and palladium.
35. The dressing of claim 34, wherein the antimicrobial metal is nanocrystalline silver.
36. The dressing of claim 34, wherein the antimicrobial metal is silver, formed as a composite with oxygen.
37. The dressing of claim 32, wherein the condition is selected from the group consisting of eczema, an insect bite, an insect sting, sunburn, erythoderma, mycosis fungoides, pyoderma gangrenosum, erythema multiforme, rosacea, onychomycosis and acne.
38. The dressing of claim 33, wherein the pharmaceutical composition is a gel, cream, lotion, paste or ointment containing the antimicrobial metal powder in an amount of 0.01 - 10% by weight, or a liquid formulated as a topical solution, spray, mist, or drops containing 0.001 - 10% by weight of the antimicrobial metal.
39. The dressing of claim 38, wherein the antimicrobial metal is nanocrystalline silver.
40. The dressing of claim 38, wherein the antimicrobial metal is silver, formed as a composite with oxygen.
41. The dressing of claim 37, wherein the condition is eczema selected from the group consisting of atopic eczema, acrodermatitis eczema, contact allergic dermatitis, contact irritant dermatitis, dyshydrotic eczema, lichen simplex chronicus, nummular eczema, seborrheic dermatitis, and stasis eczema.
42. The dressing of claim 37, wherein the condition is acne selected from the group consisting of acne vulgaris, neonatal acne, infantile acne, and pomade acne.
43. The dressing of claim 31 , wherein the hydrated dressing is selected from the group consisting of a hydrocolloid, hydrogel, polyethylene, polyurethane, polyvinylidine, siloxane and silicone dressing.
44. The dressing of claim 43, wherein the hydrated dressing is a hydrocolloid dressing.
45. The dressing of claim 44, wherein the hydrocolloid dressing comprises a hydrocolloid selected from the group consisting of alginates, starch, glycogen, gelatin, pectin, chitosan, chitin, cellulose and derivatives thereof, gum arabic, locust bean gum, karaya gum, gum tragacanth, ghatti gum, agar-agar, carrageenans, carob gum, guar gum, and xathan gum.
46. The dressing of claim 45, wherein the hydrocolloid is one or more of carboxymethyl cellulose, alginates, pectin, and glyceryl polymethacrylate.
47. The dressing of claim 31 , wherein the pharmaceutical composition of the nanocrystalline powder is delivered directly to the skin.
48. The dressing of claim 47, wherein the powder is sized with particulates no larger than 2 μm.
49. The dressing of claim 48, wherein the powder is sized with particulates no larger than 1 μm.
50. The dressing of claim 49, wherein the antimicrobial metal is nanocrystalline silver.
51. The dressing of claim 70, wherein the antimicrobial metal is nanocrystalline silver, formed as a composite with oxygen.
52. The dressing of claim 52, wherein the hydrated dressing is in a non-hydrated form and becomes hydrated when in contact with an alcohol or water-based electrolyte.
53. A kit for reducing inflammation of an inflammatory skin condition comprising: a therapeutically effective amount of one or more antimicrobial metals in a crystalline form characterized by sufficient atomic disorder such that the metal, in contact with an alcohol or water-based electrolyte, releases atoms, ions, molecules, or clusters of at least one antimicrobial metal, the one or more antimicrobial metals being provided in a dosage form to provide a localized anti-inflammatory and antimicrobial effect to the skin; and optionally a pharmaceutically acceptable carrier provided in admixture or separately from the one or more antimicrobial metals.
54. The kit of claim 53, wherein the antimicrobial metal is nanocrystalline and is formed with sufficient atomic disorder such that, in contact with an alcohol or water based electrolyte, the antimicrobial metal releases ions, atoms, molecules or clusters of the antimicrobial metal on a sustainable basis.
55. The kit of claim 54, wherein the antimicrobial metal is selected from the group consisting of silver, gold, platinum and palladium.
56. The kit of claim 55, wherein the antimicrobial metal is nanocrystalline silver!
57. The kit of claim 55, wherein the antimicrobial metal is nanocrystalline silver, formed as a composite with oxygen.
58. The kit of claim 55, wherein the oxygen content in the powder or coating is limited to an amount which does not stain the skin.
59. The kit of claim 53, wherein the one or more antimicrobial metals is provided as a coating on, or a filler in, a dressing or a hydrated dressing, or in a pharmaceutical composition with one or more pharmaceutically and dermatogically acceptable carriers, diluents, or excipients suitable for topical application.
60. The kit of claim 53, wherein the kit includes the pharmaceutically acceptable carrier provided separate from the one or more antimicrobial metals.
61. The kit of claim 60, wherein the pharmaceutically acceptable carrier is a water or alcohol based electrolyte.
62. The kit of claim 59, wherein the pharmaceutical composition includes a nanocrystalline powder or coating of the one or more antimicrobial metals in a form to generate a liquid containing dissolved species of the one or more antimicrobial metals.
63. The kit of claim 59, wherein the pharmaceutical composition is a one or more of a gel, cream, lotion, paste, ointment, or foam containing the antimicrobial metal powder in an amount of 0.01 - 10 % by weight, or a nanocrystalline powder or coating of the one or more antimicrobial metals in a form to generate a liquid containing dissolved species of the one or more antimicrobial metals in an amount of 0.001 - 10% by weight for topical application.
64. The kit of claim 63, wherein the antimicrobial metal is nanocrystalline silver.
65. The kit of claim 63, wherein the antimicrobial metal is nanocrystalline silver, formed as a composite with oxygen.
66. The kit of claim 63, wherein the oxygen content in the powder or coating is limited to an amount which does not stain the skin.
67. The kit of claim 62, wherein the coating is 150 - 10,000 nm thick.
68. The kit of claim 63, wherein the one or more antimicrobial metals are provided in admixture with one or more hydrocolloids, or wherein the kit includes a hydrated dressing including one or more hydrocolloids for occlusion.
69. The kit of claim 68, wherein the hydrocolloid is alginates, starch, glycogen, gelatin, pectin, chitosan, chitin, cellulose and derivatives thereof, gum arabic, locust bean gum, karaya gum, gum tragacanth, ghatti gum, agar-agar, carrageenans, alginates, carob gum, guar gum, and xanthan gum.
70. The kit of claim 69, wherein the hydrocolloid is one or more of carboxymethyl cellulose, alginates, pectin, and glyceryl polymethacrylate.
71. The kit of claim 69, wherein the antimicrobial metal is nanocrystalline silver.
72. The kit of claim 69, wherein the antimicrobial metal is nanocrystalline silver, formed as a composite with oxygen.
73. The kit of claim 69, wherein the oxygen content in the powder or coating is limited to an amount which does not stain the skin.
PCT/CA2002/000549 2001-04-23 2002-04-23 A medicament or a dressing containing a metal such as silver, gold, platinum or palladium as an antimicrobial agent ans their use in the treatment of inflammatory skin conditions WO2002085387A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP20020721904 EP1383522B1 (en) 2001-04-23 2002-04-23 A medicament or a dressing containing a metal such as silver, gold, platinum or palladium as an antimicrobial agent and their use in the treatment of inflammatory skin conditions
AU2002252881A AU2002252881B2 (en) 2001-04-23 2002-04-23 Use of metals to treat inflammatory skin conditions
CA 2445740 CA2445740A1 (en) 2001-04-23 2002-04-23 Use of metals to treat inflammatory skin conditions
DE2002610441 DE60210441T2 (en) 2001-04-23 2002-04-23 MEDICAMENT OR PLASTER CONTAINS A METAL SUCH AS SILVER, GOLD, PLATINUM OR PALLADIUM AS AN ANTIMICROBIAL ACTIVE INGREDIENT AND ITS USE IN THE TREATMENT OF SKIN INFUSION
JP2002582960A JP2004529930A (en) 2001-04-23 2002-04-23 Use of metals for the treatment of inflammatory skin conditions

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US28588401P 2001-04-23 2001-04-23
US60/285,884 2001-04-23
US09/840,637 2001-04-23
US09/840,637 US7008647B2 (en) 2001-04-23 2001-04-23 Treatment of acne

Publications (2)

Publication Number Publication Date
WO2002085387A2 true WO2002085387A2 (en) 2002-10-31
WO2002085387A3 WO2002085387A3 (en) 2003-01-16

Family

ID=26963436

Family Applications (5)

Application Number Title Priority Date Filing Date
PCT/CA2002/000548 WO2002085386A2 (en) 2001-04-23 2002-04-23 Medicament containing a metal such as silver, gold, platinum or palladium as an antimicrobial agent and their use to induce apoptosis in cancerous tissue
PCT/CA2002/000546 WO2002085384A2 (en) 2001-04-23 2002-04-23 Lubricious coatings for substrates
PCT/US2002/012690 WO2002085299A2 (en) 2001-04-23 2002-04-23 Therapeutic treatments using the direct application of antimicrobial metal compositions
PCT/CA2002/000547 WO2002085385A2 (en) 2001-04-23 2002-04-23 Medicament containing a metal such as silver, gold, platinum or palladium as an antimicrobial agent and their use in the treatment of diseases of the mucosa
PCT/CA2002/000549 WO2002085387A2 (en) 2001-04-23 2002-04-23 A medicament or a dressing containing a metal such as silver, gold, platinum or palladium as an antimicrobial agent ans their use in the treatment of inflammatory skin conditions

Family Applications Before (4)

Application Number Title Priority Date Filing Date
PCT/CA2002/000548 WO2002085386A2 (en) 2001-04-23 2002-04-23 Medicament containing a metal such as silver, gold, platinum or palladium as an antimicrobial agent and their use to induce apoptosis in cancerous tissue
PCT/CA2002/000546 WO2002085384A2 (en) 2001-04-23 2002-04-23 Lubricious coatings for substrates
PCT/US2002/012690 WO2002085299A2 (en) 2001-04-23 2002-04-23 Therapeutic treatments using the direct application of antimicrobial metal compositions
PCT/CA2002/000547 WO2002085385A2 (en) 2001-04-23 2002-04-23 Medicament containing a metal such as silver, gold, platinum or palladium as an antimicrobial agent and their use in the treatment of diseases of the mucosa

Country Status (9)

Country Link
US (9) US20030021854A1 (en)
EP (4) EP1383521A2 (en)
JP (4) JP2004529930A (en)
AT (1) ATE322274T1 (en)
AU (4) AU2002252881B2 (en)
CA (4) CA2443587A1 (en)
DE (1) DE60210441T2 (en)
ES (1) ES2261659T3 (en)
WO (5) WO2002085386A2 (en)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005074949A1 (en) * 2004-02-02 2005-08-18 Nucryst Pharmaceuticals Corp. Treatment of ungual and subungual diseases with antimicrobial metal compositions
DE102004031955A1 (en) * 2004-06-24 2006-01-12 Paul Hartmann Ag wound dressing
JP2007504107A (en) * 2003-08-29 2007-03-01 バイオ−ゲイト アーゲー Body care products containing porous silver particles
US7700819B2 (en) 2001-02-16 2010-04-20 Kci Licensing, Inc. Biocompatible wound dressing
US7763769B2 (en) 2001-02-16 2010-07-27 Kci Licensing, Inc. Biocompatible wound dressing
JP2011504459A (en) * 2007-10-05 2011-02-10 ウニベルシダーデ デ サンティアゴ デ コンポステラ Use of atomic quantum clusters (AQCs) as antibacterial and biocides
US8309117B2 (en) 2002-12-19 2012-11-13 Novartis, Ag Method for making medical devices having antimicrobial coatings thereon
US8865227B2 (en) 2007-12-20 2014-10-21 Smith & Nephew (Overseas) Limited Metal carbonate particles and methods of making thereof
CN108853557A (en) * 2018-07-23 2018-11-23 衢州玛济克医疗科技有限公司 A kind of wet erythema medical dressing of infant and its production method
US10449218B2 (en) 2009-05-26 2019-10-22 The General Hospital Corporation System for treating a sebaceous gland
US10912739B2 (en) 2017-10-16 2021-02-09 Peace Out Inc. Hydrocolloid-based skin treatment
US11684586B1 (en) 2022-02-28 2023-06-27 Peace Out, Llc Anhydrous hydrocolloid matrix comprising homogeneously distributed encapsulated therapeutic agents

Families Citing this family (299)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9119705B2 (en) 1998-06-08 2015-09-01 Thermotek, Inc. Method and system for thermal and compression therapy relative to the prevention of deep vein thrombosis
WO2005000324A2 (en) * 2003-06-03 2005-01-06 American Biotech Labs Colloidal silver composition having antimicrobial properties
US7135195B2 (en) * 1999-06-01 2006-11-14 American Silver, Llc Treatment of humans with colloidal silver composition
US7179849B2 (en) 1999-12-15 2007-02-20 C. R. Bard, Inc. Antimicrobial compositions containing colloids of oligodynamic metals
US9522217B2 (en) 2000-03-15 2016-12-20 Orbusneich Medical, Inc. Medical device with coating for capturing genetically-altered cells and methods for using same
US8088060B2 (en) 2000-03-15 2012-01-03 Orbusneich Medical, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
US20030185901A1 (en) * 2000-07-27 2003-10-02 Burrell Robert E. Methods of treating conditions with a metal-containing material
US20060115541A1 (en) * 2000-07-27 2006-06-01 Gillis Scott H Treatment of bladder conditions
US7008647B2 (en) * 2001-04-23 2006-03-07 Nucryst Pharmaceuticals Corp. Treatment of acne
US7427416B2 (en) * 2000-07-27 2008-09-23 Nucryst Pharmaceuticals Corp. Methods of treating conditions using metal-containing materials
DE10043151A1 (en) * 2000-08-31 2002-03-28 Peter Steinruecke Bone cement with antimicrobial effectiveness
EP1383521A2 (en) * 2001-04-23 2004-01-28 Nucryst Pharmaceuticals Corp. Medicament containing a metal such as silver, gold, platinum or palladium as an antimicrobial agent and their use to induce apoptosis in cancerous tissue
US20040092890A1 (en) * 2001-05-10 2004-05-13 Ash Stephen R. Catheter lock solution including a photo-oxidant
US7727221B2 (en) 2001-06-27 2010-06-01 Cardiac Pacemakers Inc. Method and device for electrochemical formation of therapeutic species in vivo
US20030059375A1 (en) * 2001-08-20 2003-03-27 Transave, Inc. Method for treating lung cancers
DE10146050B4 (en) * 2001-09-18 2007-11-29 Bio-Gate Ag Process for the preparation of an antimicrobial adhesive and coating material
JP3795364B2 (en) * 2001-09-27 2006-07-12 シャープ株式会社 Integrated circuit and receiver
CN1612804A (en) 2001-12-03 2005-05-04 C·R·巴德公司 Microbe-resistant medical device, microbe-resistant polymeric coating and methods for producing same
TWI255224B (en) * 2002-01-09 2006-05-21 Novartis Ag Polymeric articles having a lubricious coating and method for making the same
US8118789B2 (en) * 2002-02-20 2012-02-21 Abbott Research Group, Inc. Deodorizer devices and systems for controlling perspiration-related body odor
US7270653B2 (en) * 2002-02-20 2007-09-18 Abbott Research Group Methods of treating abnormal biological conditions using metal oxides
US6589216B1 (en) 2002-02-20 2003-07-08 Abbott Research Group, Inc. Vaginal douches, vaginal douche applicators and methods of vaginal douching
WO2004002202A1 (en) * 2002-06-21 2003-12-31 Continental Teves Ag & Co. Ohg Printed board for electronic devices controlling a motor vehicle
US6865810B2 (en) * 2002-06-27 2005-03-15 Scimed Life Systems, Inc. Methods of making medical devices
US9186322B2 (en) * 2002-08-02 2015-11-17 Insmed Incorporated Platinum aggregates and process for producing the same
AU2003302314A1 (en) * 2002-08-02 2004-07-09 Transave, Inc. Platinum aggregates and process for producing the same
US8404751B2 (en) * 2002-09-27 2013-03-26 Hallux, Inc. Subunguicide, and method for treating onychomycosis
US7485259B2 (en) * 2002-10-08 2009-02-03 Eldred Bradley J Organic compound and metal ion synergistic disinfection and purification system and method of manufacture
AU2003303306A1 (en) * 2002-10-09 2004-09-06 California Institute Of Technology Sensor web
WO2004037187A2 (en) * 2002-10-22 2004-05-06 Nucryst Pharmaceuticals Corp. Metal-containing materials, compositions and methods
WO2004037186A2 (en) * 2002-10-22 2004-05-06 Nucryst Pharmaceuticals Corp. Prophylactic treatment methods
US8066854B2 (en) * 2002-12-18 2011-11-29 Metascape Llc Antimicrobial coating methods
US8409618B2 (en) * 2002-12-20 2013-04-02 Kimberly-Clark Worldwide, Inc. Odor-reducing quinone compounds
US7666410B2 (en) 2002-12-20 2010-02-23 Kimberly-Clark Worldwide, Inc. Delivery system for functional compounds
ATE354380T1 (en) * 2003-02-03 2007-03-15 Polaschegg Hans-Dietrich Dr Te COMPOSITION FOR THE PREVENTION OF INFECTIONS THROUGH SUBCUTANEOUS PROSTHESIS
US20040151716A1 (en) * 2003-02-03 2004-08-05 Hamer Richard A. Material and method for treating microbial mediated dermatological conditions
US20040156874A1 (en) * 2003-02-11 2004-08-12 Bradley Pharmaceuticals, Inc. Urea- a topical anti-inflammatory
JPWO2004075920A1 (en) * 2003-02-26 2006-06-01 大塚製薬株式会社 Sustained release pharmaceutical composition for pulmonary administration
US20040180093A1 (en) * 2003-03-12 2004-09-16 3M Innovative Properties Company Polymer compositions with bioactive agent, medical articles, and methods
WO2004084973A2 (en) * 2003-03-24 2004-10-07 Becton, Dickinson And Company Invisible antimicrobial glove and hand antiseptic
US20040236290A1 (en) * 2003-04-23 2004-11-25 Zimmermann Stephan A. Minimally invasive vascular apparatus modified to minimize scarring at introduction site
US6874165B2 (en) * 2003-05-19 2005-04-05 Mao-Sheng Lee Modified NBR gloves
WO2004108091A2 (en) * 2003-06-06 2004-12-16 Board Of Regents, The University Of Texas System Antimicrobial flush solutions
DE10328261B4 (en) 2003-06-23 2007-10-25 Beiersdorf Ag Disinfecting coating with silver coating and its use
WO2004112852A1 (en) * 2003-06-23 2004-12-29 Beiersdorf Ag Antimicrobial wounddressing
US7480530B2 (en) * 2003-06-30 2009-01-20 Johnson & Johnson Consumer Companies, Inc. Device for treatment of barrier membranes
US8734421B2 (en) * 2003-06-30 2014-05-27 Johnson & Johnson Consumer Companies, Inc. Methods of treating pores on the skin with electricity
US20050025817A1 (en) * 2003-07-03 2005-02-03 Bhatia Kuljit S. Delivery system for topical medications
US8574278B2 (en) * 2006-05-09 2013-11-05 Thermotek, Inc. Wound care method and system with one or both of vacuum-light therapy and thermally augmented oxygenation
US8128672B2 (en) 2006-05-09 2012-03-06 Thermotek, Inc. Wound care method and system with one or both of vacuum-light therapy and thermally augmented oxygenation
DK200301128A (en) * 2003-08-05 2005-02-06 Thomsen Joern Oddershede Grant Preparation
US20050028563A1 (en) * 2003-08-08 2005-02-10 Milliken & Company Garment for use with sensitive skin, and method and fabric for us in making same
US8519146B2 (en) * 2004-09-07 2013-08-27 The University Of Akron Metal complexes of N-heterocyclic carbenes as antibiotics
US20050054774A1 (en) * 2003-09-09 2005-03-10 Scimed Life Systems, Inc. Lubricious coating
US7794737B2 (en) 2003-10-16 2010-09-14 Kimberly-Clark Worldwide, Inc. Odor absorbing extrudates
US7879350B2 (en) 2003-10-16 2011-02-01 Kimberly-Clark Worldwide, Inc. Method for reducing odor using colloidal nanoparticles
US7678367B2 (en) 2003-10-16 2010-03-16 Kimberly-Clark Worldwide, Inc. Method for reducing odor using metal-modified particles
US7745509B2 (en) * 2003-12-05 2010-06-29 3M Innovative Properties Company Polymer compositions with bioactive agent, medical articles, and methods
US20050123621A1 (en) * 2003-12-05 2005-06-09 3M Innovative Properties Company Silver coatings and methods of manufacture
US20050123590A1 (en) * 2003-12-05 2005-06-09 3M Innovative Properties Company Wound dressings and methods
US20050152955A1 (en) * 2003-12-16 2005-07-14 Akhave Jay R. Electrostatically self-assembled antimicrobial coating for medical applications
DE10359338B4 (en) * 2003-12-17 2007-07-19 Heraeus Kulzer Gmbh Antimicrobial nanosilver additive for polymerizable dental materials
GB0401821D0 (en) * 2004-01-28 2004-03-03 Qinetiq Nanomaterials Ltd Method of manufacture of polymer composites
US20050256553A1 (en) * 2004-02-09 2005-11-17 John Strisower Method and apparatus for the treatment of respiratory and other infections using ultraviolet germicidal irradiation
US7457667B2 (en) * 2004-02-19 2008-11-25 Silverleaf Medical Products, Inc. Current producing surface for a wound dressing
US7662176B2 (en) * 2004-02-19 2010-02-16 Vomaris Innovations, Inc. Footwear apparatus and methods of manufacture and use
US20050196463A1 (en) * 2004-03-03 2005-09-08 Stiles James Alexander R. NO-containing complexes
US20070065522A1 (en) * 2004-03-18 2007-03-22 Transave, Inc. Administration of high potency platinum compound formulations by inhalation
WO2005089448A2 (en) * 2004-03-18 2005-09-29 Transave, Inc. Administration of cisplatin by inhalation
US20050271746A1 (en) * 2004-05-18 2005-12-08 Abbott Chun L Topical treatments for abnormal biological conditions and method of topically treating such conditions
US7758892B1 (en) * 2004-05-20 2010-07-20 Boston Scientific Scimed, Inc. Medical devices having multiple layers
CA2566174A1 (en) * 2004-05-21 2005-12-01 Transave, Inc. Treatment of lung diseases and pre-lung disease conditions
US20060002967A1 (en) * 2004-07-01 2006-01-05 Smestad Thomas L Resorbable implant with lubricious coating
US10016583B2 (en) 2013-03-11 2018-07-10 Thermotek, Inc. Wound care and infusion method and system utilizing a thermally-treated therapeutic agent
US10765785B2 (en) 2004-07-19 2020-09-08 Thermotek, Inc. Wound care and infusion method and system utilizing a therapeutic agent
US20060034899A1 (en) * 2004-08-12 2006-02-16 Ylitalo Caroline M Biologically-active adhesive articles and methods of manufacture
US20060035039A1 (en) * 2004-08-12 2006-02-16 3M Innovative Properties Company Silver-releasing articles and methods of manufacture
CN2734238Y (en) * 2004-08-25 2005-10-19 任晓艳 Nano silver coated suture line
US20060068024A1 (en) * 2004-09-27 2006-03-30 Schroeder Kurt M Antimicrobial silver halide composition
AU2005306802A1 (en) * 2004-11-08 2006-05-26 Transave, Inc. Methods of treating cancer with lipid-based platinum compound formulations administered intraperitoneally
AP2007004039A0 (en) * 2004-11-23 2007-06-30 Internat Biotherapeutic Res In Method of delivery of therapeutic metal ions, alloys and salts
JP2008523063A (en) * 2004-12-06 2008-07-03 ノヴァセントリックス コープ Antiviral usage of metal nanomaterial composition
US20090155316A1 (en) * 2004-12-13 2009-06-18 Apt Co., Ltd. Oral Wash
US7749529B2 (en) * 2005-02-08 2010-07-06 Ash Access Technology, Inc. Catheter lock solution comprising citrate and a paraben
US20080202967A1 (en) * 2005-02-23 2008-08-28 Kerryne Krause-Neufeldt Cosmetic Product
DE102005063438A1 (en) * 2005-02-24 2007-12-27 Lohmann & Rauscher Gmbh & Co. Kg Process for the preparation of porous sponges from purified marine collagen
US8864730B2 (en) 2005-04-12 2014-10-21 Rochester Medical Corporation Silicone rubber male external catheter with absorbent and adhesive
US8399027B2 (en) * 2005-04-14 2013-03-19 3M Innovative Properties Company Silver coatings and methods of manufacture
JP4741656B2 (en) * 2005-05-02 2011-08-03 コロプラスト アクティーゼルスカブ Method for sterilizing medical devices having a hydrophilic coating
US20060275223A1 (en) * 2005-06-02 2006-12-07 Burr James B Erythritol compositions for teeth and gums
JP2009513182A (en) * 2005-07-21 2009-04-02 エフエムシー バイオポリマー エイエス Medical parts coated with a biocompatible coating that dissolves rapidly
WO2007013100A1 (en) * 2005-07-26 2007-02-01 Virchow Biotech Private Limited Gel formulation comprising platelet derived growth factor
DE102005041005B4 (en) * 2005-08-29 2022-10-20 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Biocidal composition containing nanoparticulate silver, the use of this composition and a method for the production of biocidal products using this composition
US20070185432A1 (en) * 2005-09-19 2007-08-09 Transport Pharmaceuticals, Inc. Electrokinetic system and method for delivering methotrexate
US20090311298A1 (en) * 2005-10-18 2009-12-17 Oranogenesis, In.C Antimicrobial Collagenous Constructs
US20070190182A1 (en) * 2005-11-08 2007-08-16 Pilkiewicz Frank G Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
US20070190180A1 (en) * 2005-11-08 2007-08-16 Pilkiewicz Frank G Methods of treating cancer with high potency lipid-based platinum compound formulations administered intravenously
US20070190181A1 (en) * 2005-11-08 2007-08-16 Pilkiewicz Frank G Methods of treating cancer with lipid-based platinum compound forumulations administered intravenously
US9107824B2 (en) 2005-11-08 2015-08-18 Insmed Incorporated Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
US20070122350A1 (en) * 2005-11-30 2007-05-31 Transave, Inc. Safe and effective methods of administering therapeutic agents
US20070128247A1 (en) * 2005-12-01 2007-06-07 Kato Yasushi P Method for Ionically Cross-Linking Polysaccharide Material for Thin Film Applications and Products Produced Therefrom
US8840660B2 (en) 2006-01-05 2014-09-23 Boston Scientific Scimed, Inc. Bioerodible endoprostheses and methods of making the same
US20070166399A1 (en) * 2006-01-13 2007-07-19 3M Innovative Properties Company Silver-containing antimicrobial articles and methods of manufacture
US20070166344A1 (en) * 2006-01-18 2007-07-19 Xin Qu Non-leaching surface-active film compositions for microbial adhesion prevention
US8089029B2 (en) 2006-02-01 2012-01-03 Boston Scientific Scimed, Inc. Bioabsorbable metal medical device and method of manufacture
US8053030B2 (en) * 2006-02-01 2011-11-08 Hollister Incorporated Methods of applying a hydrophilic coating to a substrate, and substrates having a hydrophilic coating
US7897800B2 (en) * 2006-02-03 2011-03-01 Jr Chem, Llc Chemical compositions and methods of making them
US7927614B2 (en) 2006-02-03 2011-04-19 Jr Chem, Llc Anti-aging treatment using copper and zinc compositions
US7687650B2 (en) 2006-02-03 2010-03-30 Jr Chem, Llc Chemical compositions and methods of making them
GB0603487D0 (en) * 2006-02-22 2006-04-05 Agt Sciences Ltd Delivery means
US20070212425A1 (en) * 2006-03-09 2007-09-13 Barna Ivan J Cidal formulations and methods of use
US20070224244A1 (en) * 2006-03-22 2007-09-27 Jan Weber Corrosion resistant coatings for biodegradable metallic implants
US20070224288A1 (en) * 2006-03-22 2007-09-27 Kiss Nail Products, Inc. Antibacterial gel coating and pedicure spa with antibacterial function
US20100048451A1 (en) * 2006-04-06 2010-02-25 Taro Pharmaceuticals North America, Inc. Novel spill-resistant formulations comprising hydrocolloidal polymers
JP5049268B2 (en) * 2006-04-07 2012-10-17 久光製薬株式会社 Microneedle device and transdermal drug administration device with microneedle
US8048150B2 (en) * 2006-04-12 2011-11-01 Boston Scientific Scimed, Inc. Endoprosthesis having a fiber meshwork disposed thereon
US8273381B1 (en) 2006-04-14 2012-09-25 Auburn University Compositions for and methods of controlling olfactory responses to odorants
WO2007122651A1 (en) 2006-04-24 2007-11-01 Nm Tech Ltd. Nanomaterials And Microdevices Technology Functional nanomaterials with antibacterial and antiviral activity
DE602006015539D1 (en) 2006-06-14 2010-08-26 Nm Tech Ltd Nanomaterials And NANOMATERIAL COATS FOR OSTEO INTEGRATED BIOMEDICAL PROSTHESES
US20070292397A1 (en) * 2006-06-19 2007-12-20 Mcnulty Amy K Method for the detection and neutralization of bacteria
US20110135742A1 (en) * 2006-06-20 2011-06-09 The Regents Of The University Of California Controlled release encapsulated anti-bacterial and anti-inflammatory nanoparticles
US20080044491A1 (en) * 2006-06-30 2008-02-21 Nucryst Pharmaceuticals Metal-containing formulations and methods of use
US20080027410A1 (en) * 2006-07-28 2008-01-31 Becton, Dickinson And Company Vascular access device non-adhering membranes
US8512294B2 (en) * 2006-07-28 2013-08-20 Becton, Dickinson And Company Vascular access device antimicrobial materials and solutions
US8197452B2 (en) * 2006-07-28 2012-06-12 Becton, Dickinson And Company Vascular access device non-adhering surfaces
CA2659761A1 (en) 2006-08-02 2008-02-07 Boston Scientific Scimed, Inc. Endoprosthesis with three-dimensional disintegration control
ES2368125T3 (en) * 2006-09-15 2011-11-14 Boston Scientific Scimed, Inc. BIOEROSIONABLE ENDOPROOTHESIS WITH BIOESTABLE INORGANIC LAYERS.
CA2663271A1 (en) 2006-09-15 2008-03-20 Boston Scientific Limited Bioerodible endoprostheses and methods of making the same
CA2663303A1 (en) * 2006-09-15 2008-03-20 Boston Scientific Limited Endoprosthesis with adjustable surface features
EP2959925B1 (en) 2006-09-15 2018-08-29 Boston Scientific Limited Medical devices and methods of making the same
US20080071353A1 (en) * 2006-09-15 2008-03-20 Boston Scientific Scimed, Inc. Endoprosthesis containing magnetic induction particles
WO2008034007A2 (en) * 2006-09-15 2008-03-20 Boston Scientific Limited Medical devices
US8808726B2 (en) * 2006-09-15 2014-08-19 Boston Scientific Scimed. Inc. Bioerodible endoprostheses and methods of making the same
JP2010503486A (en) * 2006-09-18 2010-02-04 ボストン サイエンティフィック リミテッド Endoprosthesis
WO2008036548A2 (en) 2006-09-18 2008-03-27 Boston Scientific Limited Endoprostheses
CA2663717A1 (en) * 2006-09-18 2008-03-27 Boston Scientific Limited Controlling biodegradation of a medical instrument
US7867522B2 (en) 2006-09-28 2011-01-11 Jr Chem, Llc Method of wound/burn healing using copper-zinc compositions
PL2079302T3 (en) * 2006-10-12 2014-08-29 Nm Tech Nanomaterials Microdevice Tech Ltd Use of a composition having anti-microbial properties
US20100098949A1 (en) * 2006-10-18 2010-04-22 Burton Scott A Antimicrobial articles and method of manufacture
US20080097577A1 (en) * 2006-10-20 2008-04-24 Boston Scientific Scimed, Inc. Medical device hydrogen surface treatment by electrochemical reduction
US20080103459A1 (en) * 2006-10-30 2008-05-01 Anthony Di Salvo Enzyme inhibition using nanoparticles
US20080122582A1 (en) * 2006-11-29 2008-05-29 Texas Instruments Incorporated Location Based Portable Device Feature Disabler
US20080132991A1 (en) * 2006-11-30 2008-06-05 Leonard Pinchuk Method for Ionically Cross-Linking Gellan Gum for Thin Film Applications and Medical Devices Produced Therefrom
US20080147734A1 (en) * 2006-12-18 2008-06-19 Cuticeuticals, Inc Method of topical steroidal organization
EP2277563B1 (en) 2006-12-28 2014-06-25 Boston Scientific Limited Bioerodible endoprostheses and method of making the same
CA2677640A1 (en) * 2007-02-09 2008-08-14 Poniard Pharmaceuticals, Inc. Stabilized picoplatin oral dosage form
US20080221533A1 (en) * 2007-03-09 2008-09-11 Anthem Orthopaedics Llc Implantable device with bioabsorbable layer, kit and method for use therewith, and apparatus for preparing same
US20080226701A1 (en) * 2007-03-15 2008-09-18 John Deignan Medicated patches
EP2155324A1 (en) * 2007-04-20 2010-02-24 Nitric Biotherapeutics, Inc. A single use applicator cartridge for an electrokinetic delivery system and method for self administration of medicaments
US8309222B2 (en) * 2007-04-25 2012-11-13 Covidien Lp Coated filaments
US20100069957A1 (en) * 2007-04-25 2010-03-18 Ferass Abuzaina Coated Filaments
KR20080070482A (en) * 2007-05-31 2008-07-30 (주)디딤바이오텍 A lubricating composition comprising agents which induce the mucosal immunity and a preparation method thereof
WO2008157485A1 (en) * 2007-06-15 2008-12-24 Transport Pharmaceuticals, Inc. Current concentration system and method for electrokinetic delivery of medicaments
US8133553B2 (en) 2007-06-18 2012-03-13 Zimmer, Inc. Process for forming a ceramic layer
US20080319371A1 (en) * 2007-06-19 2008-12-25 Transport Pharmaceuticals, Inc. Method and system for treating of onychomycosis with an applicator having a gel medicament layer
US8309521B2 (en) 2007-06-19 2012-11-13 Zimmer, Inc. Spacer with a coating thereon for use with an implant device
JP5159183B2 (en) * 2007-06-22 2013-03-06 アイノベックス株式会社 Composition for improvement or treatment of infertility
DE102007031650A1 (en) 2007-07-06 2009-01-08 Stada Arzneimittel Ag Dermatology for the treatment and / or care of the skin in atopic dermatitis
US8052745B2 (en) 2007-09-13 2011-11-08 Boston Scientific Scimed, Inc. Endoprosthesis
EP2200619B1 (en) * 2007-09-28 2015-08-12 Johnson & Johnson Consumer Companies, Inc. Electricity-generating particulates and the use thereof
BRPI0817416A2 (en) * 2007-10-03 2014-10-07 3M Innovantive Properties Company MULTIPLICATION LIMITING PROCESS OF MICROORGANISMS
US20110230973A1 (en) * 2007-10-10 2011-09-22 Zimmer, Inc. Method for bonding a tantalum structure to a cobalt-alloy substrate
US8608049B2 (en) * 2007-10-10 2013-12-17 Zimmer, Inc. Method for bonding a tantalum structure to a cobalt-alloy substrate
US20090143855A1 (en) * 2007-11-29 2009-06-04 Boston Scientific Scimed, Inc. Medical Device Including Drug-Loaded Fibers
US20100008970A1 (en) * 2007-12-14 2010-01-14 Boston Scientific Scimed, Inc. Drug-Eluting Endoprosthesis
US20090163887A1 (en) * 2007-12-20 2009-06-25 Arehart Kelly D Odor control cellulose granules with quinone compounds
US8273791B2 (en) 2008-01-04 2012-09-25 Jr Chem, Llc Compositions, kits and regimens for the treatment of skin, especially décolletage
US20090187256A1 (en) * 2008-01-21 2009-07-23 Zimmer, Inc. Method for forming an integral porous region in a cast implant
US20090198286A1 (en) * 2008-02-05 2009-08-06 Zimmer, Inc. Bone fracture fixation system
WO2009108147A1 (en) * 2008-02-27 2009-09-03 Qlt Usa, Inc. Dapsone to treat rosascea
WO2009126967A1 (en) * 2008-04-11 2009-10-15 Pediadermics, Llc Systems and methods for treatment kits
JP5738753B2 (en) * 2008-04-24 2015-06-24 メドトロニック,インコーポレイテッド Rehydratable polysaccharide particles and sponges
WO2009132228A1 (en) 2008-04-24 2009-10-29 Medtronic, Inc. Chitosan-containing protective composition
ES2610881T3 (en) 2008-04-24 2017-05-03 Medtronic, Inc Protective gel based on chitosan and oxidized polysaccharide
JP2011518837A (en) 2008-04-24 2011-06-30 メドトロニック,インコーポレイテッド Rehydratable thiolated polysaccharide particles and sponges
ES2530723T3 (en) * 2008-05-07 2015-03-04 Univ California Therapeutic replacement and enrichment of ocular surface lubrication
US8506944B2 (en) 2008-05-07 2013-08-13 The Regents Of The University Of California Replenishment and enrichment of ocular surface lubrication
US7998192B2 (en) 2008-05-09 2011-08-16 Boston Scientific Scimed, Inc. Endoprostheses
US8389583B2 (en) 2008-05-23 2013-03-05 Zurex Pharma, Inc. Antimicrobial compositions and methods of use
US8236046B2 (en) * 2008-06-10 2012-08-07 Boston Scientific Scimed, Inc. Bioerodible endoprosthesis
US20100004733A1 (en) * 2008-07-02 2010-01-07 Boston Scientific Scimed, Inc. Implants Including Fractal Structures
IT1391669B1 (en) * 2008-07-23 2012-01-17 Universita' Degli Studi Di Trieste NANOCOMPOSITE MATERIALS FORMED FROM A POLYSACCHARIDIC MATRIX AND METALLIC NANOPARTICLES, THEIR PREPARATION AND USE
US7985252B2 (en) 2008-07-30 2011-07-26 Boston Scientific Scimed, Inc. Bioerodible endoprosthesis
US20100030170A1 (en) * 2008-08-01 2010-02-04 Keith Alan Keller Absorptive Pad
US8150525B2 (en) * 2008-08-27 2012-04-03 Johnson & Johnson Consumer Companies, Inc. Treatment of hyperhydrosis
US20100082088A1 (en) * 2008-08-27 2010-04-01 Ali Fassih Treatment of sweating and hyperhydrosis
WO2010027189A2 (en) * 2008-09-02 2010-03-11 가톨릭대학교 산학협력단 A new use for homoisoflavanone or a salt thereof
US8382824B2 (en) 2008-10-03 2013-02-26 Boston Scientific Scimed, Inc. Medical implant having NANO-crystal grains with barrier layers of metal nitrides or fluorides
EP2218447B1 (en) * 2008-11-04 2017-04-19 PharmaSol GmbH Compositions containing lipid micro- or nanoparticles for the enhancement of the dermal action of solid particles
US20100124568A1 (en) * 2008-11-20 2010-05-20 Med-Eez, Inc Pharmaceutical articles coated with lubricious coatings
US8551517B2 (en) * 2008-12-16 2013-10-08 Kimberly-Clark Worldwide, Inc. Substrates providing multiple releases of active agents
WO2010085753A1 (en) 2009-01-23 2010-07-29 Jr Chem, Llc Rosacea treatments and kits for performing them
US8267992B2 (en) 2009-03-02 2012-09-18 Boston Scientific Scimed, Inc. Self-buffering medical implants
US20100229282A1 (en) * 2009-03-11 2010-09-16 Ansell Limited Powder-Free Anti-Blocking Coated Glove
US9149567B2 (en) * 2009-03-11 2015-10-06 Ansell Limited Powder-free antimicrobial coated glove
US20100234925A1 (en) * 2009-03-16 2010-09-16 PinPoint U.S.A., Inc. Treatment of microbiological pathogens in a toe nail with antimicrobial light
US20120089232A1 (en) 2009-03-27 2012-04-12 Jennifer Hagyoung Kang Choi Medical devices with galvanic particulates
US9192626B2 (en) 2009-06-10 2015-11-24 American Silver, Llc Dental uses of silver hydrosol
US8906883B2 (en) 2009-06-10 2014-12-09 Exthera Ab Treatment of oral mucositis by administering an ionic complex of chitosan and a negatively charged polysaccharide selected from heparin, heparan sulfate and dextran sulfate
US8821455B2 (en) * 2009-07-09 2014-09-02 Becton, Dickinson And Company Antimicrobial coating for dermally invasive devices
US20110008271A1 (en) * 2009-07-13 2011-01-13 Jr Chem, Llc Rosacea treatments using polymetal complexes
US20110022158A1 (en) * 2009-07-22 2011-01-27 Boston Scientific Scimed, Inc. Bioerodible Medical Implants
US8814922B2 (en) * 2009-07-22 2014-08-26 New Star Lasers, Inc. Method for treatment of fingernail and toenail microbial infections using infrared laser heating and low pressure
US20110065798A1 (en) * 2009-09-17 2011-03-17 Becton, Dickinson And Company Anti-infective lubricant for medical devices and methods for preparing the same
US20110091571A1 (en) * 2009-10-16 2011-04-21 Moore Michael F Method of controlling the propagation of mrsa, staph and other infections that colonize in the nose
EP2498763A4 (en) 2009-11-09 2015-10-07 Spotlight Technology Partners Llc Polysaccharide based hydrogels
AU2010314994B2 (en) 2009-11-09 2016-10-06 Spotlight Technology Partners Llc Fragmented hydrogels
KR20120091335A (en) * 2009-11-13 2012-08-17 존슨 앤드 존슨 컨수머 캄파니즈, 인코포레이티드 Galvanic skin treatment device
US8701671B2 (en) 2011-02-04 2014-04-22 Joseph E. Kovarik Non-surgical method and system for reducing snoring
US9549842B2 (en) 2011-02-04 2017-01-24 Joseph E. Kovarik Buccal bioadhesive strip and method of treating snoring and sleep apnea
JP2011135009A (en) * 2009-12-25 2011-07-07 Tokyo Electron Ltd Method and apparatus for drying substrate
KR20110091461A (en) * 2010-02-05 2011-08-11 존슨 앤드 존슨 컨수머 캄파니즈, 인코포레이티드 Lip compositions comprising galvanic particulates
CN102781406B (en) * 2010-03-01 2015-07-08 强生消费者公司 Skin care composition having desirable bulk color
US8668732B2 (en) 2010-03-23 2014-03-11 Boston Scientific Scimed, Inc. Surface treated bioerodible metal endoprostheses
US20110236491A1 (en) * 2010-03-25 2011-09-29 Jeannette Chantalat Topical anti-inflammatory composition
US9999702B2 (en) 2010-04-09 2018-06-19 Kci Licensing Inc. Apparatuses, methods, and compositions for the treatment and prophylaxis of chronic wounds
US20110301553A1 (en) * 2010-06-04 2011-12-08 Smiths Medical Asd, Inc. Antimicrobial lubricant
RU2452498C2 (en) * 2010-07-20 2012-06-10 Общество с ограниченной ответственностью "Научно-производственное объединение "Ликом" Method for preparing anti-tuberculosis drug
DK3210591T3 (en) 2010-08-27 2019-04-15 Sienna Biopharmaceuticals Inc COMPOSITIONS AND METHODS OF TARGETED THERMO MODULATION
US9572880B2 (en) 2010-08-27 2017-02-21 Sienna Biopharmaceuticals, Inc. Ultrasound delivery of nanoparticles
JP5646277B2 (en) * 2010-10-25 2014-12-24 クラシエホームプロダクツ株式会社 Disinfectant and acne treatment / prevention agent
US9572329B2 (en) * 2010-11-18 2017-02-21 Samuel P Hopkins Antimicrobial containing fish hook and method of using and manufacturing same
US8952057B2 (en) 2011-01-11 2015-02-10 Jr Chem, Llc Compositions for anorectal use and methods for treating anorectal disorders
US9987224B2 (en) 2011-02-04 2018-06-05 Joseph E. Kovarik Method and system for preventing migraine headaches, cluster headaches and dizziness
US10512661B2 (en) 2011-02-04 2019-12-24 Joseph E. Kovarik Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease
US10548761B2 (en) 2011-02-04 2020-02-04 Joseph E. Kovarik Method and system for reducing the likelihood of colorectal cancer in a human being
US10687975B2 (en) 2011-02-04 2020-06-23 Joseph E. Kovarik Method and system to facilitate the growth of desired bacteria in a human's mouth
US11357722B2 (en) 2011-02-04 2022-06-14 Seed Health, Inc. Method and system for preventing sore throat in humans
US11273187B2 (en) 2015-11-30 2022-03-15 Joseph E. Kovarik Method and system for reducing the likelihood of developing depression in an individual
US11844720B2 (en) 2011-02-04 2023-12-19 Seed Health, Inc. Method and system to reduce the likelihood of dental caries and halitosis
US10842834B2 (en) 2016-01-06 2020-11-24 Joseph E. Kovarik Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease
US11523934B2 (en) 2011-02-04 2022-12-13 Seed Health, Inc. Method and system to facilitate the growth of desired bacteria in a human's mouth
US10245288B2 (en) 2011-02-04 2019-04-02 Joseph E. Kovarik Method and system for reducing the likelihood of developing NASH in an individual diagnosed with non-alcoholic fatty liver disease
US10086018B2 (en) 2011-02-04 2018-10-02 Joseph E. Kovarik Method and system for reducing the likelihood of colorectal cancer in a human being
US11419903B2 (en) 2015-11-30 2022-08-23 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
CN106214110B (en) 2011-02-16 2018-03-20 通用医疗公司 photo-coupler for endoscope
US9707375B2 (en) 2011-03-14 2017-07-18 Rochester Medical Corporation, a subsidiary of C. R. Bard, Inc. Catheter grip and method
US8597264B2 (en) 2011-03-24 2013-12-03 Kci Licensing, Inc. Apparatuses, methods, and compositions for the treatment and prophylaxis of chronic wounds
WO2012131931A1 (en) * 2011-03-30 2012-10-04 ダイワボウホールディングス株式会社 Wound-covering material
CA2829095C (en) * 2011-03-30 2019-08-27 Gr Intellectual Reserve, Llc Novel gold-platinum based bi-metallic nanocrystal suspensions, electrochemical manufacturing processes therefor and uses for the same
GB2497115A (en) * 2011-12-01 2013-06-05 Lrc Products Coated condom
JP6017883B2 (en) * 2012-08-08 2016-11-02 バイオエポック株式会社 Manufacturing method of toothpaste
WO2014039533A2 (en) 2012-09-04 2014-03-13 Eleison Pharmaceuticals, Llc Preventing pulmonary recurrence of cancer with lipid-complexed cisplatin
CN102872159A (en) * 2012-09-29 2013-01-16 广东同德药业有限公司 Nano-silver chitosan gel foam preparation for treating vaginal bacterial inflammation, and preparation method thereof
RU2646809C2 (en) 2012-10-11 2018-03-07 Нанокомпозикс, Инк. Silver nanoplates compositions and methods
CN102872160A (en) * 2012-10-26 2013-01-16 广东同德药业有限公司 Nano-silver foaming agent used for sterilizing wounds of scalds and burns and ulcer wounds
AU2013334061A1 (en) * 2012-10-26 2015-05-14 Sienna Labs, Inc. Metastable silver nanoparticle composites
US9872969B2 (en) 2012-11-20 2018-01-23 Rochester Medical Corporation, a subsidiary of C.R. Bard, Inc. Catheter in bag without additional packaging
US10092728B2 (en) 2012-11-20 2018-10-09 Rochester Medical Corporation, a subsidiary of C.R. Bard, Inc. Sheath for securing urinary catheter
US20140377318A1 (en) * 2012-12-06 2014-12-25 S. Douglas Cornell Antimicrobial sanitizer systems and methods of killing or inhibiting pathogens
EP2764876A1 (en) * 2013-02-11 2014-08-13 Lacerta Technologies Inc. Bone substitute material with biologically active coating
US9750928B2 (en) 2013-02-13 2017-09-05 Becton, Dickinson And Company Blood control IV catheter with stationary septum activator
US9695323B2 (en) 2013-02-13 2017-07-04 Becton, Dickinson And Company UV curable solventless antimicrobial compositions
GB2511528A (en) 2013-03-06 2014-09-10 Speciality Fibres And Materials Ltd Absorbent materials
US9750927B2 (en) 2013-03-11 2017-09-05 Becton, Dickinson And Company Blood control catheter with antimicrobial needle lube
US9327095B2 (en) 2013-03-11 2016-05-03 Becton, Dickinson And Company Blood control catheter with antimicrobial needle lube
EP2968886A1 (en) 2013-03-14 2016-01-20 Hallux, Inc. Method of treating infections, diseases or disorders of nail unit
US20140271919A1 (en) * 2013-03-15 2014-09-18 Chun Lim Abbott Topical Copper Ion Treatments and Methods of Treatment Using Topical Copper Ion Treatments in the Genital-Rectal Areas of the Body
US10398733B2 (en) 2013-03-15 2019-09-03 Cda Research Group, Inc. Topical copper ion treatments and methods of treatment using topical copper ion treatments in the dermatological areas of the body
US10792337B2 (en) 2013-03-15 2020-10-06 Kci Licensing, Inc. Wound healing compositions
US11000545B2 (en) 2013-03-15 2021-05-11 Cda Research Group, Inc. Copper ion compositions and methods of treatment for conditions caused by coronavirus and influenza
US11007143B2 (en) * 2013-03-15 2021-05-18 Cda Research Group, Inc. Topical copper ion treatments and methods of treatment using topical copper ion treatments in the oral-respiratory-otic areas of the body
US11318089B2 (en) 2013-03-15 2022-05-03 Cda Research Group, Inc. Topical copper ion treatments and methods of making topical copper ion treatments for use in various anatomical areas of the body
US11083750B2 (en) 2013-03-15 2021-08-10 Cda Research Group, Inc. Methods of treatment using topical copper ion formulations
US9095566B1 (en) * 2013-06-28 2015-08-04 Edward Quicksilver Yavitz Eyelash and eyelid margin infections
US11833177B2 (en) 2013-12-20 2023-12-05 Seed Health, Inc. Probiotic to enhance an individual's skin microbiome
US11826388B2 (en) 2013-12-20 2023-11-28 Seed Health, Inc. Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation
US11839632B2 (en) 2013-12-20 2023-12-12 Seed Health, Inc. Topical application of CRISPR-modified bacteria to treat acne vulgaris
US20150182673A1 (en) 2013-12-30 2015-07-02 Boston Scientific Scimed, Inc. Functionalized lubricious medical device coatings
CN104814831A (en) * 2014-01-30 2015-08-05 柯惠有限合伙公司 Preparation of occlusive dressings
US10376686B2 (en) 2014-04-23 2019-08-13 Becton, Dickinson And Company Antimicrobial caps for medical connectors
US9789279B2 (en) 2014-04-23 2017-10-17 Becton, Dickinson And Company Antimicrobial obturator for use with vascular access devices
US9675793B2 (en) 2014-04-23 2017-06-13 Becton, Dickinson And Company Catheter tubing with extraluminal antimicrobial coating
US10232088B2 (en) 2014-07-08 2019-03-19 Becton, Dickinson And Company Antimicrobial coating forming kink resistant feature on a vascular access device
CN106659820A (en) 2014-08-26 2017-05-10 C·R·巴德股份有限公司 Urinary catheter
US9459442B2 (en) 2014-09-23 2016-10-04 Scott Miller Optical coupler for optical imaging visualization device
CN104577135B (en) * 2015-01-04 2017-01-18 哈尔滨工业大学 Preparation method of three-dimensional silver mesh
US10548467B2 (en) 2015-06-02 2020-02-04 GI Scientific, LLC Conductive optical element
US10856724B2 (en) 2015-07-21 2020-12-08 GI Scientific, LLC Endoscope accessory with angularly adjustable exit portal
RU2611999C2 (en) * 2015-08-05 2017-03-01 Федеральное государственное бюджетное учреждение науки Иркутский институт химии им. А.Е. Фаворского Сибирского отделения Российской академии наук Silver nanocomposite based on arabinogalactan conjugate and flavonoids with antimicrobial and antitumor action and preparation method thereof
US10040957B2 (en) * 2015-09-17 2018-08-07 Eastman Kodak Company Ink jettable, UV-curable compositions
DE102015115878B4 (en) * 2015-09-21 2018-03-29 Aap Implantate Ag A method of treating a metallic surface and bodies having a treated metallic surface
US10493244B2 (en) 2015-10-28 2019-12-03 Becton, Dickinson And Company Extension tubing strain relief
CN108601930B (en) * 2016-02-08 2021-12-14 祥丰医疗私人有限公司 Drug eluting balloon
US10792477B2 (en) 2016-02-08 2020-10-06 Orbusneich Medical Pte. Ltd. Drug eluting balloon
BR102016016340A2 (en) * 2016-07-14 2018-02-06 Francisco Pianowski Luiz ANTIMICROBIAN MUCOSAL FORMULATION AND USE OF ANTIMICROBIAN MUCOSAL FORMULATION
US11330931B2 (en) 2016-09-29 2022-05-17 Levo Oil Infusion Apparatus and method for infusing and dispensing oils, and drying and heating infusing materials
US10537658B2 (en) 2017-03-28 2020-01-21 DePuy Synthes Products, Inc. Orthopedic implant having a crystalline gallium-containing hydroxyapatite coating and methods for making the same
US10537661B2 (en) 2017-03-28 2020-01-21 DePuy Synthes Products, Inc. Orthopedic implant having a crystalline calcium phosphate coating and methods for making the same
AU2018337731C1 (en) 2017-09-19 2024-02-01 C.R. Bard, Inc. Urinary catheter bridging device, systems and methods thereof
RU2659580C1 (en) * 2017-10-16 2018-07-05 Федеральное государственное бюджетное образовательное учреждение высшего образования "Кировский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО Кировский ГМУ Минздрава России) Method for obtaining agent for topical treatment of skin lesions based on nanoscale silver particles, ointment base and solid additives
JP7365409B2 (en) 2018-06-28 2023-10-19 エイアールエックス エルエルシー Dispensing method for producing soluble unit dose membrane constructs
CN109646456A (en) * 2018-12-31 2019-04-19 四川金凯医疗器械有限公司 It is a kind of for treating the new type gel of periodontitis
CN109731103B (en) * 2019-01-20 2022-03-22 桂林理工大学 Preparation method of P-type molecular sieve-chitosan-sodium alginate-potassium diformate sustained-release antibacterial agent
US11193184B2 (en) 2019-02-22 2021-12-07 Cda Research Group, Inc. System for use in producing a metal ion suspension and process of using same
RU2730480C1 (en) * 2019-07-30 2020-08-24 Общество с ограниченной ответственностью "БиоМед" Method of administering a pharmaceutical substance into a polymer substrate of a dressing
DE102021205475A1 (en) 2021-05-28 2022-12-01 FNT-GmbH Antimicrobial composition, method of making an antimicrobial composition and use of an antimicrobial composition
CN113479975A (en) * 2021-07-01 2021-10-08 辽宁锦海医药科技有限公司 Preparation method and application of oxidation potential acidic water
KR20230081979A (en) * 2021-11-30 2023-06-08 경희대학교 산학협력단 Composition for anti-inflammation comprising gold nanoparticle-peanut sprout extract as an active ingredient

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989009054A1 (en) * 1988-03-23 1989-10-05 Smithkline Beecham Corporation Topically applied gold organic complex
WO1995013704A1 (en) * 1993-11-18 1995-05-26 Westaim Technologies Inc. Anti-microbial materials
WO1998041095A2 (en) * 1997-03-17 1998-09-24 Westaim Technologies Inc. Anti-microbial coatings having indicator properties and wound dressings
WO2000027390A1 (en) * 1998-11-09 2000-05-18 Ira Jay Newman Ionic silver complex
WO2000078281A1 (en) * 1999-06-17 2000-12-28 The Procter & Gamble Company An anti-microbial body care product
WO2001049303A1 (en) * 2000-01-06 2001-07-12 Marantech Holding, Llc Multivalent electron active compositions and methods of making and using same
WO2002009729A2 (en) * 2000-07-27 2002-02-07 Nucryst Pharmaceuticals Corp. Treatment of hyperproliferative skin disorders and diseases

Family Cites Families (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB420052A (en) 1932-10-17 1934-11-23 Consortium Elektrochem Ind Manufacture of shaped articles from polyvinyl alcohols
FR732895A (en) 1932-10-18 1932-09-25 Consortium Elektrochem Ind Articles spun in polyvinyl alcohol
FR882M (en) 1961-01-18 1961-10-06
GB1270410A (en) 1969-09-25 1972-04-12 Allor Corp Colloidal composition and method of preparing the same
US3757786A (en) 1970-11-06 1973-09-11 D Smith Synthetic surgical sutures
US3800792A (en) 1972-04-17 1974-04-02 Johnson & Johnson Laminated collagen film dressing
US3988434A (en) * 1972-08-07 1976-10-26 Schole Murray L Dental preparation
US3918446A (en) 1974-05-03 1975-11-11 E Med Corp Securement device for intravenous catheter and its tubing
US4059105A (en) * 1976-03-24 1977-11-22 Omnimed, Inc. Cannula securing device
DE2748882A1 (en) 1977-11-02 1979-05-03 Arnis Dr Med Rava Plaster protecting wound against infection - esp. during application of intravenous catheter, permitting continuous use for ten days
DE2929706C2 (en) 1979-07-21 1982-09-30 Drägerwerk AG, 2400 Lübeck Breathing air humidifiers and warmers for ventilation systems
US4324237A (en) * 1980-02-26 1982-04-13 E-Med Corporation Intravenous catheter and tubing securement and dressing device with a window over the puncture or wound site
GB2073024B (en) 1980-03-27 1984-06-27 Nat Res Dev Antimicrobial surgical implants
US4476590A (en) 1980-03-27 1984-10-16 National Research Development Corporation Antimicrobial surgical implants
DE3176658D1 (en) 1981-12-10 1988-03-31 Revlon Process for making metallic leafing pigments
JPS58126910A (en) 1982-01-21 1983-07-28 Nippon Steel Corp Dephosphorizing method of molten metal
GB2140684B (en) 1983-04-25 1986-07-30 Stavros Christodoulou Mineral oil composition for use in the treatment of eczema
JPS6021912A (en) 1983-07-14 1985-02-04 Mitsubishi Rayon Co Ltd Manufacture of metallized synthetic fiber staple
US4828832A (en) 1983-09-07 1989-05-09 Laboratorios Biochemie De Mexico Method of manufacturing a composition for treating skin lesions
EP0136768A3 (en) 1983-09-07 1986-07-30 Laboratorios Biochemie De Mexico S.A. DE C.V. Composition and method for treatingskin lesions
US4581028A (en) 1984-04-30 1986-04-08 The Trustees Of Columbia University In The City Of New York Infection-resistant materials and method of making same through use of sulfonamides
GB8421706D0 (en) * 1984-08-28 1984-10-03 Pharmaceutical Holdings Ltd Pharmaceutical preparations
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4633863A (en) 1985-09-27 1987-01-06 Filips Chester P Arterial anchor bandage
US4960413A (en) 1985-11-09 1990-10-02 The Shirley Institute Wound dressing
US5122418A (en) 1985-12-09 1992-06-16 Shiseido Company Ltd. Composite powder and production process
US4847049A (en) * 1985-12-18 1989-07-11 Vitaphore Corporation Method of forming chelated collagen having bactericidal properties
JPS62185807A (en) 1986-02-08 1987-08-14 Mitsubishi Shindo Kk Production of metallic flat powder
GB8607159D0 (en) * 1986-03-22 1986-04-30 Smith & Nephew Ass Pharmaceutical composition
GB8612598D0 (en) 1986-05-23 1986-07-02 Tarnpure Ltd Liquid/gas interface apparatus
US5236421A (en) 1986-05-28 1993-08-17 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Fixing system for fastening catheters, cannulas or the like to the skin surface and process for the sterile fastening thereof
EP0254413A3 (en) 1986-06-13 1989-11-08 Yoshiaki Matsuo Silver-ionic water and its uses
US4952411A (en) 1987-02-25 1990-08-28 Trustees Of Columbia University In The City Of New York Method of inhibiting the transmission of AIDS virus
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US5143717A (en) 1987-12-30 1992-09-01 Code Blue Medical Corporation Burn foam and delivery system
US5019096A (en) 1988-02-11 1991-05-28 Trustees Of Columbia University In The City Of New York Infection-resistant compositions, medical devices and surfaces and methods for preparing and using same
DE3807944A1 (en) 1988-03-10 1989-09-21 Braun Melsungen Ag Device for fastening a catheter or a cannula on the skin surface
AU4045489A (en) 1988-08-18 1990-03-23 Konrad Minninger Silver sulfadiazine containing pharmaceutical product for the local external therapy
US4956350A (en) 1988-08-18 1990-09-11 Minnesota Mining And Manufacturing Company Wound filling compositions
US4908355A (en) 1989-01-09 1990-03-13 Dow Corning Corporation Skin treatment method
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5270358A (en) * 1989-12-28 1993-12-14 Minnesota Mining And Manufacturing Company Composite of a disperesed gel in an adhesive matrix
JP3169621B2 (en) 1991-01-29 2001-05-28 株式会社タカミツ Antimicrobial external preparation
EP0570452A1 (en) 1991-02-06 1993-11-24 Minnesota Mining And Manufacturing Company Improved surgical hardware with bacteriostatic silver coating, and method of using same
US5484886A (en) * 1991-04-25 1996-01-16 Merck & Co., Inc. Human neurokinin-1 receptor
US5348799A (en) 1991-09-03 1994-09-20 Minnesota Mining And Manufacturing Company Antistatic coatings comprising chitosan acid salt and metal oxide particles
GEP20002074B (en) 1992-05-19 2000-05-10 Westaim Tech Inc Ca Modified Material and Method for its Production
US5681575A (en) 1992-05-19 1997-10-28 Westaim Technologies Inc. Anti-microbial coating for medical devices
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
USD349958S (en) 1992-07-24 1994-08-23 Bioject Inc. Needleless injector
CN1034090C (en) 1992-08-06 1997-02-19 蒋建华 Long-acting broad-spectrum antiseptic fabric and its producing method
IT1256111B (en) 1992-11-23 1995-11-28 Lifegroup Spa SALTS OF TRAUMATIC ACID WITH CICATRIZING AND ANTIBACTERIAL ACTIVITY
JP2981528B2 (en) 1992-12-25 1999-11-22 三菱電機株式会社 Cathode ray tube and method of manufacturing the same
JP3513199B2 (en) * 1993-01-01 2004-03-31 キヤノン株式会社 Liquid ejecting head, liquid ejecting head cartridge and recording apparatus using the same, and method of manufacturing liquid ejecting head
US5631066A (en) * 1993-01-25 1997-05-20 Chronopol, Inc. Process for making metalized films and films produced therefrom
US5534288A (en) 1993-03-23 1996-07-09 United States Surgical Corporation Infection-resistant surgical devices and methods of making them
US5848995A (en) 1993-04-09 1998-12-15 Walder; Anthony J. Anti-infective medical article and method for its preparation
US5454889A (en) * 1993-08-19 1995-10-03 Ici Canada Inc. Prill coating
WO1995012602A1 (en) 1993-11-05 1995-05-11 Meiji Milk Products Co., Ltd. Antibacterial, antifungal and antiviral agent
US5454886A (en) 1993-11-18 1995-10-03 Westaim Technologies Inc. Process of activating anti-microbial materials
US5372589A (en) 1993-11-24 1994-12-13 Davis; W. Gordon Fenestrated transparent catheter securing device and method
WO1995014484A1 (en) 1993-11-26 1995-06-01 Kimurakogyo Co., Ltd. In vivo free-radical generator
US5817325A (en) 1996-10-28 1998-10-06 Biopolymerix, Inc. Contact-killing antimicrobial devices
JPH07220702A (en) * 1994-02-02 1995-08-18 Nec Corp Battery pack
EP0788305B1 (en) * 1994-03-28 2004-11-03 The Trustees of Columbia University in the City of New York Composition for inactivating irritants in fluids
US5899880A (en) 1994-04-08 1999-05-04 Powderject Research Limited Needleless syringe using supersonic gas flow for particle delivery
US5563132A (en) 1994-06-21 1996-10-08 Bodaness; Richard S. Two-step cancer treatment method
US6544357B1 (en) * 1994-08-01 2003-04-08 Franz Hehmann Selected processing for non-equilibrium light alloys and products
US5578073A (en) 1994-09-16 1996-11-26 Ramot Of Tel Aviv University Thromboresistant surface treatment for biomaterials
US5569207A (en) 1994-10-13 1996-10-29 Quinton Instrument Company Hydrocolloid dressing
GB9424562D0 (en) 1994-12-06 1995-01-25 Giltech Ltd Product
US5589177A (en) 1994-12-06 1996-12-31 Helene Curtis, Inc. Rinse-off water-in-oil-in-water compositions
GB9502879D0 (en) 1995-02-14 1995-04-05 Oxford Biosciences Ltd Particle delivery
CA2224164C (en) 1995-06-07 2007-12-11 Robert S. Neuwirth Intrauterine chemical necrosing method and composition
CA2225808C (en) 1995-06-30 2002-12-17 Christopher C. Capelli Silver-based pharmaceutical compositions
US6013050A (en) 1995-10-20 2000-01-11 Powderject Research Limited Particle delivery
DE19541735A1 (en) 1995-11-09 1997-05-15 Iris Roller Use of hydrothermal rock deposits e.g. calcite precursors
US5686096A (en) 1995-12-22 1997-11-11 Becton Dickinson And Company Medical device for the protection of a catheter penetration site
US6201164B1 (en) 1996-07-11 2001-03-13 Coloplast A/S Hydrocolloid wound gel
US5895419A (en) * 1996-09-30 1999-04-20 St. Jude Medical, Inc. Coated prosthetic cardiac device
DE19640365A1 (en) 1996-09-30 1998-04-02 Basf Ag Polymer-hydrogen peroxide complexes
EP0834319A1 (en) * 1996-10-07 1998-04-08 Kartar Dr. Lalvani Mineral and vitamin combinations in arthritic pain
GB9623962D0 (en) * 1996-11-15 1997-01-08 Tillotts Pharma Ag Pharmaceutical composition
US7625420B1 (en) 1997-02-24 2009-12-01 Cabot Corporation Copper powders methods for producing powders and devices fabricated from same
GB2324732B (en) 1997-05-02 2001-09-26 Johnson & Johnson Medical Absorbent wound dressings
WO1998051273A1 (en) 1997-05-12 1998-11-19 Sage Pharmaceuticals, Inc. Topical spray for burn treatment and anti-infection
US6071543A (en) 1997-06-02 2000-06-06 Cellegy Pharmaceuticals, Inc. Pyridine-thiols reverse mucocutaneous aging
KR20010013377A (en) 1997-06-04 2001-02-26 데이비드 엠 모이어 Mild, leave-on antimicrobial compositions
EP0991702B2 (en) 1997-06-20 2017-07-19 Coloplast A/S A hydrophilic coating
DE19728489A1 (en) 1997-07-03 1999-01-07 Huels Chemische Werke Ag Medical device for improving the skin fixation of indwelling catheters and other transcutaneous implants with a reduced risk of infection
US6165440A (en) 1997-07-09 2000-12-26 Board Of Regents, The University Of Texas System Radiation and nanoparticles for enhancement of drug delivery in solid tumors
US6153210A (en) * 1997-08-14 2000-11-28 Periodontix, Inc. Use of locally delivered metal ions for treatment of periodontal disease
JP3411195B2 (en) 1997-08-18 2003-05-26 栄一 築地 Active oxygen remover
JPH11116488A (en) 1997-10-08 1999-04-27 Toagosei Co Ltd Carcinostatic agent
JP4039719B2 (en) * 1997-10-17 2008-01-30 富士フイルム株式会社 Antitumor agent
US6312643B1 (en) * 1997-10-24 2001-11-06 The United States Of America As Represented By The Secretary Of The Air Force Synthesis of nanoscale aluminum alloy powders and devices therefrom
HU221676B1 (en) * 1998-02-20 2002-12-28 István Budai Pharmaceutical composition, containing ethanol or water-ethanol solution having iodine and silver nitrate and process for producing it
FR2775696B1 (en) * 1998-03-05 2000-04-14 Saint Gobain Vitrage SUBSTRATE WITH PHOTOCATALYTIC COATING
US20020014406A1 (en) * 1998-05-21 2002-02-07 Hiroshi Takashima Aluminum target material for sputtering and method for producing same
US6123925A (en) 1998-07-27 2000-09-26 Healthshield Technologies L.L.C. Antibiotic toothpaste
US6071541A (en) 1998-07-31 2000-06-06 Murad; Howard Pharmaceutical compositions and methods for managing skin conditions
US6398999B1 (en) * 1998-10-23 2002-06-04 Avery Dennison Corporation Process for making high aspect ratio reflective metal flakes
US6238986B1 (en) * 1998-11-06 2001-05-29 Advanced Micro Devices, Inc. Formation of junctions by diffusion from a doped film at silicidation
US6096002A (en) * 1998-11-18 2000-08-01 Bioject, Inc. NGAS powered self-resetting needle-less hypodermic jet injection apparatus and method
US6436422B1 (en) 1998-11-23 2002-08-20 Agion Technologies L.L.C. Antibiotic hydrophilic polymer coating
US6365130B1 (en) 1998-11-23 2002-04-02 Agion Technologies L.L.C. Antimicrobial chewing gum
US6224579B1 (en) * 1999-03-31 2001-05-01 The Trustees Of Columbia University In The City Of New York Triclosan and silver compound containing medical devices
US6258385B1 (en) 1999-04-22 2001-07-10 Marantech Holding, Llc Tetrasilver tetroxide treatment for skin conditions
JP4454062B2 (en) 1999-05-17 2010-04-21 敬 三宅 Ultrafine particle silver milky body and method for producing the same
CN1161511C (en) 1999-07-27 2004-08-11 蒋建华 Long-acting wide-spectrum antiseptic nanometer silver fabric and its making method
JP2001151681A (en) 1999-11-24 2001-06-05 Lintec Corp Prophylactic and/or therapeutic agent for systema digestorium disease
CN1108786C (en) 1999-12-28 2003-05-21 天津市化妆品科学技术研究所 Silver foil cosmetics
US7137968B1 (en) 2000-03-13 2006-11-21 Nucryst Pharmaceuticals Corp. Transcutaneous medical device dressings and method of use
US6224898B1 (en) 2000-03-23 2001-05-01 The United States Of America As Represented By The Secretary Of The Army Antimicrobial dendrimer nanocomposites and a method of treating wounds
US6719987B2 (en) * 2000-04-17 2004-04-13 Nucryst Pharmaceuticals Corp. Antimicrobial bioabsorbable materials
SE516537C2 (en) * 2000-05-19 2002-01-29 Alfa Laval Ab Flat pack and plate heat exchanger
US6592888B1 (en) 2000-05-31 2003-07-15 Jentec, Inc. Composition for wound dressings safely using metallic compounds to produce anti-microbial properties
PT1395289E (en) * 2000-06-08 2011-03-16 Sang Dr Christine Treatment of neuropathic pain with a n-methyl-d-aspartate (nmda) receptor antagonists
US7008647B2 (en) 2001-04-23 2006-03-07 Nucryst Pharmaceuticals Corp. Treatment of acne
US20030170314A1 (en) * 2000-07-27 2003-09-11 Burrell Robert E. Compositions of metal-containing compounds
DE10037353A1 (en) 2000-07-29 2002-02-07 Hans E Sachse Catheter with bioabsorbable coating to prevent rising infections
CN1279222A (en) 2000-07-31 2001-01-10 金华尖峰陶瓷有限责任公司 Antibacterial inorganic ceramics and its production technology
CN1291667A (en) 2000-08-14 2001-04-18 骏安科技投资有限公司 Nanometer silver anti-bacteria cloth and its industrial production technology
CN1147640C (en) 2000-09-19 2004-04-28 南京希科集团有限公司 Antibacterial fabric containing nm-class silver powder and its making method
CN1159488C (en) 2001-01-20 2004-07-28 南京希科集团有限公司 Antibacterial flexible material containing nm silver and its preparing process and application
CN1179646C (en) 2001-04-20 2004-12-15 朱红军 Aggregation-preventing nanometer wide-spectrum antibacterial silve powder and its inductrial production process
EP1383521A2 (en) * 2001-04-23 2004-01-28 Nucryst Pharmaceuticals Corp. Medicament containing a metal such as silver, gold, platinum or palladium as an antimicrobial agent and their use to induce apoptosis in cancerous tissue
CN1183285C (en) 2001-04-25 2005-01-05 朱红军 Aggregation-preventing wide-spectrum nanometer antibiotic silver yarn and its industrial production process

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989009054A1 (en) * 1988-03-23 1989-10-05 Smithkline Beecham Corporation Topically applied gold organic complex
WO1995013704A1 (en) * 1993-11-18 1995-05-26 Westaim Technologies Inc. Anti-microbial materials
WO1998041095A2 (en) * 1997-03-17 1998-09-24 Westaim Technologies Inc. Anti-microbial coatings having indicator properties and wound dressings
WO2000027390A1 (en) * 1998-11-09 2000-05-18 Ira Jay Newman Ionic silver complex
WO2000078281A1 (en) * 1999-06-17 2000-12-28 The Procter & Gamble Company An anti-microbial body care product
WO2001049303A1 (en) * 2000-01-06 2001-07-12 Marantech Holding, Llc Multivalent electron active compositions and methods of making and using same
WO2002009729A2 (en) * 2000-07-27 2002-02-07 Nucryst Pharmaceuticals Corp. Treatment of hyperproliferative skin disorders and diseases

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch, Week 199241 Derwent Publications Ltd., London, GB; Class B06, AN 1992-337727 XP002215314 & JP 04 244029 A (SHINANEN NEW CERAMIC KK) , 1 September 1992 (1992-09-01) *
DATABASE WPI Section Ch, Week 199919 Derwent Publications Ltd., London, GB; Class B06, AN 1999-226104 XP002214210 & JP 11 060493 A (TSUKIJI E), 2 March 1999 (1999-03-02) *
DATABASE WPI Section Ch, Week 200006 Derwent Publications Ltd., London, GB; Class B06, AN 2000-065287 XP002215305 & HU 9 800 078 A (BUDAI I), 28 September 1999 (1999-09-28) *

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8084664B2 (en) 2001-02-16 2011-12-27 Kci Licensing, Inc. Biocompatible wound dressing
US8735644B2 (en) 2001-02-16 2014-05-27 Kci Licensing, Inc. Biocompatible wound dressing
US8163974B2 (en) 2001-02-16 2012-04-24 Kci Licensing, Inc. Biocompatible wound dressing
US7700819B2 (en) 2001-02-16 2010-04-20 Kci Licensing, Inc. Biocompatible wound dressing
US7763769B2 (en) 2001-02-16 2010-07-27 Kci Licensing, Inc. Biocompatible wound dressing
US8309117B2 (en) 2002-12-19 2012-11-13 Novartis, Ag Method for making medical devices having antimicrobial coatings thereon
US8637071B2 (en) 2002-12-19 2014-01-28 Novartis Ag Method for making medical devices having antimicrobial coatings thereon
JP2007504107A (en) * 2003-08-29 2007-03-01 バイオ−ゲイト アーゲー Body care products containing porous silver particles
WO2005074949A1 (en) * 2004-02-02 2005-08-18 Nucryst Pharmaceuticals Corp. Treatment of ungual and subungual diseases with antimicrobial metal compositions
DE102004031955A1 (en) * 2004-06-24 2006-01-12 Paul Hartmann Ag wound dressing
JP2011504459A (en) * 2007-10-05 2011-02-10 ウニベルシダーデ デ サンティアゴ デ コンポステラ Use of atomic quantum clusters (AQCs) as antibacterial and biocides
US8865227B2 (en) 2007-12-20 2014-10-21 Smith & Nephew (Overseas) Limited Metal carbonate particles and methods of making thereof
US10449218B2 (en) 2009-05-26 2019-10-22 The General Hospital Corporation System for treating a sebaceous gland
US10912739B2 (en) 2017-10-16 2021-02-09 Peace Out Inc. Hydrocolloid-based skin treatment
CN108853557A (en) * 2018-07-23 2018-11-23 衢州玛济克医疗科技有限公司 A kind of wet erythema medical dressing of infant and its production method
US11684586B1 (en) 2022-02-28 2023-06-27 Peace Out, Llc Anhydrous hydrocolloid matrix comprising homogeneously distributed encapsulated therapeutic agents

Also Published As

Publication number Publication date
US20060083792A1 (en) 2006-04-20
WO2002085299A2 (en) 2002-10-31
WO2002085384A3 (en) 2003-08-21
CA2445740A1 (en) 2002-10-31
WO2002085386A3 (en) 2003-01-16
US6723350B2 (en) 2004-04-20
ES2261659T3 (en) 2006-11-16
US20040157073A1 (en) 2004-08-12
EP1383520A2 (en) 2004-01-28
CA2445734A1 (en) 2002-10-31
US6989156B2 (en) 2006-01-24
WO2002085387A3 (en) 2003-01-16
US20020182265A1 (en) 2002-12-05
DE60210441T2 (en) 2006-11-16
JP2005507368A (en) 2005-03-17
JP2004529929A (en) 2004-09-30
DE60210441D1 (en) 2006-05-18
EP1390013A4 (en) 2005-01-12
EP1390013A2 (en) 2004-02-25
EP1383522A2 (en) 2004-01-28
AU2002249046A1 (en) 2002-11-05
US20060204591A1 (en) 2006-09-14
AU2002252881B2 (en) 2007-07-26
EP1383520B1 (en) 2013-09-18
EP1383522B1 (en) 2006-04-05
WO2002085299A3 (en) 2003-10-16
US20030086977A1 (en) 2003-05-08
JP2004529930A (en) 2004-09-30
WO2002085385A3 (en) 2003-01-16
US6939568B2 (en) 2005-09-06
CA2443587A1 (en) 2002-10-31
US20030054046A1 (en) 2003-03-20
WO2002085386A2 (en) 2002-10-31
US20050271743A1 (en) 2005-12-08
CA2445729A1 (en) 2002-10-31
WO2002085385A2 (en) 2002-10-31
WO2002085384A2 (en) 2002-10-31
AU2002303438B2 (en) 2007-10-25
AU2002252879B2 (en) 2007-08-02
US20030099718A1 (en) 2003-05-29
US20030021854A1 (en) 2003-01-30
CA2445729C (en) 2013-07-02
EP1383521A2 (en) 2004-01-28
ATE322274T1 (en) 2006-04-15
JP2004525980A (en) 2004-08-26
US7087249B2 (en) 2006-08-08

Similar Documents

Publication Publication Date Title
US6939568B2 (en) Treatment of inflammatory skin conditions
AU2002252881A1 (en) Use of metals to treat inflammatory skin conditions
US7008647B2 (en) Treatment of acne
US7255881B2 (en) Metal-containing materials
US6989157B2 (en) Dry powders of metal-containing compounds
US7470437B2 (en) Methods of treating conditions with a metal-containing material
US20030170314A1 (en) Compositions of metal-containing compounds
AU2002252879A1 (en) Use of metals to treat mucosal membranes
US7078060B2 (en) Solutions and aerosols of metal-containing compounds
WO2005074949A1 (en) Treatment of ungual and subungual diseases with antimicrobial metal compositions
US7001617B2 (en) Method of induction of apoptosis and inhibition of matrix metalloproteinases using antimicrobial metals
US20040191329A1 (en) Compositions and methods of metal-containing materials
US20030194444A1 (en) Methods of treating skin and integument conditions
US7427416B2 (en) Methods of treating conditions using metal-containing materials
US20030206966A1 (en) Methods of inducing apoptosis and modulating metalloproteinases
US20060115541A1 (en) Treatment of bladder conditions
CA2500836A1 (en) Metal-containing materials, compositions and methods
AU2002252880A1 (en) Medicament containing a metal such as silver, gold, platinum or palladium as an antimicrobial agent and their use to induce apoptosis in cancerous tissue

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002252881

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2445740

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002582960

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002721904

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002721904

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 2002721904

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 2002252881

Country of ref document: AU